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ABSTRACT 
The accumulation of leukocytes in non-lymphoid tissues and their structural 
organization into tertiary lymphoid structures (TLS), a process known as ectopic 
lymphoid neogenesis (ELN), is observed in response to chronic inflammation 
and in the target organ of several autoimmune diseases. TLS strongly resemble 
secondary lymphoid organs with specialised high-endothelial venules (HEV), 
segregated B/T cell areas and presence of follicular dendritic cells (FDC) 
networks promoting in situ affinity maturation of the antibody response. TLS 
have been associated with a growing number of autoimmune conditions and 
usually their presence is prognostic for undesirable disease progression. In 
Sjögren’s syndrome (SS), an autoimmune disease affecting the salivary and 
lachrymal glands leading to exocrine dysfunction, TLS develop in the salivary 
glands (SG) of around one-third of the patients. 
The immunobiology of the SG and the pathogenesis of SS have been poorly 
clarified and to date a robust and reproducible inducible animal model of SS 
and TLS in the SG is still absent. In my PhD, I developed and validated a novel 
inducible model of ELN in murine SG that also reproduces several features of 
SS. The retrograde administration of a replication-deficient adenovirus (AdV) in 
the SGs of wild-type C57Bl/6 mice was able to induce within three weeks fully 
formed TLS that displayed B/T cell segregation, FDC networks, HEVs and were 
positive for markers of germinal centres. Moreover, the AdV-treated mice 
showed a significant reduction of salivary flow and in 75% of the cases 
development of anti-nuclear antibodies. 
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The investigation of the dynamic recruitment of different innate leukocyte 
subsets infiltrating the SG in response to AdV delivery highlighted the presence 
of a tightly regulated influx of inflammatory monocytes, granulocytes and natural 
killer (NK) cells in response to viral infection of the SG preceding the formation 
of TLS. 
In summary, during my PhD I have developed and validated a novel inducible 
model of ELN and SS-like disease in the SG of wild-type mice. This model, 
which is amenable to gene targeting, could be invaluable in dissecting the 
mechanisms leading to TLS formation and SG pathology as well as 
understanding the interrelations between viral infection, autoimmunity and 
exocrine dysfunction in SS. 
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1 Introduction 
1.1 Ectopic lymphoid neogenesis in host defence and pathology 
The immune system, in contrast with other compartmentalised systems within 
organs in animals, is a diffuse system whereby its fundamental components, 
the immune cells, are not only present in specialised tissues, but most of them 
constantly recirculate the whole organism to perform their functions. 
Nevertheless, for the immune system to work correctly and protect the 
organism, specialised tissues are necessary where the various types of immune 
cells either develop, mature, or both. These structures are termed primary and 
secondary lymphoid organs. A third type of lymphoid structure has been 
described, that shares many features with secondary lymphoid organs but in 
contrast to those it is inducible in adult individuals and not formed during 
embryogenesis or early life. These structures, termed tertiary or ectopic 
lymphoid structures, are involved in a plethora of different phenomena, from 
host-defence to graft-rejection and autoimmunity, and understanding them can 
shed more light on the immune system plasticity and adaptability and on the 
processes that lead to pathology and disease.  
1.1.1 Secondary and tertiary lymphoid organs 
The structures where leukocytes preferentially interact with each other and 
enter in contact with antigens collected in the periphery are called secondary 
lymphoid organs (SLO). Among those there are: the spleen, pivotal against 
blood-borne pathogens; lymph nodes that collect leukocytes that patrol the 
periphery; Peyer’s patches in the intestine and tonsils in the oropharyngeal 
tract. Moreover, mucosa-associated lymphoid tissue (MALT), consisting of the 
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sparse lymphoid follicles present in the body mucosae, is considered a SLO. 
SLO are characterised by a highly organised microarchitecture where B and T 
lymphocytes localise in the so-called B and T cell areas respectively. This 
architecture allows antigen-presenting cells (APC) to localise in the T cell area 
where they can present the antigen to and activate T lymphocytes. Primed T 
cells then can migrate at the boundaries and into the B cell area where in turn 
activate their cognate B cell counterparts: this process in turn leads to the 
germinal centre (GC) formation where activated B cells undergo the proliferation 
and affinity maturation processes that eventually leads to the production of high 
affinity antibodies (Figure 1.1). 
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Figure 1.1: The spleen and lymph nodes. (A) Lymphocytes enter the white 
pulp of the spleen from the marginal zone and entry is mediated by signaling 
through chemokine receptors: B cells are attracted to the B-cell follicles by 
CXCL13, whereas T cells are directed to the T-cell zone by responding to 
CCL19 and CCL21. (B) Most lymphocytes enter a lymph node through 
specialized blood vessels that are known as high endothelial venules (HEVs) 
and then migrate to the B-cell follicles or the T-cell zone, following CXCL13, and 
CCL19/CCL21 gradients respectively. Lymphocytes leave the lymph nodes via 
efferent lymphatic vessels, and eventually return to the bloodstream from the 
lymph. (C) A fibrous capsule and an underlying subcapsular sinus surround the 
three distinct regions of a lymph node: cortex, paracortex and medulla. The 
cortex contains primary B cell follicles composed of B cells and FDCs. Antigen 
stimulation triggers a strong B cells proliferation that culminates with the 
formation of secondary follicles called germinal centers. The paracortex is 
composed of T cells and DCs while the deeper medulla entails the medullary 
cords, which are separated by lymph filled spaces called medullary sinuses. 
HEVs and lymphatic vessels form the lymph node vasculature. While 
lymphocytes enter the lymph nodes via HEVs and exit via efferent lymphatic 
vessels, DCs enter via afferent lymphatic vessels. Activated DCs from the 
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Producing antibodies. The red pulp is also known to be 
a site where PLASMABLASTS and PLASMA CELLS lodge. After 
antigen-specific differentiation in the follicles of the 
white pulp, plasmablasts migrate into the red pulp, 
initially just outside the marginal zone16. However, the 
exact anatomical position and cellular interactions that 
are involved in the retention of these cells are not clear 
(reviewed in REF. 17). The position of plasmablasts in 
the red pulp resembles the localization of plasmablasts 
in the medullary cords of lymph nodes, and this extra-
follicular antibody production leads to rapid entry of 
antibody into the bloodstream. Evidence indicates that 
plasmablasts are attracted to the red pulp after upregu-
lating their expression of the chemokine receptor CXC-
chemokine receptor 4 (CXCR4); this receptor binds 
the chemokine CXC-chemokine ligand 12 (CXCL12), 
which is expressed in the red pulp18. This coincides with 
downregulation of expression of the chemokine recep-
tors CXCR5 and CC-chemokine receptor 7 (CCR7), 
which bind the homeostatic chemokines that are pres-
ent in the B-cell follicles and T-cell zone of the white 
pulp. Interestingly, it has been found that plasmablasts 
require CD11chi dendritic cells (DCs) to survive in the 
red pulp and to make the transition into plasma cells19. 
The presence of CD11chi DCs in the T-cell zone of the 
white pulp, as well as in the bridging channels that 
extend into the red pulp, might be of assistance in this 
transition. The bridging channels are where antibody-
forming cells have been described to temporarily reside 
after antigenic challenge20.
Organization of the lymphoid compartments
In this section, we describe the structure of the lymphoid 
region of the spleen — the white pulp — with an empha-
sis on new insights into how the cells of the immune 
system migrate and lodge in the various compartments 
of the white pulp.
White pulp. The white pulp is organized as lymphoid 
sheaths, with T- and B-cell compartments, around the 
branching arterial vessels, so it closely resembles 
the structure of a lymph node. The correct organiza-
tion and maintenance of the white pulp is controlled by 
specific chemokines that attract T and B cells to their 
respective domains, thereby establishing specific zones 
within the white pulp (FIG. 3). In the T-cell zone (also 
known as the periarteriolar lymphoid sheath, PALS), 
T cells interact with DCs and passing B cells, whereas 
in the B-cell follicles (also known as the B-cell zones), 
clonal expansion of activated B cells can take place, 
which leads to isotype switching and somatic hyper-
mutation. CXCL13 is required for B cells to migrate to 
the B-cell follicles21, whereas CC-chemokine ligand 19 
(CCL19) and CCL21 are involved in attracting T cells 
and DCs to the T-cell zones of the white pulp22,23 
(FIG. 3). Expression of these chemokines is controlled 
by lymphotoxin-α1β2 (LT-α1β2) and tumour-necrosis 
factor (TNF)24. When signalling through the LT-β 
receptor (LT-βR) or TNF receptor 1 (TNFR1) is lacking, 
levels of the homeostatic chemokines CXCL13, CCL19 
and CCL21 are reduced in the spleen, which results in 
disorganization of white-pulp regions24 TABLE 1. Both 
LT-βR and TNFR1 are expressed by radiation-resistant 
stromal cells, whereas their ligands are expressed by 
haematopoietic cells, most probably B cells, as occurs in 
RADIATION CHIMERAS25–27. After engagement of these recep-
tors, nuclear factor-κB becomes activated, resulting in 
induction of expression of the various chemokines. 
Figure 2 | Venous sinuses in the red pulp of the spleen. Schema of a venous sinus located 
in the cords of the red pulp. Blood from the cords collects in the sinuses (shown by arrows). 
The venous sinuses consist of a lining of endothelial cells that are positioned in parallel and 
connected by stress fibres to annular fibres, which are composed of extracellular-matrix 
components. The stress fibres run along the long axis of the endothelial cells and are most 
prominent where the endothelial cells are in contact. Contractility of the stress fibres allows 
the formation of slits between the endothelial cells, thereby regulating the passage of blood 
and blood cells from the red-pulp cords into the sinuses and back into the venous system. 
Because the red-pulp cords contain a large number of macrophages, ageing erythrocytes 
that are no longer able to pass through the slits are phagocytosed.
Figure 3 | Comparison of lymphoid compartments and the migration pathways of 
lymphocytes into the splenic white pulp and the lymph nodes. a | The spleen. 
Lymphocytes enter the white pulp of the spleen from the marginal zone, and entry is 
mediated by signalling through chemokine receptors. B cells are attracted to the B-cell 
follicles by CXC-chemokine ligand 13 (CXCL13), whereas T cells are directed to the T-cell 
zone by responding to CC-chemokine ligand 19 (CCL19) and CCL21. It is unclear how 
lymphocytes eventually leave the white pulp. b | The lymph nodes. Few lymphocytes enter 
a lymph node from the afferent lymphatic vessels. Most enter through specialized blood 
vessels that are known as high endothelial venules (HEVs) and then migrate to the B-cell 
follicles or the T-cell zone, which again is regulated by CXCL13, and CCL19 and CCL21, 
respectively. Lymphocytes exit lymph nodes in efferent lymphatic vessels, and they then 
re-enter the bloodstream from the lymph. 
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lymph nodes, the latest, at embryonic day 16 (ref. 13). Prolonged 
interactions between lymphoid tissue–inducer and stromal-
organizer cells promote the development of HEVs, which sup-
port the selective entry of naive T cells and B cells into the lymph 
node through the expression of vascular addressins and chemo-
kines14,15. L-selectin, expressed on naive lymphocytes, interacts with 
peripheral node addressin (PNAd) expressed on HEVs to facilitate 
lymphocyte recruitment into lymph nodes15,16. PNAd, recognized by 
the monoclonal antibody MECA 79, is a shared carbohydrate-based 
determinant found on several scaffold proteins, including GlyCAM-
1, CD34, and podocalyxin17–19. Optimal binding of L-selectin to 
PNAd requires three post-translational modifications: sialylation, 
fucosylation and sulfation. The last two modifications are medi-
ated by the coordinated activity of fucosyl transferases (FucTIV and 
FucTVII) and at least one sulfotransferase (HEC-GlcNAc6ST, also 
called LSST, HEC-6ST and GlcNAcST-2)20–23. In addition to PNAd, 
HEVs can express another vascular addressin called MAdCAM-1. 
Immediately aft r birth, all HEV  express MAdCAM-1, the ligand 
for the integrin α4β7 (ref. 24), which is rapidly replaced by PNAd 
in mouse peripheral lymph nodes25; thus, PNAd functions as the 
main L-selectin ligand that contributes to the ‘mature’ peripheral 
lymph node HEV phenotype. In contrast to peripheral lymph nodes, 
mucosal lymph nodes contain HEVs that maintain expression of 
MAdCAM-1 in addition to PNAd25.
Tumor necrosis factor family in lymph node organogenesis
The immediate tumor necrosis factor–lymphotoxin (TNF-LT) 
family includes three proteins: TNF, LT-α and LT-β26. These cyto-
kines are members of a ‘superfamily’ of proteins comprising at least 19 
ligands and 29 receptors that have many biological activities associated 
with cancer, infectious disease, allergy, autoimmunity, transplantation 
biology and lymphoid organ development27. Individually, TNF (a type 
II transmembrane homotrimeric complex that can be released from cell 
surfaces through the activity of TNF convertase) and LT-α (a soluble 
homotrimeric complex) can bind to the TNF receptors TNFRI and 
TNFRII. In contrast, LT-β (a membrane-bound protein) must form 
a functional heterotrimeric complex with LT-α1β2 to bind its receptor, 
LT-βR28–31. The involvement of additional cytokines and transcription 
factors, including TRANCE, LIGHT, IL-7, Id2 and RORγ, in this process 
has been summarized before2. Here we concentrate on LT-α and LT-β, in 
part because of their well documented activities in lymphoid neogenesis 
(discussed below).
Several lines of evidence demonstrate that LT-α and LT-β have 
crucial, nonredundant functions in lymphoid organ development. 
Mice deficient in LT-α (Lta–/– mice), for example, lack all lymph 
nodes and Peyer’s patches and have highly disorganized spleen 
and nasal-associated lymphoid tissue32–35. Transgenic expression 
of LT-α under control of the rat insulin gene promoter element 
(RIP–LT-α) partially restores lymphoid organ development and 
function to Lta–/– mice36. In contrast, LT-β-deficient (Ltb–/–) mice 
lack all peripheral lymph nodes and Peyer’s patches but retain 
mucosal, cervical and sacral lymph nodes and have less prominent 
splenic and nasal-associated lymphoid tissue defects than those of 
Lta–/– mice34,37–40. It is becoming increasingly apparent that LT-
α1β2 signaling through LT-βR controls secondary lymphoid organ 
development through the regulation of lymphoid chemokine and 
HEV gene expression41–43. The mechanisms by which LT-α regulates 
this developmental process are less well defined, given that LT-α, as 
the LT-α3 homotrimer or in complex with LT-β, can signal through 
TNFR or LT-βR, respectively.
Structure and function of lymph nodes
The lymph node cortex contains densely packed B cells and follicular 
dendritic cells (FDCs) arranged into discrete clusters called primary 
follicles, whereas the paracortex is composed of a less dense accu-
mulation of T cells and dendritic cells (DCs). Lymphocytes enter 
the lymph node by extravasation across HEVs; soluble antigen and 
DCs enter via afferent lymphatic vessels at multiple sites along the 
capsule44. Filtered lymph and cells leave the lymph node via a single 
efferent lymphatic vessel for later delivery to the venous blood.
The recruitment and positioning of lymphocytes and DCs in the 
lymph node is orchestrated by the compartmentalized expression 
of lymphoid chemokines (also called homeostatic chemokines)45. 
The lymphoid chemokine family includes three ligands, CCL19, 
CCL21 and CXCL13, and two receptors, CCR7 and CXCR5. CCL19 
(also called ELC) and CCL21 (also called SLC) are constitutively 
expressed by T cell–zone stromal cells and share the chemokine 
receptor CCR7, which orchestrates the homing of naive and central 
memory T cells and DCs to the T cell compartment46. In addition, 
CCL21 is expressed by lymph node HEVs and lymphatic vessel endo-
thelium in nonlymphoid tissues. Lymphatic expression of CCL21 is 
thought to participate in the emigration of mature DCs out of the 
peripheral tissues and into afferent lymphatic vessels47. The chemo-
kine CXCL13 (also called BLC) is constitutively expressed by follicu-
lar stromal cells and is required for the homing of CXCR5+ B cells 
and a small subset of T cells to the follicular compartment48. All of 
Figure 1  Lymph node structure. A fibrous capsule and an underlying 
subcapsular sinus surround the cellular contents of the lymph node. The 
lymph node can be separated into three d tin t regions: cortex, paracortex 
and medulla. The cortex contains discrete lymphoid nodules, composed 
of B cells and FDCs, called ‘primary follicles’. After antigen stimulation, 
B cells undergo intense proliferation, giving rise to secondary follicles 
called germinal centers. Inside the cortex lies the paracortex, which is 
composed of T cells and DCs. The deeper medulla consists of lymphatic 
tissue called medullary cords, which are separated by lymph filled spaces 
called medullary sinuses. The lymph node vasculature includes HEVs and 
lymphatic vessels. T cells and B cells circulate constantly through the lymph 
node by entering HEVs and xiting via efferent lymphatic vessels. DCs enter 
via afferent lymphatic ves els. Lymph, containi g DCs and soluble antigen, 
enters the lymph node at several points through afferent lymphatic vessels 
and deposits antigens in the subcapsular sinus. Once in the lymph node, 
cell location is ‘orchestrated’ by lymphoid chemokines. CXCL13, expressed 
in the B cell follicles, guides B cells to them; CCL19 and CCL21, expressed 
in the T cell zone, ‘position’ T cells and DCs in the paracortex. In addition, 
lymphoid chemokines expressed on HEVs facilitate the recruitment of 
lymphocytes to lymph nodes. 
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periphery enter the lymph node in lymph, which also contains soluble antigen, 
at several points through afferent lymphatic vessels and deposits antigens in 
the subcapsular sinus. Adapted by permission from Macmillan Publishers Ltd: 
[1] and [2].   
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Tertiary lymphoid Structures (TLS) can be defined as aggregates of lymphoid 
cells forming ectopically in non-lymphoid locations in response to chronic 
antigenic stimuli. As it will be discussed in more details below, TLS are often 
characterized by phenotypic features normally present in SLO such as B/T cell 
compartmentalization, the presence of specialized vessels in the T cell-rich area 
with the appearance of high-endothelial venules (HEV) and the differentiation of 
networks of stromal follicular dendritic cells (FDC) [3]. TLS formation has been 
observed in organ-specific autoimmune diseases [2],[3] but also during the 
course of microbial infections [4]-[6], solid tumours [7]-[10] and graft rejection 
[11]-[13]. Thus, it appears that TLS development is a stereotyped process in 
response to chronic antigenic stimulation, either towards allo- or self-antigens 
[14]. 
1.1.2 Characteristics of tertiary lymphoid structures 
As anticipated above, TLS present many of the characteristic features of SLO, 
namely the presence of segregated B and T cell areas, a network of follicular 
dendritic cells (FDC) in the B cell area and specialised HEV for leukocyte 
trafficking (Figure 1.2).  
FDC present in the B cell areas of SLO and TLS form networks that are 
essential for maturation of B cells inside the follicles. In fact, FDC produce a 
plethora of pro-survival signals and expose on their surface unprocessed 
antigens (Ag) in the form of antigen-antibody complexes (immune complexes) 
creating a static network of Ag-bearing cells among which B cells can move. 
Engagement of the B cell receptor (BCR) by one of these antigens is essential 
for B cell survival and proliferation and all the mechanisms taking place during 
the GC reaction (discussed later in section 1.1.2.1), in particular 
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immunoglobulin class switch recombination (CSR) and somatic hypermutation 
(SHM), production of B memory cells, selection of somatically mutated B-cells 
with high affinity receptors and antibody affinity maturation [15]. Moreover, as 
will be discussed shortly, FDCs also provide the main chemotactic signal for B 
cell localisation in the B cell area.  Another important feature of SLO that is 
present in TLS is the presence of a specialised vasculature, the so-called HEV. 
HEVs are composed by a layer of endothelial cells surrounded by a basal 
lamina that are both thicker in comparison to normal venules. Most leukocytes 
enter lymph nodes across HEVs following the initial interaction between L-
selectin on their surface with peripheral-node addressin (PNAd), which is 
expressed on the luminal surface of HEVs. Conversely, leukocyte migration in 
the gut lymphoid tissue, such as Peyer’s patches (PP), requires the interaction 
of α4β7-integrin with mucosal vascular addressin cell-adhesion molecule 1 
(MADCAM1) expressed on the HEVs of PP and the intestinal lamina propria 
[16].The interaction between PNAd and L-selectin allows the rolling of the 
leukocytes on the endothelial surface. At this stage the interaction between β2 
integrin/LFA1 complex expressed on the leukocyte membrane and the 
adhesion molecule ICAM1 present on the endothelium, causes the stabilisation 
of the cell-venule contact. Leukocyte can then gain access to the tissue through 
transmigration between adjacent endothelium cells following by their positioning 
in response to chemotactic stimuli. Critically, HEVs allows the preferential 
recruitment of lymphocytes to SLO, thus excluding most of the remaining 
leukocytes: this phenomenon cannot be attributed solely to the specific 
expression of the adhesion molecules on the lumen of HEVs and selectins on 
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the surface of lymphocytes, as the same set of molecules is expressed on other 
leukocytes that do not gain access to the tissue 
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Figure 1.2: Schematic model of the hypothesised cellular and cytokine–
chemokine mechanisms in the development of ELN. (A) The innate branch 
of the immune system initiates the inflammatory response that in turn attracts 
lymphocytes from the periphery into the target tissue. This first inflammatory 
phase is regulated by inflammatory cytokines, such as interferon-γ (IFNγ), 
interleukin-1β (IL-1β) and tumour-necrosis factor (TNF), that promote the 
synthesis of adhesion molecules and chemokines. (B) Persistent activation of 
innate and adaptive immune cells due to chronic antigenic stimulation in the 
inflamed tissue lead to increased expression of lymphotoxin-α1β2 (Ltβ) by 
activated B and T cells, and of lymphoid chemokines by resident stromal cells 
and other parenchymal cells, but also DCs and macrophages. (C) Activated 
endothelial cells acquire a HEV phenotype that helps the recruitment of 
lymphocytes and DCs to TLS. CCL19 and CCL21 potentially produced by 
stromal cells are responsible for the formation of T cell areas. It is also 
speculated that stromal cells would acquire the phenotypic and functional 
properties of follicular dendritic cells (FDCs), and among those CXCL13 
production that would promote B cell area and GC organization. Other 
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cytokines that mediate lymphocyte survival and/or proliferation contribute to the 
formation of an optimal milieu for continuous lymphocyte growth and 
differentiation. Reprinted by permission from Macmillan Publishers Ltd: [3] 
copyright 2006.  
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It is now clear that the specific set of surface molecules expressed by HEVs 
facilitates the rolling and stabilisation of the lymphocytes, but the activation of 
the extravasation program depends on other signals. In particular, the presence 
on the luminal surface of the HEVs of specific chemoattractant molecules is 
essential for an effective and specific extravasation of leukocytes [16] [17]. 
Early studies on transgenic animals demonstrated that the lymphotoxin-
β/lymphoid chemokines axis, which is required for SLO development, is also 
critically involved in TLS formation in adult life [18]-[20]. Specifically, lymphoid 
chemokines CCL19 and CCL21, which are mainly produced within the T-cell 
rich area by stromal reticular cells in association with HEVs expressing PNAd, 
allow the recruitment and positioning of L-selectin+/CCR7+ naïve and memory 
T cells within SLO where T cells receive a strong survival signal from stromal 
cells mediated by IL-7 [21],[22]. On the other hand, another lymphoid 
chemokine, CXCL13, mainly produced by FDC and germinal centre dendritic 
cells (GCDC) within the B cell area, drives the migration and localization within 
B cell follicles of CXCR5-positive B cells together with a subset of 
CXCR5+/PD1+/ICOS+ T helper cells which act as strong costimulators for B 
cells, mainly via IL-21 release, and are defined as T-follicular helper cells (Tfh) 
[23]-[26]. Expression of these chemokines is in turn critically regulated by the 
binding of the lymphotoxin-β receptor (LTβR) by the membrane-bound 
heterotrimeric member of the TNF family lymphotoxin-α1β2 (LTβ) which is 
produced by several cell types at different stages of the lymphoneogenetic 
process, including lymphoid inducer cells and B cells [27],[28]. It has now been 
conclusively demonstrated that the lymphotoxin-β/lymphoid chemokines axis is 
ectopically expressed in the context of TLS developing in several autoimmune 
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conditions including the rheumatoid synovial tissue [29], SS salivary glands 
[30]-[32], the meninges of multiple sclerosis patients [33] and Hashimoto’s 
thyroiditis [34],[35], among others. The involvement of ELN in autoimmunity will 
be discussed in sections 1.1.4 and 1.2.3. 
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Figure 1.3: Comparison between secondary and tertiary lymphoid organ 
development. Once established during embryogenesis, lymph nodes cannot 
be ablated. Nevertheless inflammation can lead to drastic changes in LN, such 
as increased cell number, blood and lymph flow and neo-lymphoangiogenesis, 
which correspond to an increase in size. TLS, on the other hand, that can arise 
at anytime and at nearly any anatomical location in the adult in nonlymphoid 
tissues. When unresolved inflammation becomes chronic, cytokine and/or 
chemokine production by stromal and hematopoietic cells can induce ELN. In 
general, TLS can be reversed once the inflammation-inducing antigen is 
removed or with therapeutic treatment. Figure amended from [2].   
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1.1.2.1 Germinal centres in TLS 
Two fundamental questions regarding ectopic lymphoid tissues in autoimmune 
diseases are whether they have the capacity to elicit a humoral response in situ 
and whether they contribute to autoimmunity over and above SLO. In SLO, the 
antigen-driven activation of the follicle culminates with the formation of GC, 
which is sustained by the presence of FDC networks and support B cell 
survival, affinity maturation and antigen selection, eventually leading to the 
generation of plasma cells and memory B cells (Figure 1.4) [36]. Within the GC, 
activated B cells selectively express the enzyme activation-induced cytidine-
deaminase (AID) which is a critical regulator of the two fundamental processes 
taking place within the GC: SHM and CSR of the Ig genes [37].  
TLS are not only reminiscent of SLO phenotypically but also functionally as they 
support in situ AID expression leading to the production of class-switched 
antibodies, as demonstrated by the detection of circular transcripts, [38],[39] 
and diversification of the antibody repertoire [5]. Moreover, in graft-rejection and 
cancer where ELN is observed (discussed later in section 1.1.5), specific anti-
graft and anti-tumour antibodies are detected [11],[40]. Importantly, in 
autoimmunity TLS support the local production of disease-specific 
autoantibodies such as citrullinated antigens in rheumatoid arthritis [39], 
ribonucleoproteins Ro and La in SS [32], anti-thyroglobulin and anti-
thyroperoxidase in Hashimoto’s thyroiditis [35] and anti-acetylcholine receptor 
(AchR) antibodies in myasthenia gravis patients’ thymuses [41]. Finally, in 
animal models of infection with pathogens capable of driving ELN, the 
hallmarks of GC activation and an in situ humoral immunity directed against the 
pathogen are observed [42],[43]. Thus, although the formation of TLS is a 
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stereotyped process common to several inflammatory environments, the 
antigenic force driving the development of functional ectopic GC is specific for 
each condition and leads to the in situ generation of specific antibodies (or auto-
antibodies).
 Figure 1.4: The germinal centre microenvironment. Antigen-activated B cells 
differentiate into centroblasts that undergo clonal expansion in the dark zone of 
the germinal centre and then differentiate into centrocytes and move to the light 
zone. During this progression the B cell receptor undergoes the process of 
somatic hypermutation (SHM) in the dark zone that introduces base-pair 
changes into the region of the rearranged genes encoding the immunoglobulin 
variable region (IgV) of the heavy chain and light chain. Some of the mutations 
introduced during SHM lead to a change in the amino-acid sequence. The 
modified antigen receptor, thanks to the presence of specialized T cells (T-
follicular helper cells) and FDCs in the light zone, is selected for improved 
binding to the antigen. Mutated B cells that produce an unfavourable antibody 
undergo apoptosis. Moreover, subsets of B cells also undergo immunoglobulin 
class-switch recombination (CSR) that is the change of the immunoglobulin 
isotype. Also centroblasts and centrocytes can circulate several times between 
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dark and light zones to increase the antibody specificity for the antigen and this 
process seems to be mediated by a stromal cells-produced chemokine 
gradient. Antigen-selected B cells eventually differentiate into memory B cells or 
plasma cells. Reprinted by permission from Macmillan Publishers Ltd: [36] 
copyright 2008. 
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1.1.3 Initiation of the ELN programme 
Our knowledge of the ELN process and its role in immunity is rapidly increasing 
but far from satisfactory. In fact, while we have now a substantial amount of 
data regarding the chemotactic signals required for TLS formation and what are 
the molecular switches that trigger chemokines production in ELN target 
tissues, we know very little about the very early cellular and molecular events 
that activate the ELN programme in these tissues. In particular, there is 
emerging evidence that the cell types responsible for the production of the 
critical factors involved in the ELN process differs compared to the established 
model of lymphoid organogenesis. Recent studies have focused on three 
cellular categories: lymphoid-tissue inducer cells, IL-17-producing cells and 
cells belonging to the myeloid lineage.  
During lymphoid organogenesis (Figure 1.5), VCAM-1+/ICAM-1+/LTβR+ 
embryonic mesenchimal “organizer” cells (lymphoid-tissue organiser cells, LTo) 
pre-natally produce lymphoid chemokines in response to close interaction with 
CD3−/CD4+/CD45+/IL-7Rα+/RANK+ embryonic hematopoietic “inducer” cells 
(lymphoid-tissue inducer cells, LTi) that also express CXCR5 [44]. After the 
anchoring of the LTi cells to the SLO anlagen, IL-7 and the member of TNF-
family RANK-ligand (RANKL) produced by LTo promote survival and activation 
of these inducer cells. In particular, LTi cells upregulate the production of LTβ, 
which in turn triggers LTβR on LTo cells: this interaction promotes the synthesis 
and the release of CXCL13 and CCL19/21 and the expression of adhesion 
molecules and the differentiation of HEV [2],[44]. Mice deficient for the 
transcription factor RORγt, necessary for the development of LTi, do not 
develop peripheral SLO [45]. Interestingly, LTβ blockade in pregnant mice also 
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leads to a progeny deficient of LNs and PP and with disrupted spleen 
architecture [46]. As it will be discussed in detail later, the LTβ/LTβR interaction 
that is fundamental in embryogenesis, in the adult is important not only in SLO 
homeostasis but also in TLS formation [47]. On the other hand, a role of LTi in 
ELN has often been speculated but the topic has been only recently studied in 
detail. In mice, adult CD4+CD3- LTi are found into SLO in small numbers but 
they are functional in their organising role as LTi transfer into adult LTα-/- mice 
restored the normal splenic architectures that in these animals is otherwise 
disrupted [48]. Moreover, adult LTi transferred in neonatal CXCR5-/- animals 
that lack almost completely PPs and isolated lymphoid follicles in the gut, 
restored the intestinal lymphoid tissues, proving that adult LTi can function as 
their embryonic counterpart in organising neonatal lymphoid tissues [49]. 
Despite these evidences, proof of a direct involvement of adult LTi in the 
induction of TLS either in mice or in humans is still missing. 
In the last few years an important role for IL-17 in ELN has been hypothesised. 
This cytokine has been found to be relevant for TLS formation in the brain of 
mice in the EAE model of multiple sclerosis [50] and in the lungs of mice 
challenged with influenza virus or bacterial LPS [51] while in chronic graft 
rejection the level of IL-17-producing cells, co-expressing podoplanin, positively 
correlates with the speed of graft rejection and the presence of germinal centres 
in the graft [52]. Despite IL-17-producing T-helper cells (Th17) have been 
considered the main producers of the cytokine, recently a new cell subset has 
been found to contribute to IL-17 production at mucosal sites. IL-17-producing 
innate lymphoid cells (ILC17) belong to a novel family of non-T non-B cells 
named innate lymphoid cells (ILC), as they derive for the common lymphoid 
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progenitor but do not express any T or B cell receptor [53]. According to this 
definition, also LTi and NK cells belong to the ILC family. Interestingly, the 
differentiation of ILC17, Th17 and LTi cells depends on the expression of the 
same transcription factor RORγt [54], suggesting that the cells that share the 
expression of this protein might also share a role in the organisation of lymphoid 
tissues in embryogenesis and in adulthood. 
Other recent studies highlighted the importance of myeloid cells in ELN. In a 
model of acute colitis (dextran sulphate sodium induced colitis, DSS), TLS 
formation has been shown to be independent from LTi and Th17 cells, as 
RORγt-/- animals, that are deficient in both subsets and have an impaired 
lymphoid tissue in the gut, develop intestine TLS as and above their wild-type 
counterparts [55]. Formation of intestinal TLS depends on the intestinal 
microbiota and even in the absence of peripheral lymph nodes, RORγt-/- 
animals were able to control intestinal flora by developing supernumerary TLS. 
In a similar work, Furtado and colleagues recently confirmed that TLS form in 
the intestine of RORγt-/-. Strikingly, the authors also shown that TNFα 
overexpression in RORγt-/- mice was able to partially restore the presence of 
peripheral lymph nodes, and that these lymph nodes were structurally and 
functionally indistinguishable from those present in wild-type animals [56]. 
Furthermore, the authors found that CD11b+F4/80+ myeloid cells were the 
main producers of TNFα in the lymph node anlagen and that TNFα-dependent 
LTβR engagement triggered the maturation of stromal cells and the secretion of 
lymphoid chemokines by these cells. Overall, these two works showed that LTi 
cells are dispensable for TLS formation and that TNFα-producing myeloid cells 
can trigger peripheral lymph node formation in the absence of LTi.  
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Stromal cells activation, perhaps driven by resident macrophages and dendritic 
cells (DC) that continuously probe peripheral tissues for stress signals and 
pathogens, and the consequent lymphoid chemokines production, is probably 
the main cause for the initial lymphocytic influx that characterises the early ELN 
programme. Nevertheless, cells from the innate immune system have been 
shown to be able to produce lymphoid chemokines in vitro as well as in some 
human diseases characterised by TLS formation. For instance, human in vitro-
differentiated monocyte-derived DCs are capable of producing high amount of 
CXCL13 when stimulated with IL-10 and LPS [57]. Interestingly, in a mouse 
model of influenza virus, DCs are important for the maintenance of TLS arising 
in the lungs of infected animals (discussed in detail in section 1.1.7.1) but not 
for the formation of these structures [58]. It is thus likely that CXCL13 produced 
by DCs has a more important role in the later phases of ELN than in TLS 
formation.  
In the inflamed synovium of rheumatoid arthritis (RA) patients, other cells 
belonging to the myeloid lineage have been shown to be potent producers of 
CXCL13. CD11c+CD68+ dendritic cells found in the ectopic lymphoid follicles of 
RA patients are positive for CXCL13 production [59] and the same authors 
reported that blood monocytes and monocyte-derived macrophages 
differentiated in vitro produce CXCL13 in response to LPS stimulation. 
Interestingly, in vivo activated monocytes from RA patients were also able to 
spontaneously induce differentiation of Th17 cells [60] that, as reported above 
in this section, might have an important role in TLS formation in autoimmunity, 
infection and in graft rejection.  
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Figure 1.5: A model of SLO development. A) Production of lymphoid 
chemokines and adhesion molecules by stromal organiser cells is triggered via 
stimulation of LTβR by LTβ that is expressed by CD3-/CD4+/CD45+ 
haematopoietic inducer cells (LTi). B) Lymphocytes from the blood are recruited 
thanks to the presence of lymphoid chemokines on the surface of HEV in the 
SLO anlagen that also express adhesion molecules such as ICAM1, 
MADCAM1 and PNAd. In particular LTi and lymphocytes express CCR7 and 
CXCR5 receptor and are attracted by the relative chemotactic stimuli produced 
by the developing SLO, CCL19 and CCL21 for the former and CXCL13 for the 
latter. C) In the last phases of SLO organisation, T cell area is organized by 
CCL19 and CCL21 produced by stromal cells and dendritic cells that attracts T 
CCR7+ T cells and antigen-experienced mature DC from the periphery, whereas 
FDC and GC DCs produce CXCL13 that attracts CXCR5+ B cells into the 
follicles. At this stage, B and T cells are the main source of LTβ, which with TNF 
induces lymphoid chemokines expression by stromal cells and maintains the 
homeostasis of mature SLO. Lymphoid chemokines, in turn, induce expression 
of LTβ in lymphocytes establishing a positive feedback loop. Reprinted by 
permission from Macmillan Publishers Ltd: [3] copyright 2006.  
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The data reported above are clearly incomplete and insufficient to have a 
precise idea of the early phases of ELN. Nevertheless, taken together, these 
evidences suggest that the ELN programme can be initiated by different cell 
types and through several different mechanisms that all ultimately terminate 
with the activation of the LTβ/LTβR pathway and consequent lymphoid 
chemokines production. The B-cell attracting chemokine CXCL13 appears to be 
pivotal both for the early lymphocytic infiltration and for the late maintenance of 
TLS. Accordingly, following the initial B cell recruitment, the interaction between 
LTβ expressed on B cells and LTβR present on activated stromal cells 
establishes a positive feedback loop promoting lymphoid chemokines 
production and further cell recruitment [3]. Cells of the innate immune 
compartment, from lymphoid and/or myeloid lineage, can probably drive this 
initial lymphocyte influx by inducing CXCL13 secretion in activated stromal cells 
and/or by direct secretion of the chemokine at the site of inflammation. 
Moreover, there is growing evidence that the innate immune system might be 
responsible for the development of an adaptive immune response (e.g. the 
differentiation of Th17 cells) that possibly favours ELN in infection and chronic 
inflammation and autoimmunity.  
1.1.4 Ectopic lymphoid neogenesis in autoimmunity 
Given the pivotal role of chronic antigen stimulation for the generation of TLS, 
ELN is more often observed in organ-specific autoimmune conditions, where 
the driving antigen(s) are chronically expressed (whether a self or non-self 
molecule). ELN has been now confirmed for a vast number of very different 
autoimmune diseases, in particular the joints in rheumatoid arthritis (RA), the 
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meninges in multiple sclerosis (MS), the thymus in myasthenia gravis (MG), the 
thyroid in autoimmune thyroiditis and the salivary glands of SS. 
I will first review these conditions in humans and in their animal model 
counterparts and I will dedicate the next section to a more exhaustive analysis 
of SS. 
1.1.4.1 Rheumatoid arthritis 
RA is a chronic, systemic inflammatory disease that affects primarily the joints 
leading to inflammation of the synovial tissue, followed by destruction of the 
cartilage and bone erosion [61]. RA affects around 1% of the worldwide 
population. RA pathology is characterised by the presence of specific 
autoantibodies, in particular rheumatoid factor (RF) and anti-citrullinated protein 
antibodies (ACPA) and it is thus considered an autoimmune disease [14],[61].  
A sizable portion of RA patients (about 40%) develops TLS in the joint 
synovium [62],[63]. Studies on the ELN phenomenon in RA confirmed that also 
in the rheumatoid joints the TLS formation depends on the ectopic expression 
of the lymphoid chemokines CXCL13 and CCL21 and that upregulation of these 
chemokines is associated with higher levels of LTβ (reviewed in [64]). 
Interestingly, the presence of CXCL13 and CCL21 is associated not only with 
fully organised TLS but also with the small, sparse and poorly organised 
lymphoid infiltrates [29]. In the last years our laboratory has helped to shed 
some light on the role of these structures in the pathogenesis and evolution of 
RA. We and others demonstrated that CXCL13 is not only produced by FDC 
networks in the ectopic follicles, but also by cells of the monocyte/macrophage 
lineage [59] and a subset of memory T cells [65]. Additionally, TLS that display 
FDC networks invariably expressed the AID enzyme, demonstrating that the 
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molecular machinery to promote Ig class switching and affinity maturation of the 
antibodies is present within RA synovial TLS. Finally, when transplanting 
synovial grafts from RA patients into SCID mice (which are devoid of an 
adaptive immune system), synovial tissue of AID+ patients was capable to 
produce human ACPA antibodies up to 4 weeks after engraftment. 
Furthermore, there was a close positive correlation between the level of ACPA 
antibodies in the blood and the expression level of AID. The same work proved 
that CSR is occurring in situ in the AID+ transplanted synovia and that AID 
presence correlates with higher levels of CXCL13 and B cell pro-survival factors 
[39].  
Despite TLS-positive RA patients present a more active disease [62] it is still 
controversial whether TLS identify a distinct clinical phenotype of RA patients. 
Additionally, it is clear that ACPA and RF autoantibodies can be produced also 
outside the joints as no association could be made between the presence of 
ectopic follicles and a specific pattern of autoantibodies production [66]. 
1.1.4.2 Other autoimmune diseases 
In the last decade the presence of TLS in the target organs of several organ-
specific autoimmune diseases has been reported and documented at various 
levels of depth. For example, in autoimmune thyroiditis, the first disease ever 
defined “autoimmune” (Hashimoto’s thyroiditis, HT), lymphoid infiltrates are 
observed in the thyroid gland. These infiltrates show B/T cell 
compartmentalisation, often with distinguishable light and dark areas in the B 
cell area, regions of intense proliferation and apoptosis and in general a striking 
similarity to SLO [35]. Furthermore, biopsies from patients with autoimmune 
thyroiditis have high expression levels of LTβ and lymphoid chemokines 
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(among which CCL21 and CXCL13) in comparison with controls [34]. Finally, 
specific anti-thyroglobulin and anti-thyroperoxidase antibodies plasma cells are 
present in the TLS in autoimmune thyroiditis patients [35], strongly supporting 
the concept that antigen-specific plasma cells undergo in situ maturation and 
differentiation.  
The thymus is the organ where ELN is observed in MG: B cells isolated from 
MG patients’ thymuses are positive for activation markers and are capable to 
produce anti-AchR antibodies [41], one of the diagnostic test for autoimmune 
MG in the clinical setting, which are also pathogenic and responsible for the 
typical muscular weakness that characterises this disease. A direct study 
analysing the gene repertoire of isolated GC-B cells from MG patients showed 
that these ectopic follicles behave like GCs normally present in SLO, both in 
terms of immunoglobulins diversification and selection [67]; also in this setting 
CXCL13 expression has been proven pivotal for the development of TLS within 
the MG thymus [68]. 
Type-I diabetes (T1D) has been long considered mainly a T-cell mediated 
autoimmune disease, characterised by the destruction of pancreatic islets by 
autoreactive T lymphocytes. Despite the relevance of T cells, one of the 
hallmarks of T1D is the presence of autoantibodies against islet antigens (e.g. 
anti-insulin antibodies) [69]. Recent evidences have shed new light on the 
relevance of B cells in the disease, mainly using a robust autoimmune diabetes 
murine model, the non-obese diabetic (NOD) mouse. Of relevance, not only B 
cell infiltration is an important feature of the histology of NOD animals 
pancreata, but also B cells are necessary for the initiation of insulitis [70]. 
Indeed, ELN takes place in NOD pancreas, and this phenomenon is dependent 
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upon the expression of the lymphotoxin/lymphoid chemokines axis. Once again, 
TLS in this tissue were functional as they expressed activation markers (e.g. 
AID enzyme activity) and promoted autoimmunity as demonstrated by the 
perifollicular accumulation of pancreatic CD138+ plasma cells reactive against 
insulin [71]. Moreover, it has been shown that B cells undergo affinity 
maturation towards pancreatic antigens in situ, suggesting that TLS in the NOD 
pancreata support the selection of autoreactive B cell clones in this model [72]. 
MS is a chronic inflammatory disease of the central nervous system with a 
recognised involvement of T cells. Also in MS a more important involvement of 
B cells and humoral immunity has been speculated in the last decade. 
Presence of B cells in the immune infiltrates of MS brains has long been 
observed together with an oligoclonal expansion of the immunoglobulin 
repertoire; additionally, some studies have associated higher level of IgG with 
more aggressive forms of MS. The role of B cells in the pathology has been 
finally confirmed in MS patients treated with B cell depleting antibodies where a 
reduction in the brain lesions was observed in comparison with placebo-treated 
controls [73]. Importantly, the presence of lymphoid follicles in the brain of MS, 
which has eluded investigators in the field, has finally been observed in the 
meninges of MS patients. B/T lymphoid follicles expressing lymphoid 
chemokines and B cell survival factors are observed in human MS brains and 
also in a mouse model of MS, i.e. EAE [33],[74]. Furthermore, TLS in the MS 
brain (observed more often in patients with a particular form of disease 
progression, the so called secondary progressive MS) are adjacent to 
meningeal lesions, suggesting a pathogenic role of these follicles in some forms 
of MS [75]. 
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1.1.5 Tertiary Lymphoid in graft rejection and cancer 
If ELN is an antigen-driven phenomenon and the formation of TLS occurs in the 
organ where the antigenic stimulus is present, even if the antigen eliciting the 
immune response is not always known, it is not surprising that TLS form in 
allogeneic transplantations, where the graft itself represents a continuous 
source of non-self antigens. The observation of lymphoid infiltrates in grafts 
dates back in time, never the less only recently the association between 
allograft rejection and the presence of TLS in the graft has been highlighted as 
an important step in graft rejection [12],[13]. Not surprisingly, there is a growing 
evidence of anti-graft antibodies generation and B cell clonal expansion in the 
chronically rejected transplant patients [11],[40].  
Leukocyte infiltration in solid tumours is a prognostic factor for many different 
type of cancer. So far, investigations have mainly focused on the cancer-
promoting role of the various subsets of infiltrating lymphoid cells, with a 
particular attention to macrophages that can often promote cancer growth and 
vascularization. Nevertheless, there is growing evidence of the formation of TLS 
in the vicinity of colon, lungs, breast and other types of adenocarcinoma, 
suggesting that the development of TLS represents an attempt to mount an 
anti-cancer immune response in the vicinity of, and related to, the tumour mass. 
Recently, it has been shown that different types of cancer-related immune cell 
infiltration can lead to very different clinical outcomes and prognosis [10]. TLS 
were also found in the colon mucosa of colorectal cancer patients while in 
studies on human breast carcinoma, not only cancer-associated ELN was 
observed, but also an oligoclonal antigen-driven expansion of B cells with in situ 
production of tumour-specific antibodies was demonstrated [8]. Similar findings 
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were reported for human melanoma where AID activation within B cell follicles 
was observed in skin metastases [7] as well as lung cancer, where the 
presence of tumour-induced bronchial-associated lymphoid tissue (Ti-BALT) 
was associated with a favourable clinical outcome [9].  
1.1.6 Tertiary lymphoid structures in chronic bacterial infection 
Given the capacity of ELN to mount an efficient adaptive immune response at 
site of chronic antigen stimulation, it is not surprising that the formation of TLS 
have also been frequently observed in chronic infections, either caused by 
bacterial or viral pathogens. I will discuss in more detail the virus-induced TLS 
formation in section 1.1.7. 
When considering chronic bacterial infections, probably the best characterised 
scenario for ELN formation is the Helicobacter pylori-induced gastritis.  Bacterial 
infection of the gastric mucosa leads to the formation of MALT (in this case 
often called gastric mucosa-associated lymphoid tissue, GALT) and this 
process is critically dependent on the ectopic expression of CXCL13 and the 
presence of its receptor CXCR5 [6],[76]. As expected, bacterial infection is also 
associated with the development of HEV in the mucosa [77] and it has been 
proven that the appearance of GALT is specifically associated with the 
presence of H. pylori. Accordingly, GALT is normally absent in healthy 
individuals and in patients affected by non-bacterial gastritis, whilst H. pylori 
eradication following antibiotics results in a significant reduction of the lymphoid 
infiltrate [78],[79].  
Importantly, chronic H. pylori infection is also associated with the appearance of 
primary gastric B cell lymphoma of the MALT, and eradication of bacterial 
infection results in a regression of the malignancy up to a certain degree of 
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accumulated genetic abnormalities, after which the survival and proliferation of 
malignant B cell clones becomes uncoupled from the signals received by the 
chronic inflammatory milieu [80]. This is of particular relevance to understand 
the implications of persistent TLS in the development of more severe 
pathologies, as the appearance of MALT lymphoma in salivary glands positive 
for TLS is also a feature of SS (discussed in section 1.2.1). 
An emerging role for TLS in the control of tuberculosis has emerged from 
studies conducted both in humans and infected mice. Tuberculosis is an 
infectious disease caused by the pathogen Mycobacterium tuberculosis. The 
hallmark of the disease is the formation of granulomata in the lungs. A 
granuloma is an aggregate of multinucleated macrophages forming around a 
persistent stimulus that cannot be eradicated. Tuberculosis is inextricably linked 
with granuloma: the name of the disease itself refers to lung granulomata, the 
tubercles, the first described forms of granuloma.  Because of this, research on 
tuberculosis has mainly focused on understanding the relationship and the 
interplay between the pathogen and the granuloma, that has always been 
considered a barrier against bacterial dissemination and thus protective 
(reviewed in [81]). More recently, not only this protective role of granuloma 
formation has been questioned but also a new interest has been growing 
around the other lymphoid structures forming together with the granuloma [81]. 
TLS showing B/T cells infiltrates and positive for HEV were found in proximity to 
granulomata (i.e. forming a ring around granulomata) in lung specimens from 
tuberculosis patients as well as murine models of the disease [82],[83]. 
Moreover, in the murine model, the relevance of the lymphoid chemokines in 
the development of TLS in the lungs was demonstrated, as gene and protein 
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expression of these molecules was present in the samples. Interestingly, CCR7-
deficient animals showed disrupted TLS in the lungs and an increased level of 
pulmonary inflammation but were still capable of controlling the infection [84]. 
When considering non-mucosal tissues, Lyme’s disease is a good example of a 
pathology caused by a bacterial agent, Borrelia burgdorferi, which presents 
features of ELN. Borrelia is transmitted to humans via a tick bite and if left 
untreated can cause a plethora of symptoms in different organs. One of the 
most common late-stage manifestations is arthritis: in a subset of patients 
arthritis symptoms do not disappear even after a course of antibiotics despite 
an apparent absence of the bacterium [85]. Biopsies from this treatment-
resistant subgroup show infiltration of lymphocytes with B/T cells discrete areas 
but also FDC networks and clusters of plasma cells. The analysis of the 
immunoglobulin repertoire from plasma cells obtained from patients’ biopsies 
revealed a high number of nucleotide substitutions in comparison to germline, 
suggesting an antigen-driven process of SHM. The authors speculate that in 
these patients, since the infection has been supposedly eradicated, the process 
of antibody affinity maturation is probably driven by self-antigens because of 
their molecular-mimicry with bacterial components [5].  
1.1.7 Tertiary lymphoid structures in viral infection 
Viral infections represent one of the major challenges in terms of immune 
system adaptation to pathogen invasion. Viruses can in fact mount a plethora of 
different countermeasures against immune surveillance and response, 
exploiting the host defence mechanisms. In this scenario, many theories 
regarding autoimmunity development postulate that some of the body 
responses to persistent viral infections and some of the strategies that viruses 
 54 
evolved to resist and replicate in the host, might eventually lead to breach of 
tolerance and self-reactivity as a side effect. Here I will report two cases of 
virus-induced TLS development: in the first I will discuss the protective role of 
influenza-induced lung-specific TLS as inductive sites for an efficient adaptive 
immune response; in the second, I will focus on the hepatitis C virus-driven ELN 
in the liver, and the systemic consequences of an unresolved chronic infection 
in terms of autoimmunity development. 
1.1.7.1 Tertiary lymphoid structures as anti-viral immunity inductive sites 
A classic example of TLS formation following infection is influenza virus-induced 
lymphoid neogenesis in the lungs of rodents. In some species, such as pig and 
rabbit, a lymphoid tissue similar to that found in the gut (gut-associated 
lymphoid tissue, GALT) is constitutively present in the bronchial tract. This 
bronchus-associated lymphoid tissue (BALT) is absent in human and rodents in 
normal conditions but can be induced upon infection and/or chronic 
inflammation and has been thus termed inducible-BALT (iBALT) [86]. iBALT is 
characterized by the classic structural hallmarks of SLO and TLS such as B cell 
follicles surrounded by a more loose T cell area; PNAd+ HEV (in contrast with 
GALT MadCAM+ HEV), and, in contrast with both GALT and specialized BALT 
of pigs and rabbits, absence of M cells [87],[88]. In the Influenza virus model of 
lymphoid neogenesis, it is possible to observe the formation of TLS already 
within 10 days after virus administration. These inducible TLS are 
characterized, as expected, by densely packed B cell follicles displaying 
markers of functionality, such as FDC networks and differentiation of GC B 
cells, as demonstrated by the expression of GL7, an antigen expressed by 
murine germinal centre B cells undergoing productive immunoglobulin class 
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switching [89]. These B cell follicles are surrounded by a T cell-rich area 
populated by proliferating CD4 and CD8 cells in close proximity with PNAd+ 
HEV, and develop in association with the expression of high levels of CXCL13, 
CCL19 and CCL21 transcripts [90]. Recent evidence suggests that TLS 
maintenance in the lungs of Influenza virus-infected mice requires the influx of 
CD11b+CD11c+ dendritic cells, which appear to represent a major source of 
LTβ, as well as lymphoid chemokines CXCL13, CCL21 and CCL19, particularly 
at later stages of infection and after viral clearance [58]. Importantly, ectopic GC 
in the iBALT of Influenza virus-infected mice promote the in situ differentiation of 
virus-specific (i.e. anti-nucleoprotein) plasma cells [58]. Even more importantly, 
bronchial TLS are required for the maintenance of systemic humoral antiviral 
immunity, as demonstrated by the reduced titres of serum hemagglutinin-
inhibiting antibodies and the lower number of nucleoprotein-specific plasma cell 
numbers in the bone marrow of mice in which the formation of iBALT was 
ablated [58]. In keeping with a non-redundant role of the iBALT in this model, 
LTα-deficient mice, which lacks conventional SLO, are still capable of 
developing functional TLS and express lymphoid chemokines at levels 
comparable to their wild-type littermates [90],[91]. Additionally, bronchial TLS 
are sufficient in promoting antiviral immunity, as demonstrated by the 
generation of protective titres of virus-specific circulating IgM and IgG, and are 
also capable of producing and maintaining immunological memory upon re-
challenge [43]. Overall, the above evidence strongly supports the conclusion 
that the formation of TLS, particularly at permissive mucosal sites, is required 
and sufficient to promote protective immunity over and above SLO, thus directly 
contributing to immune surveillance and viral clearance.  
 56 
1.1.7.2 Virus-induced tertiary lymphoid structures as a bridge to 
autoimmunity 
Hepatitis C virus (HCV) infection-induced TLS formation is one of the best-
characterised examples of ELN following chronic infection. A striking feature of 
HCV infection and of the subsequent chronic hepatitis that develops in 80% of 
the cases, is that HCV itself is not a cytolytic virus and that viral replication can 
be detected in patients where liver damage is absent while tissue damage is 
largely dependent on the immune reaction towards the pathogen [92]. 
Moreover, the formation of lymphoid infiltrates in chronic HCV infection, the 
intraportal lymphoid follicles, has long been known as a hallmark of the disease 
[93]. Murakami and colleagues showed that B cells in the intrahepatic follicles 
display markers of a GC response further supporting the hypothesis that these 
structures represent inductive sites for B cell antigen-driven differentiation [94]. 
Accordingly, clonally-related intrahepatic CD4+ T cell were found to react 
specifically with HCV epitopes and significantly more efficient in promoting an 
IgA antibody response when cultured with B cells in comparison with T cells 
isolated from peripheral blood of the same patients [95]. Thus, antigen-specific 
T cell priming is likely to take place within intrahepatic TLS. This is of particular 
importance as a prompt and potent T cell response from HCV-specific CD4+ 
helper and CD8+ cytotoxic T cells, in the context of selective HLA alleles have 
been linked to viral control and clearance [96] [97]. Conversely, despite the 
evidence of B cell activation, the humoral response by itself seems unable to 
fully protect from HCV infection as re-inoculum of the virus in chimpanzees 
elicits a new viremia in the presence of neutralizing anti-HCV antibodies [98]. 
The mechanisms leading to lack of viral clearance and the establishment of 
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chronic HCV infection are still largely undefined despite intensive investigations 
focusing both on viral mechanisms of escape of immune surveillance as well as 
defective anti-viral immune responses [99], but it is clear that intrahepatic TLS 
play a central role in regulating complex viral-host interactions. In fact, lack of 
viral clearance progressively leads to chronic B cell activation within TLS that, in 
a subset of HCV+ patients, contributes to the development of extra-hepatic 
manifestations and autoimmunity, manifested as mixed cryoglobulinemia (MC). 
Type II cryoglobulins are monoclonal IgM that precipitates at low temperatures 
and display rheumatoid factor activity and can give rise to systemic 
manifestations such as cutaneous vasculitis and glomerulonephritis. 
Interestingly, despite this deregulated antibody production, HCV+ patients with 
MC show a decrease in the total number of B cells. In a recent study, this 
phenomenon has been attributed to an increased tendency of naïve B cells to 
die of apoptosis. According to this hypothesis, to maintain B cell homeostasis 
more immature B cells are produced by the bone marrow [100]. Moreover, and 
in addition to the monoclonal B cell activation in MC, the IgM memory B cell 
subset is expanded in a polyclonal fashion in HCV patients with MC and 
analysis of the Ig genes in these expanded clones showed level of SHM 
suggestive of Ag-driven selection. Furthermore, some of the clones showed 
self-reactivity further supporting the idea that HCV chronic infection can 
influence tolerance mechanisms, allowing the expansion of autoreactive B cell 
clones [101] [97] .  
Finally, two more evidences strongly support a link between HCV infection and 
a deregulation of the B cell behaviour in the context of TLS. In particular, one of 
the core proteins encoded by the HCV genome has been shown to interact with 
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the cytoplasmic tail of LTβ-receptor [102]: the effect of this interaction, far from 
being completely elucidated, could be a constant activation of the LTβ pathway 
in the infected cells. To support this hypothesis, there is evidence that 
cryoglobulinemia in HCV+ patients is closely associated with serum and lesional 
levels of CXCL13 [103]. This suggests that intrahepatic evolution from a 
polyclonal to an oligo- and then monoclonal autoreactive B cell activation is a 
result of chronic antigenic stimulation taking place within TLS. 
1.2 Sjögren’s syndrome as a model disease of ectopic lymphoid 
neogenesis in mucosa 
The Swedish ophthalmologist Henrik Sjögren in 1932 described a disease 
characterised by xerostomia (dry mouth), keratoconjunctivitis sicca (dry eyes) 
and RA. That disease became known worldwide as Sjögren’s Syndrome.  
SS is a chronic autoimmune disease that affects mainly exocrine glands, 
salivary (SG) and lachrymal, and eventually leads to glandular dysfunction. 
Falling in the category of autoimmune disease, SS patients produce 
autoantibodies and might be affected by several extra-glandular systemic 
features [104].  
SS can present alone (primary SS, pSS) or in association with other 
autoimmune rheumatic diseases (secondary SS, sSS). The prevalence of pSS 
in the general population is approximately 0.5-1%, while sSS appears in 
approximately 30% of the patients affected by other autoimmune diseases 
[104].  
Despite the presence of important extra-glandular manifestations, SS is a 
tissue-specific autoimmune disease. The exocrine glands, in particular the SG, 
represent a very interesting tissue: “frontier” to the body, not only they are a 
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natural barrier, but being located in the oral cavity they also are in continuous 
contact with commensal and pathogenic microorganisms. Furthermore, SG 
have to fulfil their physiological function of saliva production and systemic 
regulation of nitric oxide (NO) levels [105],[106].  
As we will discuss in depth in the next sections, one of the clinical signs of SS is 
the presence of lymphocytic infiltration in the salivary and lachrymal glands that 
often organises in fully formed TLS.  
Several pathogens have been regarded as triggers for SS development and 
although this issue is still controversial, recent evidences point towards a role 
for chronic infection of the SG mucosa. 
Because of their involvement in host-pathogen interaction and as target-organ 
of autoimmunity, SG represent an ideal tissue where to conduct studies on both 
these aspects and the potential combined and reciprocal effects of infection and 
autoimmunity. 
1.2.1 Sjögren’s syndrome: definition and clinical manifestations 
Even if SS can manifest at various ages and in both sexes, the female-to-male 
ratio is 9:1 and middle-aged women are primarily affected. As indicated above, 
prevalence of SS is approximately 0.5-1% and thus SS is considered one of the 
most common autoimmune diseases.  
There is little epidemiology for SS outside Europe, North America and some 
countries of Asia: the highest prevalence of the disease is found in northern 
Europe, but comparable percentages are observed in North America and 
mainland Europe while the lowest rates have been observed in Asia [107] 
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Figure 1.6: Sjögren’s syndrome diagnostic criteria. Reprinted from [107], 
Copyright 2010, with permission from Elsevier. 
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The ductal epithelium appears to be the main target of the inflammatory 
autoimmune process. Because epithelia from other exocrine glands, other than 
the salivary and lachrymal, can be affected during the disease, some authors 
define SS as an “autoimmune epithelitis” [108].   
SS patients complain of dry mouth and dry eyes, the so-called sicca syndrome, 
one of the main hallmarks of disease. Xerostomia causes difficulties in 
swallowing, taste alterations and often dental caries, mucositis and candidiasis 
[109]. As a consequence of an insufficient lachrymal flow, patients develop 
keratoconjunctivitis sicca. It is still debated whether these glandular 
dysfunctions are caused by a disruption of the gland parenchyma or by an 
interference, supposedly caused by autoantibodies, with the neurological stimuli 
(i.e. acetylcholine acting on muscarinic receptors) that induce saliva and tear 
secretion [109]. 
As reported above, SS also can present extra-glandular features. A high 
percentage of patients report musculoskeletal manifestations, and articular 
symptoms develop in 1/3 of the patients before the appearance of the sicca 
syndrome. Myalgia is often present, and frequently associated with fatigue. The 
articular involvement is symmetric and often polyarticular: mono-oligoarticular 
features only appear early in the course of disease [109]. Typically, arthritis in 
pSS is non erosive, while an erosive disease develop in sSS associated with 
RA. 
For a haematological point of view, SS can present a series of abnormalities 
with different prevalence in various populations, among which anaemia, 
lymphopenia, gammopathies and lymphoproliferative disorders [110]. Skin 
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xerosis and, less frequently, vasculitis, urticarial vasculitis and annular lesions 
can be observed [109],[111]. 
Peripheral neuropathies and at a less extent central nervous system 
manifestations are observed [109]. 
Respiratory system signs, nasal bleeding, hyposimia, xerotrachea and bronchial 
hyperactivity can affect a vast percentage of SS patients [112].  
Dysphagia and oesophageal dysmotility can be observed as a consequence of 
the broad involvement of the glandular epithelium of the gastrointestinal tract 
[113]. For similar reasons, SS patients might develop acute pancreatitis, and 
other pancreas symptoms, as the exocrine component of this organ can also be 
a target of the disease [114]. Also in terms of mucosal dysfunction, 
gynaecological symptoms are often reported, again due to dryness and 
development of infection as a consequence of impaired vaginal exocrine gland 
secretion [109]. 
The liver of SS patients is seldom affected by chronic active hepatitis with portal 
fibrosis and periductal involvement [114],[115]. Interestingly, as insurgence of 
sicca has been associated with liver manifestations during the course of HCV 
and HCV has a particular tropism for the SG, HCV infection is an exclusion 
criterion for SS diagnosis [116]. I will discuss in more details the specific role of 
viral infections and HCV in SS in section 1.2.5. 
Renal involvement is also observed but is not one of the most common effects 
of SS. Reported symptoms are: renal tubular acidosis, glomerulonephritis (rare), 
mild proteinuria (common) and defects in urine concentration. Kidneys 
manifestations have been ascribed to the presence of anti-tubular antibodies or 
to lymphocyte-mediated tissue damage [109]. 
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SS can frequently appear along other autoimmune diseases, the most common 
being Hashimoto’s thyroiditis and coeliac disease [117].  
The most important and serious complication of SS is the development of 
malignancies, in particular MALT-lymphoma of the salivary glands. MALT-
lymphomas develop in approximately 5% of pSS, they are mainly non-Hodgkin 
B cell lymphomas arising usually in the parotid glands and the presence of 
lymphoma represent the major factor contributing to SS morbidity and 
increased mortality [118].  
1.2.2 Aetiology and immunobiology of Sjögren’s syndrome 
SS certain aetiology is still not completely understood. As a complex disease, 
the causes of SS insurgence are multiple: genetic background, immunological 
abnormalities and pathogens play a major role in aetiology, but gender and 
other environmental factors are likely also important [104].  
Early analysis of the major histocompatibility complex genes reveals a high 
association of certain histocompatibility antigens (such as HLA DRB1*03 and 
DQB1*02) with the production of the classic SS antibodies, anti-Ro/SSA and 
anti-La/SSB [119],[120]. These observations have been confirmed and 
expanded in more recent genome-wide association studies (GWASs) 
[121],[122] that have also found strong disease associations in single-
nucleotide polymorphisms (SNPs) present in the interferon pathway and certain 
NK cells receptor genes (discussed in more details in section 1.2.5.1) [123]. 
Taken together, these observations reveal that susceptibility loci can be found 
in genes regulating both the innate and adaptive arms of immune system.  
Several viral infections have been claimed to be relevant for development of 
SS. To date no clear correlation between a specific pathogen and SS has been 
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found and the topic is one of the most controversial in the field of SS and in 
general in the debate about autoimmune diseases. I will discuss old and new 
piece of information regarding the relative involvement in SS pathogenesis of 
HCV, Epstein-Barr Virus (EBV), human T-lymphotropic type-I virus (HTLV-I), 
Coxsackie virus and cytomegalovirus (CMV) in section 1.2.5. 
 
In the diagnosis of SS, together with the presence of circulating autoantibodies 
directed against the ribonucleoproteins Ro/SSA and La/SSB, one of the 
hallmarks of the disease, and an essential criterion to be met for classification, 
is the presence of a positive histopathology in the minor salivary glands. In SS 
the typical inflammatory infiltrate affecting the SG is the formation of at least 
one aggregate of more than 50 lymphocytes per 4 mm2 of glandular tissue, 
called focus [116],[124]. The majority of the data describing these inflammatory 
foci derives from studies on minor and major salivary glands and this is mainly 
because the disease commonly affects these tissues but also because they can 
be easily taken with minor surgical procedures (in particular the labial SG 
biopsies).  
Anatomically, SGs are divided in major and minor: parotid, submandibular and 
sublingual glands belong to the former, labial, buccal and palatine to the latter. 
Blood and lymphatic vessels, but also nerves, intercalate the parenchyma of the 
glands, composed of acini and ducts. The acini are the basic secretory 
components and they can be serous, mucous or mixed. Histologically they are 
a single layer of cuboidal epithelium secreting the various components of saliva 
into a central lumen. Intercalated ducts proceed from the acinar units and join in 
striated ducts: the epithelium of the latters is responsible for the transformation 
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of the saliva into a hypotonic solution thanks to active and passive ion 
transporters. In turn striated ducts terminate into interlobular or secretory ducts 
that collect from the various lobes of the SGs and open in the mouth. 
Myoepithelial cells surround intercalated ducts and acini and are connected with 
both the sympathetic and parasympathetic nervous system that regulate saliva 
secretion [125].  
Typically the SS infiltrate is organised around the excretory ducts (mostly at the 
level of intercalated ducts) and the diagnostic parameter used to classify it in 
SS is the Chisolm and Mason score.  The diagnosis is positive for SS with at 
least a focus score. A more detailed description of the immune infiltrate is given 
in the section 1.2.3. 
 
As briefly mentioned above, the epithelium plays a pivotal role in SS, that lead 
some authors to define the disease as an “autoimmune epithelitis” also because 
of the involvement of epithelia other than that of SGs in the pathology [108]. SG 
epithelial cells from SS express mRNA for lymphoid chemokines, suggesting 
that this cell type might be among the first to produce chemotactic clues for B 
and T cell recruitment to the gland [126]. Furthermore, SS ductal epithelial cells 
derived from patients and cultured in vitro retain the expression of costimulatory 
molecules (e.g. CD80/86 [127], CD40 [128] and HLA-DR/DP/DQ [129]). Also, 
the expression of adhesion molecules has also been demonstrated both in 
histology and in cultured epithelial cells from SS SGs [130]. Moreover, Th1 
cytokines mRNA levels were higher in SS patients and those cytokines, when 
added to cultured SG epithelial cells from patients, augmented their expression 
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of HLA and adhesion molecules [130], suggesting that epithelial cells can 
function as APCs.  
Furthermore, elevated expression of Fas and Fas ligand in ductal epithelium 
suggests an increased apoptosis rate in SS SGs [131]. Interestingly, some of 
the typical autoantigens of SS, i.e. Ro-SSA and La/SSB, are expressed in 
apoptotic blebs [132] and thus an amplified presence of apoptotic bodies and 
self-antigens in an environment prone to favour an adaptive immune response 
might be partially responsible for breach of self tolerance leading to the initiation 
and perpetuation of the autoimmune process. Nevertheless, it is important to 
stress that, given the importance of pathogens in SS, it is still unclear whether 
SG epithelial cells involvement in the disease has a primary pathogenic role or 
it is merely a secondary effect to pathogen infection and the subsequent 
immune response.  
1.2.3 Ectopic lymphoid neogenesis in Sjögren’s syndrome 
The immune infiltrate present in SS SGs is composed mainly of 
lymphomonocytic cells, in particular B and T lymphocytes. T cells are mainly of 
the CD4+/CD45RO+ phenotype. CD8+ T lymphocytes are also present at a 
lesser extent and preferentially localised around the acinar units where they 
probably contribute to the glandular damage and the loss of salivary function via 
the secretion of granzyme/perforins [133]. B cells are also present and their 
number increases with the development of the inflammatory infiltrate, thus it is 
more likely to observed higher frequencies later in the disease course [134].  
Members of my group and other groups have demonstrated that the expression 
of lymphoid chemokines CXCL13 and CCL21 is closely associated with the 
progressive acquisition of lymphoid features in SS SG such as T/B cell 
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segregation and FDC networks development [31]. However, expression of both 
CXCL13 and CCL21 in SS did not require the full development of TLS 
suggesting that lymphoid chemokines act upstream to this process [31]. In the 
SS SG, CXCL13 and CCL21 retained an expression pattern highly reminiscent 
of SLO, with CXCL13 confined to the B cell-rich areas and CCL21 expressed in 
the surrounding T cell area (i.e. mainly produced by perivascular cells in close 
association with HEV [21],[135]). Of relevance, in SS patients with TLS, both 
resident cells and infiltrating immune cells produce lymphoid chemokines. 
Among infiltrating cells, CD68+ macrophages and CD3+ T cells have the 
capacity to produce CXCL13 within TLS [136] as previously described in the 
rheumatoid synovium [65],[136]. Conversely, among non-lymphoid cells, ductal 
epithelial cells can be an important source of CXCL13, CCL19 and CCL21, 
together with CXCL12, as shown by in situ hybridization and 
immunohistochemistry [32],[126]. Additionally, my laboratory and others 
showed that stromal reticular-like cells within inflammatory foci and endothelial 
cells can express CXCL13, although CXCL13 expression in blood vessels is 
likely the result of transcytosis rather than primary production [30],[135]. Finally, 
a recent study found an association between genetic variants in the Ltα/Ltβ/TNF 
family and SS insurgence, again highlighting the role of the whole 
lymphotoxin/lymphoid chemokines axis in the generation of TLS in SS [137]. 
Thus, it appears that the interaction between resident (i.e. epithelial and stromal 
cells) and infiltrating immune cells of both the innate and adaptive immune 
system contributes to trigger lymphoid neogenesis in the SG, although the 
exact hierarchical series of cellular and molecular events underlying this 
process are yet to be elucidated.  
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More observations coming from others and our group also provided evidence 
that the TLS arising in SS SG are likely to be functional and support B cell 
activation and differentiation [38] and are critically implicated in disease-specific 
autoimmunity. In support to this hypothesis, hypermutation is observed in the 
immunoglobulin genes of B cells present in highly organised TLS [138]. 
Furthermore, these B cells can be autoreactive and produce autoantibodies 
such as anti-Ro/La [32],[139],[140] and in general higher titres of G 
immunoglobulins, rheumatoid factor and anti-Ro/La are observed in SS patients 
positive for GC markers in comparison to patients devoid of these structures 
[141]. A more conclusive evidence of GC functionality in SS SGs comes from 
the observation that the enzyme AID, necessary for the CSR and SHM 
processes, is invariably expressed in the foci with features of SLO and 
expression of FDC network markers [38].  
Finally, there is now strong evidence that the presence of TLS in the SG of SS 
patients is an important biomarker of a more severe disease associated with 
extraglandular manifestation and evolution towards B cell lymphoma of the 
MALT [38],[136],[142],[143].  
1.2.4 Autoantibodies 
Antibodies directed towards the ribonucleoparticles Ro and La, two self-
antigens, have been historically considered the classic SS autoantibodies, 
despite being also found in systemic lupus erythematosus (SLE) patients. SS 
also present in their circulation anti-nuclear antibodies (ANA), RF, type II 
cryoglobulins and to a lesser extent anti-mitochondrial, anti-centromere and 
anti-smooth muscle antibodies [144]. Another set of autoantibodies is present in 
SS and the members, anti-α-fodrin, anti-carbonic anhydrase II and anti-
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muscarinic acetylcholine receptor 3 (M3R), have been variously described, 
albeit not conclusively, as pathogenic and able to affect exocrine function 
[144],[145].  
The ribonuceloparticles (RNP) Ro and La are complexes composed of proteins 
(Ro 52kDa, Ro 60 kDa and La 48 kDa) and small uridine-rich hY RNAs  (human 
cytoplasmic RNAs) that are 85-112 nucleotides-long RNA polymerase III 
transcripts [144],[146]. Ro60 protein seems involved in post-transcriptional 
modification of RNA polymerase III transcripts, while Ro52 is involved in 
ubiquitination [144],[146]. The phosphoprotein La is a regulator of all RNA 
polymerase III transcripts and it is also capable to bind to several viral RNAs 
[144],[146]. Anti-Ro/SSA and anti-La/SSB autoantibodies are unable to 
recognise the isolated small RNAs without the presence of Ro and La proteins. 
These autoantibodies are found in approximately 60% (anti-Ro) and 40% (anti-
La) of SS patients, most commonly in combination, while anti-La are very rarely 
found alone [144],[146].  
Muscarinic receptors are acetylcholine G-protein-coupled seven-
transmembrane domain receptors, they are classified in 5 subtypes (M1-M5) 
with M3R being involved in particular in endocrine and exocrine glands 
secretion, smooth muscle contraction and endothelial cells calcium regulation 
[147]. Acetylcholine stimulation of M3R in the acinar cells of the SGs induces a 
change in intracellular calcium concentration that in turn leads to activation of 
membrane channels that secrete sodium and chlorine ions in the lumen of the 
acini. This in turn osmotically drags water in the lumen for the formation of 
saliva [147]. Among the autoantibodies characteristic of SS, anti-M3R 
antibodies have been claimed to be pathogenic and one of the main causes of 
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sicca syndrome as they can interfere with the influx of calcium in response to 
acetylcholine, thus impairing saliva production and secretion. In particular, one 
of the most important observations is that sera from SS patients and from 
experimental mouse models of SS were able to induce salivary hypofunction 
when injected in mice devoid of B cells, and a similar effect was obtained when 
injecting monoclonal antibodies to M3R in immunodeficient mice [147]. 
Unfortunately, at the moment there is no gold standard for the detection of anti-
muscarinic receptor 3 antibodies in the blood of SS patients and up until such 
an assay is available for clinical use there will be controversies about the real 
presence and pathological role of such antibodies, making it difficult to correlate 
epidemiologic data in order to understand whether or not this class of 
autoantibodies designates a specific subtype of SS patients.   
SS patients can also develop autoantibodies against α-fodrin, the main cortical 
cytoskeleton component of eukaryotic cells. This observation was first made in 
a mouse model of SS and extended to human patients [145]. Antibodies against 
α-fodrin [148] can be found in 55-64% of pSS and 40-86% of sSS. α-fodrin has 
been associated with apoptosis and in particular its abnormal externalisation in 
apoptotic salivary gland cells has been reported [149]. The granzyme-B 
enzyme, pivotal in the CD8+ T cells cytotoxic process, can also cleave α-fodrin 
and M3R present in salivary gland epithelial cells, thus producing novel 
epitopes and potentially boosting the process of breach of tolerance towards 
common self antigens [150]. To support this hypothesis, another study found a 
novel cleaved form of α-fodrin which was recognised by autoantibodies present 
in around 25% of patients enrolled within a sizeable cohort of American SS 
patients [151]. Finally, EBV reactivation, that has also been recently associated 
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with SS as discussed in section 1.2.5.2, induces an increase in caspase activity 
and as a consequence an abnormal production of α-fodrin proteolysis [152]. 
1.2.5 Chronic viral infection in Sjögren’s syndrome 
Several groups have investigated whether the SG of SS patients display an 
aberrant expression of sialotropic viruses capable of triggering autoimmunity as 
a result of a persistent chronic infection. In this section I shall first review 
indirect evidence that the type I (and type II) interferon pathways, critically 
involved in anti-viral immunity, are aberrantly activated in SS patients; I shall 
then summarize the evidence in support of (or against) the role of viruses in SS 
over the last 30 years.  
1.2.5.1 Evidence of aberrant type I and type II interferon activation in SS 
patients  
If viruses were etiological agents, or at least significant contributors to the 
pathogenesis of SS, in the presence of persistent viral infections one would 
expect circumstantial signs in support of the activation in the SS SG of critical 
immune-defence mechanisms regulating viral infection in physiological 
conditions. In this regards, type I (IFN-I) and type II (IFN-II) interferons are 
critically involved in host protection from viral pathogens via their ability to inhibit 
viral replication, promote DC maturation, enhance NK and CD8+ T cells 
cytotoxicity, induce phagocytic activity in macrophages and favour B cells 
survival and antibody production [153]. In keeping with this scenario, IFN-
regulated genes have been found differentially expressed in SG biopsies from 
SS versus controls [154] and in IFN-stimulated SG epithelial cells from SS 
patients IFN-related gene transcripts were more abundant in comparison with 
controls [155]. Plasmacytoid dendritic cells (pDC) are the main producer of 
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type-I interferon in response to microbial stimuli [156] and interestingly pDCs 
have been found in biopsies from SS SGs but not in control specimens [155]. 
Moreover, around 50% of SS patients, but not healthy controls, displayed 
detectable plasma levels of IFN-α and peripheral-blood mononuclear cells 
(PBMC) from SS patients had a significantly higher expression levels of IFN-α 
compared to controls [157]. More recently, Brkic and colleagues demonstrated 
that circulating monocytes from pSS patients with an upregulated expression of 
IFN-related genes, the so-called type-I IFN signature, had a higher disease 
index score and higher levels of circulating autoantibodies. Interestingly, the 
serum from this SS sub-group of patients was capable of inducing in cultured 
monocytes the expression of BAFF [158], a cytokine member of the TNF family 
which acts as a pivotal regulator of B cell survival and activation and  has been 
strongly linked with B cell dysregulation in SS [159]. Interestingly, BAFF can 
also be induced in vitro in ductal epithelial cells by the synthetic double-
stranded RNA (dsRNA) analogue and by the Toll-like receptor 3 (TLR-3) ligand 
poly(I:C) as well by viral dsRNA [160]. 
This excessive activity of type-I interferons in SS, and more in general in 
autoimmunity, has been ascribed to several causes, such as the activation of 
pDCs in various autoimmune diseases, the lack of a tight regulation of pDC 
activation in susceptible individuals and the observation that many 
autoimmunity-associated risk genes are in the IFN-I signalling pathway [153]. 
From this perspective, since persistent viral infection of SG does not lead per se 
to autoimmunity in normal individuals, it is conceivable that in SS patients the 
abnormal IFN-I response may be related to genetic susceptibilities conferred by 
variability within interferon-related genes. In this regard, single nucleotide 
 73 
polymorphisms (SNPs) in two genes involved in type-I IFN signalling, IRF-5 and 
STAT4, have been found associated with a higher risk to develop SS both in 
case control studies [161],[162] as well as a recently published genome-wide 
association study (GWAS) [121]. More recently susceptibility for SS 
development has also been found in the type-II interferon (IFN-γ) pathway 
whereby a significant association was found between the rs11575837 SNP in 
the promoter region of the NCR/NKp30 gene and SS [123]. This SNP confers a 
protective effect in terms of SS development and was associated with a 
reduced production of IFN-γ in NK cells upon NKp30 stimulation in comparison 
to individuals who did not carry the rs11575837 SNP. 
Overall, the above observations strongly suggest that a genetic background 
particularly susceptible to IFN-related genes activation upon viral infection might 
predispose to SS development.  
1.2.5.2 Epstein-Barr virus (EBV) 
EBV is a B lymphotropic herpesvirus capable of establishing an asymptomatic 
life-long infection and can cause infectious mononucleosis. EBV infects most of 
the world population and its characterized by an active lytic cycle during which 
the virus duplicates and propagates and a latent cycle when the virus remains 
silent in B cells [163]. EBV latency is maintained by the expression of a limited 
set of proteins including the main latency proteins LMP1 and LMP2A which 
mimic the signalling properties of CD40 and the B-cell receptor, respectively, 
and regulate activation, growth, and survival of the infected B cells in the 
absence of cognate antigen [164]. Interestingly, while in vivo EBV tends to 
switch to and stay in the latent cycle with temporary activation flares of the lytic 
program, in vitro it induces B cell transformation, leading to activation, 
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proliferation and expansion [165], the same process that in vivo may lead to B 
cell malignancies such as Hodgkin’s and Burkitt’s lymphoma [166]. As other 
viruses, EBV uses mucosal tissue to disseminate from infected individuals. Due 
to its tropism for the SG and the capacity to preferentially infect B cell, it is not 
surprising that EBV has attracted significant interest aimed at investigating 
whether the SG of SS patients display dysregulated EBV infection and 
persistence. Despite extensive studies, in SS there is significant controversy 
regarding whether EBV is implicated in disease pathogenesis. There is also 
conflicting evidence regarding the expression of EBV proteins/nucleic acids in 
SS-SG compared to sicca or healthy controls. Several studies have reported 
increased EBV expression in SS patients compared to sicca controls [167]-
[173], while others failed to observe differential expression in SS SG [174]-
[176].  
Interestingly, B cell lines obtained from SS patients were shown to be more 
efficient in producing transforming EBV in comparison with non-SS controls, 
suggesting a more frequent reactivation of EBV lytic cycle in SS patients 
[169],[170]. When comparing EBV reactivation in SS to other autoimmune 
diseases with a known B cell involvement, it was shown that B cells from 
peripheral blood of SS patients were more efficient than the same subset from 
RA and SLE patients in EBV production [177], suggesting that the polyclonal 
activation of B cells in SS patients may somehow be correlated with the 
presence and activation of EBV.  
Together with EBV-induced B cell activation, other mechanisms, such as 
molecular mimicry, have been implicated in support of a role of EBV in 
contributing to breach of self tolerance and development of autoimmunity in SS. 
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Molecular mimicry implies that a microbial epitope structurally similar to a self-
antigen could be processed via the major histocompatibility complex (MHC) and 
presented to T cells, thus activating auto-reactive clones that escaped the 
selection process [178]. In the case of EBV, several examples of possible 
molecular mimicry between SS auto-antigens and viral proteins have been 
demonstrated, although the impact of such mechanisms in contributing to 
autoimmunity and chronic inflammation has not been formally demonstrated. 
Interestingly, anti-Ro/La autoantibodies can precipitate protein antigens linked 
with EBV-encoded small RNA (EBERs) [179] while the EBV transcriptional 
transactivator EBNA1 mimics Ro52 [180]. Additionally, EBV can induce the 
cleavage of α-fodrin [152], a cytoskeletal molecule that is cleaved during 
apoptosis into the antigenic 120kDa form which is a target of autoantibodies 
found in SS sera, as described in more details in section 1.2.4 [145]. Finally, 
screening of a random peptide library with sera from SS patients allowed the 
isolation of a specific peptide which is targeted by circulating autoantibodies in 
SS patients with shared homology between an EBV early antigen, α-fodrin and 
tear lipocalin, a molecule found in tears and saliva [181]. Thus, EBV may play a 
role in SS development via different mechanisms: B cell reactivation, 
persistence and immune evasion in epithelial cells, induction of apoptosis and 
consequent unmasking of cryptic antigens that could lead to the activation of 
self-reactive T/B cells through molecular mimicry.  
1.2.5.3 Human T-lymphotropic virus Type 1 (HTLV-1) 
During the 1980s two different observations lead to the association of the 
human T-lymhpotropic virus 1 (HTLV-1) and SS. HTLV-1 is a T lymphotropic 
retrovirus responsible of some forms of T-cell acute leukaemia and tropical 
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spastic paresis. The first observation was a case report of HTLV-1 patients with 
tropical spastic paresis, who also showed features of SS [182].The second 
observation came from a transgenic mouse model expressing a HTLV-1 gene, 
tax, that manifested SG exocrinopathy and lymphocytic infiltration resembling 
SS [183]. Following these initial discoveries, further investigations focused on 
the possible link between HTLV-1 retrovirus and SS development, in particular 
in those regions endemic for HTLV-1, such as Japan and Caribbean Islands. 
The first studies demonstrated that HTLV-1-infected SS patients were 
characterised by a stronger peripheral blood mononuclear cell proliferation and 
increased rated of extraglandular manifestations [184]. In the same period, 
another group showed that SS biopsies were positive for a protein encoded by 
the viral gene gag, also in individuals seronegative for HTLV-1 antibodies. This 
allowed to speculate over the presence of an endogenous retrovirus in SG 
epithelial cells, capable of inducing chronic inflammation in SS [185]. Mariette et 
al. found, by in situ hybridization, a positive signal for tax gene in SG biopsies of 
SS patients without any detectable antibodies to HTLV-1 [186] and similar 
results were found in Japanese SS patients by Sumida et al. [187]. More 
recently, Lee et al. replicated the same observations and hypothesised that 
patients with HTLV-1-associated SS might represent a distinct clinical subgroup 
from idiopathic SS patients, with different serological features and magnitude of 
lymphocytic infiltration [188]. Ohyama and colleagues found in the infiltrated SG 
of HTLV-1-infected SS patients that T cells, but not acinar or ductal cells, were 
positive for HTLV-1 proviral DNA while viral loads were higher in SG in 
comparison to PBMCs obtained from the same patients. Thus, HTLV-1 infection 
in the peripheral compartment and/or in the affected tissue might directly 
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activate autoreactive T cells while the SG microenvironment might be 
permissive for the homing, rescuing from apoptosis and proliferation of HTLV-1-
infected T cells [189]. Recently, another Japanese group confirmed the 
association between HTLV-1 infection (by anti-viral serum antibodies) and the 
presence of SS in a large cohort of Japan patients [190]. Importantly, when 
considering other geographic areas where HTLV-1 is not endemic, the 
correlation between the presence of anti-HTLV-1 antibodies in serum (or 
positive PCR signal for HTLV-1 genome) and presence of SS is lost [191]. 
1.2.5.4 Coxsackieviruses 
Among all the viral infections that have been associated with SS insurgence, a 
special consideration has to be dedicated to the recently hypothesised role of 
Coxsackieviruses in the development of this disease, as this class of viruses do 
not show particular tropism for any immune system cell nor for SG tissue. 
Coxsackieviruses are enteroviruses belonging to the picornaviridae family, 
capable to infect different tissues and leading to acute manifestations, even if 
recent evidence shows that establishment of a persistent infection is also 
possible (reviewed in [192]). In 2004, Triantafyllopoulou et al. noticed, using a 
differential display technique, that specimens from primary SS patients showed 
a band that was not present in controls and secondary SS samples and that 
was identified as P2A, a protein synthesized by Coxsackie virus B4 strain [193]. 
Triantafyllopoulou and colleagues showed that Coxsackie virus strains B4 and 
A13 genomes were present in biopsies of primary SS patients but not in 
controls, and when they stained minor SG with an antibody against the viral 
capsid particle VP1, they detected a positive signal in the B cell area of the 
infiltrates and in the ductal epithelial cells [193]. Further analysis on the 
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peptides encoded by the Coxsackie viral genome lead to the identification of a 
homology between the protein sequences of viral particle P2B and the Ro60 
epitope (one of the epitopes towards which SS patients more often develop 
autoantibodies). When testing reactivity of sera from SS patients and controls 
against these peptides, Stathopoulou and colleagues showed that anti-Ra and 
anti-Ro/La SS sera, but not control sera, reacted with both P2B peptide and 
Ro60 and the autoantibodies isolated with the Ro60 peptide were capable of 
reacting with the viral peptide [194], further supporting the hypothesis that 
molecular mimicry may play a very important role in driving autoimmune 
reactions specially in the context of persistent infections.  
Although significant emphasis was generated by the above data, Gottenberg et 
al. failed to replicate those observations in a French cohort of SS patients using 
the same PCR technique [195]. A possible explanation for such discrepancy 
might be related to different epidemiology of enteroviruses in different 
geographical regions, as also observed for enteroviral infections and the 
development of autoimmune diabetes [196], although also different genetic 
susceptibility in diverse ethical cohorts might account for such discrepancies. 
1.2.5.5 Cytomegalovirus (CMV) 
Similar considerations to the other viruses can be extended to human CMV 
infection and SS. As for EBV, controversial issues arise when considering this 
virus as a possible etiological agent of the disease. Around 70-90% of the world 
population has encountered CMV and the quest for the detection of CMV 
genome in the SG of SS patients and non-immune sicca patients invariably lead 
to the detection of the viral genome in both groups [168]. CMV is probably one 
of the most well-studied viral pathogens and we know that the virus has several 
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different strategies to evade the immune system surveillance [197] [198]. 
Moreover, specie-specific CMV viruses exist for rodents and primates, allowing 
the use of a wide range of animal models.  
One of the most striking and conserved CMV evasion mechanism is the 
production of a viral homologue of interleukin 10 (IL-10) [199]. IL-10 is a pivotal 
anti-inflammatory cytokine involved in a plethora of immunomodulatory 
processes, such as the inhibition of inflammatory cytokines production (e.g. IL-
2, TNFα, IFN-γ), induction of antibody production by B cells, down-regulation of 
allergic reactions, etc. [200]. Despite a low sequence homology, cmvIL-10 can 
compete for IL-10 receptor complex and it is capable to activate the IL-10 
signalling pathway. The evolution of an IL-10 homolog has been proven to be 
important in CMV infection and in the ability of the host to clear the pathogen; 
accordingly, rhesus macaques infected with specie-specific strains of CMV 
which where engineered to express or deplete cmvIL-10 showed that the viral 
version of the cytokine was required to dampen both the innate and adaptive 
immune response and establish a successful systemic infection [201].  
Perhaps the most interesting piece of information about a role of CMV in SS 
development comes from animal studies. In mice, the lpr mutation impairs the 
Fas mediated apoptotic pathway. The effects of lpr/lpr mutation varies greatly 
from strain to strain and, on a C57Bl/6 background, the mutation induces a mild 
autoimmunity late in the animals’ life, mainly involving kidneys but not SG. Fleck 
et al. showed that intra-peritoneal injection of murine CMV in C57Bl/6 wild type 
and lpr/lpr mice lead to the development of acute sialoadenitis and SG 
infiltration in both genotypes, but in the lpr/lpr animals it also lead to the 
development of anti-Ro and anti-La antibodies, the most typical autoantibodies 
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associated to SS [202]. It is noteworthy the fact that this is the only SS model 
capable to develop anti-Ro/La antibodies, as in the NOD model, one of the 
standard SS murine models, only a small percentage of the animals develop 
anti-Ro antibodies and anti-La antibodies are undetectable [203]. Interestingly, 
in the rat variant of CMV infection the virus is present and replicates exclusively 
within a specific class of salivary gland epithelial cells, the striated duct cells, 
leaving largely uninfected the acinar and other ductal cells [204]. 
1.2.5.6 Hepatitis C virus (HCV) 
HCV is a single stranded RNA virus, member of the family of Flaviviridae. HCV 
is a blood-borne pathogen that can establish a chronic infection in the liver in 
80% of HCV-infected individuals. Not only HCV-induced TLS are likely to be 
involved in hepatotoxicity, but chronic B cell activation within liver TLS can, in a 
subset of HCV+ patients, contributes to the development of extra-hepatic 
manifestations and autoimmunity, manifested as mixed cryoglobulinemia [103].  
Although HCV is an exclusion criterion for SS [116], in a sizeable proportion of 
HCV+ patients the virus can give rise to SG lymphocytic infiltration and sicca 
symptoms often indistinguishable from SS (reviewed in [205]). Interestingly, 
HCV is present and capable of replicating in SG of SS and non-SS sicca 
patients [206],[207]. Moreover, mice transgenic for HCV envelope genes 
spontaneously develop sialoadenitis [208]. Additionally, type II cryoglobulinemia 
is a relatively frequent complication in patients with SS and it is closely 
associated with TLS formation [143]. Based on the above, it is clear that chronic 
HCV infection is critically related to TLS formation, both in the liver and SG, and 
mimic several clinical features and immunological disturbances observed in SS 
patients (with the notable exception of the lack of anti-Ro/SSA and anti-La/SSB 
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autoantibodies) whereby some authors proposed to consider patients with SS-
like HCV-induced manifestations as a particular subgroup of SS patients [209]. 
Irrespectively of this debate, HCV is a clear example of a virus with SG tropism 
capable of inducing SS-like lesions resembling TLS together with clinical 
features of dryness which could serve as a model pathogen to investigate the 
mechanisms leading to TLS formation, autoimmunity and exocrine dysfunction. 
1.2.6 Animal models of Sjögren’s syndrome 
Despite an exact model of SS in rodents capable to replicate all the features of 
the disease is still missing, several murine strains display characteristics of SS 
and have been helpful to investigate the immunobiology of the pathology.  
Here I will briefly review the two main spontaneous models of SS, the NOD and 
the MRL/lpr mice, together with some less-used models that resemble several 
of the typical features of SS.  
The non-obese diabetic (NOD) mouse strain was generated via repetitive 
brother-sister mating of animals of the ICR strain that spontaneously developed 
diabetes [210]. NOD strain animals always develop autoimmune insulitis that 
progresses into overt diabetes in 70% of the females and 3% of the males 
[211]. The incidence and sex distribution of sialoadenitis in NOD mice is 
comparable to that of insulitis, while lachrymal glands involvement is more 
frequently observed in male animals. Moreover, SG infiltration is observed 
when the animals are 10 weeks old and onwards, significantly later than insulitis 
that is observed as soon as week 4. A typical feature of NOD mice is that after 
the initial immune infiltration, by week 16 a reduction in salivary flow is 
observed, which is absent in other SS models.  
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The histology of the inflammatory infiltrates in NOD SGs is highly reminiscent of 
the foci observed in SS SGs: aggregates organise around a central duct or a 
blood vessel and are mainly composed of CD4+ and CD8+ T cells, with the 
former more abundant than the latter. Also, B220+ B cells are observed. 
Interestingly, NOD mice infiltrates also show a B/T cell areas formation, as 
observed in SS and this segregation is more evident in older animals, 
supporting the hypothesis that in this model the infiltrate organises in time, as 
observed in human SS SGs [212]. Recent findings from my laboratory helped to 
elucidate the real nature of the inflammatory infiltrates both in the pancreas and 
SG of NOD mice, as a full phenotypic and functional characterisation of these 
aggregates was missing. In particular, we showed that the NOD SG infiltrates 
display full features of TLS such as FDC networks, GL7+ GC B cells, 
development of HEVs and markers of B cell functionality such as an increased 
expression of the cytokines involved in the GC B cell survival and proliferation 
and of the enzyme AID. The data also confirmed the intrinsic Ag-dependent 
nature of the ELN process: in fact, NOD mice develop autoantibodies against 
insulin which are produced in pancreatic but not SG TLS and the destruction of 
the pancreatic islets corresponds to the down regulation of the genes involved 
in TLS formation and functionality and with the disappearance of these 
structures ([71] and Astorri et al. unpublished data).  
Genetic analysis of NOD animals’ genome revealed several susceptibility loci 
associated with development of diabetes versus SG pathology [213],[214]: from 
this point of view, NOD strain better reproduces the multiple genetic factors 
involved in autoimmunity development in comparison to other models where 
self-reactivity is driven by a single genetic defect. Interestingly, it has been also 
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shown that in NOD mice some loci are more strongly associated with the 
development of diabetes and others with sialoadenitis [215], suggesting that the 
two autoimmune processes occur differently in their respective target organs. In 
particular, among the over 20 identified mouse insulin-dependent diabetes 
mellitus (Idd) loci, only the Idd3 and Idd5 alleles were found to confer genetic 
susceptibility to develop sialoadenitis, but not insulitis in NOD mice, suggesting 
that the development of the SG versus pancreatic disease in this strain is 
regulated by different genetic/epigenetic mechanisms [216]. 
Another robust and widely used murine model of SS is represented by the 
MRL/lpr strain. The MRL/lpr mouse derives from the MRL/n strain that is per se 
an autoimmune-prone strain. The lpr (lymphoproliferative) mutation, that is the 
only difference between MRL/lpr and MRL/n, affects the Fas gene that is one of 
the main players in the regulation/induction of apoptosis [217]. The MRL/lpr 
mouse strain is mainly used as a model of systemic lupus erythematous, but 
these animals also develop SG infiltrates in the submandibular (but also 
sublingual and parotid) glands. As I mentioned in section 1.2.5.5, lpr animals 
also develop a plethora of different autoantibodies among which anti-Ro and 
anti-La antibodies that are observed only in a smaller percentage of NOD 
animals [217]. On the other hand, lpr mice do not show any salivary flow 
impairment, which is a characteristic of the NOD strain.  
Other minor models of SS exist, e.g. NZB/W mice, TGF-β knock-out mice and 
NFS/sld mice thymectomised at 3 days of age [217]. Any one of these models 
shows some of the features of SS or of a particular clinical SS sub-type.  
Collectively, all the minor and major SS murine models develop a spontaneous 
disease with variable penetrance and severity which is underlined by mono- or 
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polygenic abnormalities that make the accurate pinpointing of the mechanisms 
leading to breach of tolerance, autoimmunity, sialoadenitis and exocrine 
functional impairment a very difficult and laborious enterprise.  
Of notice, no model of inducible SS-like disease in rodents (with the exception 
of an SS-like model induced by Ro immunization that reproduces the disease 
features only on Balb/c mice [218] which is currently difficult to reproduce due to 
the long time necessary to induce the symptoms [219]) has been described so 
far. Such a model would offer significant advantages over existing models in 
dissecting and clarifying the key pathogenic events leading to sialoadenitis and 
salivary hyposecretion. 
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2 Rationale of the thesis and aims 
In the course of gene-delivery experiments aimed at establishing the role of an 
increased expression of certain molecules in the SG of various mouse strains, 
but also aimed at therapeutic gene transfer with anti-inflammatory molecules, I 
and other members of my laboratory observed an unexpected phenomenon. In 
time course and dose-response experiments using a replication-defective 
adenoviral vector encoding for a traceable gene (LacZ or Luciferase) injected 
directly in the submandibular salivary gland of C57/Bl6 mice, we observed that 
high-doses of the reporter gene-encoding adenovirus induced a strong early 
inflammatory response which, surprisingly, was followed by the development of 
a focal lymphocytic infiltration that histologically was very reminiscent of the 
inflammatory foci observed in the SG of patients with SS and of female NOD 
mice. 
My lab has long been interested in the formation of ectopic follicles in SS SGs 
and in particular in the formation of TLS formation, which, as I reported in the 
previous chapter, represent a common feature in the background of chronic 
antigenic stimulation, whether the stimulus is of exogenous (chronic pathogen 
infection) or endogenous (tumour, graft) origin.  
It is also clear that, so far, an elegant and comprehensive model of inducible 
TLS formation in the salivary glands was missing. The available animal models 
of SS, although invaluable to understand some of the immunobiology of SS, 
they all presented flaws difficult to overcome. The key problem of the classic SS 
models is represented by their genetic background and spontaneous 
development: a complex genetic susceptibility is necessary for the development 
of the SS-like syndrome in mice but at the same time the chronic nature of the 
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process, the variable incidence and the slow and unsynchronised progression 
of the disease made it difficult to identify neatly the mechanisms involved in the 
pathogenic process. Additionally, the use of knockout or transgenic mice was 
only possible after tedious backcrossing, thus impairing the use of genetic 
modifications.  
 
For these reasons and given the preliminary observations reported above, the 
main aims of my PhD project were as follows: 
 
1- To develop and validate a robust inducible murine model of sialoadenitis on a 
wild-type background, using the delivery of reporter gene-encoding replication-
deficient adenoviruses. The results of this preliminary work are reported in 
section 4.1. 
 
2-To investigate whether the SS-like lesions in the SG triggered by AdV delivery 
represented simple accumulation of lymphocytes or displayed cellular, 
molecular and functional features of TLS. The results of this work are reported 
in section 4.2. 
 
3- To clarify whether, together with the histological lesions typical of SS, other 
hallmarks of SS were reproduced in this putative model of SS, including 
development of autoimmunity and exocrine dysfunction. The results of this work 
are reported in section 4.3. 
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4- To address whether the formation of SS-like lesions were associated with the 
development of a protective immunity against the pathogen followed by viral 
clearance or where dependent on the viral escape from the local immune 
response with the establishment of a persistent infection. The results of this 
work are reported in section 4.4. 
 
After having addressed the above aims, in the second part of my PhD project I 
moved to investigate the following aspects according to the aims below: 
 
5- To dissect the recruitment rate and tissue positioning of different innate 
immune cells subsets following AdV delivery in the SGs with particular focus on 
the first wave of immune response. The results of this work are reported in 
section 5.1. 
 
6- To address the role of specific cell type, namely NK cells and myeloid 
subsets in the formation of SS-like lesions and the development of TLS. The 
results of this work are reported in section 5.2. 
 
Overall, if successful my PhD work could have the potential to i) generate and 
validate a novel model of inducible sialoadenitis, ii) to establish a novel platform 
to study the cellular and molecular events leading to TLS formation, iii) to 
investigate the mechanisms regulating breach of tolerance and exocrine 
dysfunction, two hallmarks of SS and iv) dissect critical pathogen-host 
interactions responsible for viral control and viral persistence in the SG. 
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3 Materials and methods 
3.1 Reporter-encoding human adenovirus 5 expansion and 
purification 
In preliminary experiments, we discovered that first generation adenoviruses 
(AdV), which were established as potential vectors for gene transfer 
experiments directly in the SG, at high doses (>108 pfu, see below) induced the 
formation of SS-like lesions in the submandibular glands, with the development 
of periductal lymphomonocytic aggregates or foci. Thus, in order to establish 
whether such ectopic aggregates displayed cellular, molecular and functional 
characteristics of TLS, throughout my PhD work I have used first generation 
E1/E3 deficient human adenovirus 5. These vectors have the advantage of 
being easy and rapid to produce, and safe to use and yield high-titres, which I 
then used to deliver at high-doses and in small volumes in the submandibular 
glands of mice via a retrograde cannulation technique. 
I have used two different reporter genes for the aims of this thesis: firefly 
luciferase or bacterial β-galctosidase. Luciferase-encoding adenovirus 
(LucAdV) was a kind girft of Dr. Wim Van Der Berg, Radboud University 
Medical Centre, Nijmegen, The Netherlands. Galactosidase-encoding 
adenovirus (LacZAdV) was a kind gift of Dr. Luigi Gnudi, King’s College 
London, London, UK.  
In this section I will describe the protocols that have been used and perfected to 
expand, purify and quantify the adenoviruses.  
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Adenoviral vectors have been used in the past two decades for gene therapy 
purposes and more generally to transfect tissues or cell lines refractory to other 
transfection method [220]. The viral strains usually used are human adenovirus 
type 2 and 5. Adenoviruses are double-strand DNA viruses, 51 human 
serotypes have been characterised so far. The adenoviral genome is 
constituted by two sets of genes: the early phase genes (E1-E4) and the late 
phase genes (L1-L5). Early phase genes are the first to be transcribed and 
translated and encode for proteins necessary for viral replication and resistance 
against host defences, in particular E1 is necessary for the expression of the 
other early genes. Late phase genes encode for structural proteins necessary 
for the formation of the capsid and viral genome packaging. These viruses have 
a series of characteristics that favoured their popularity as vectors: i) their 
genome and biology are well characterised, ii) the viral genome does not 
integrate into the host genome, which makes AdV safer and particularly suitable 
for transient expression of transgenes and iii) they can accommodate inserts up 
to the size of 37kb. During the years three different generations of adenoviral 
vectors have been developed: first generation AdV are defective in E1 and/or 
E3 genes; second generation are defective in E1 and various other early genes; 
third generation AdV are called “gutted” vectors because they lack the entire 
genome except for the ITR regions and the packaging sequence. All these 
vectors relies on packaging cell lines for their production: lacking completely or 
in part of the early genes, the helper cell line must have in trans the missing 
genes for efficient viral production. In the case of first generation AdV, the 
helper cell line is the human embryonic kidney 293 cell line (Hek293).  
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Figure 3.1: Comparison of the first, second and third generation 
adenoviral vectors. Reprinted by permission from Macmillan Publishers Ltd: 
[220], copyright 2000. 
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Despite the larger insert that second and third generation AdV can 
accommodate, first generation AdV are still the favourite vectors: their 
construction is relatively easy, the transgene capacity is compatible with most 
gene transfer applications and they are easy to grow to high titres.  
AdV vectors have also downsides that made their use, especially in gene 
therapy, less popular during the years. This is mainly because i) the transgene 
does not integrate in the genome, thus its expression is transient; ii) first 
generation AdV in particular elicit a strong immune response due to the 
production of viral proteins in the infected cells, therefore a re-challenge in vivo 
for prolonged transfer gene expression is not efficient as the first administration 
induces a strong inflammatory response in the host.  
Various methodologies have been developed to modify and add inserts in the 
adenoviral genome. These techniques can be broadly divided in two groups:  
methods requiring DNA recombination in mammalian cells and methods 
requiring the assembly of the viral genome before transfection in mammalian 
cells. With the former methods, the recombination between a DNA molecule 
encoding for the leftmost region of the viral genome followed by the gene of 
interest and the rightmost part of the viral genome is required. The rightmost 
sequence must slightly overlap the 3’ region of the leftmost sequence to allow 
recombination between the two molecules. The recombination is achieved in 
the Hek293 helper cell line. These methods have the advantage that the final 
viral genome is obtained directly in one round of transfection in the host cell 
line. The main disadvantages are that i) to produce the leftmost fragment 
restriction enzymes cutting in the E1 region of viral genome are used and the 
fragment obtained from digestion are similar in size to undigested viral DNA and 
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therefore is difficult to separate the two DNA species before transfection in 293 
cells, increasing the risk of generating replication-competent virions as well as 
desired replication-defective ones; moreover ii) recombination in mammalian 
cells is not an efficient process. To overcome these issues various modification 
to the basic technique have been studied but most of them are tedious and time 
consuming and thus reduce the advantage of having recombination and virion 
production all in one step 
The methods requiring recombination before transfection into mammalian cells 
are based on the production of the recombinant genome in bacterial cells, thus 
reducing the risk of parental viral genome contamination. The main 
disadvantage is that the lack of selective pressure in bacteria might lead to 
mutations in the recombinant genome thus impairing the viability of the virus. 
For this procedure, the cDNA of the reporter gene to be transfected is cloned 
inside a commercial AdV transfer vector plasmid: these vectors contains short 
adenoviral sequences from the E1 region of the adenovirus 5 genome, flanking 
a sequence containing a strong promoter of transcription (usually CMV) the 
multiple cloning site (where the insertion cassette with the gene of interest is 
positioned via specific digestions with restriction enzymes followed by ligations 
to reconstitute the circular plasmid DNA) and a poly-adenylation signal. The 
gene of interest is first cloned in this transfer vector. The obtained vector, which 
also bears an antibiotic resistance gene (usually ampicillin) is then transfected 
into competent bacterial cells, which are selected for antibiotic-resistance 
allowing amplification of the plasmid for downstream use. Following purification, 
the plasmid DNA is then co-transfected together with another larger commercial 
plasmid encoding the AdV5 genome, defective for sections of the E3 and E1 
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regions. The AdV regions present in the transfer vector facilitate the 
homologous recombination with the E1 region of the plasmid encoding for the 
viral genome, allowing the insertion of the gene of interest into the AdV 
genome. Recombination is then confirmed by restriction digest mapping of the 
obtained plasmid. The recombined plasmid is then transformed in bacterial cells 
for large-scale plasmid purification. Finally the obtained plasmid is purified, 
linearised and used to transfect Hek293 cells for production of bulk amount of 
viral particles bearing the recombinant genome. Alternatively, homologous 
recombination can be directly achieved in Hek293 cells following co-
precipitation (usually using calcium phosphate) of the shuttle and AdV plasmids 
with direct formation of complete viral particles harbouring the transferred gene 
of interest. Because Hek293 cells provide the missing E1-E3 AdV genes for the 
formation of the full viral capside, this is the only cell type where the virus has 
full replication and lytic capacity allowing large scale amplification of the viral 
particles which can be monitored by the formation of cytolytic plaques in the 
Hek293 cell monolayer. Other plasmid-based kits can be used, where the 
transgene is first cloned inside a shuttle plasmid with particular restriction sites 
that after the shuttle plasmid digestion allow its ligation inside another plasmid 
(bearing the same restriction sites) encoding an E1-E3 defective viral genome 
(example Figure 3.2 and Figure 3.3).  
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Figure 3.2: Shuttle plasmid bearing a resistance gene for kanamicine and 
bacterial origin of replication. A multiple cloning site (MCS) is located 
between CMV promoter and SV40 polyadenilation sites. The gene of interest is 
cloned in the MCS region and after expansion and selection, the plasmid is 
digested with I-Cei I and PI-Sce I enzymes. (BD biosciences product).	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Figure 3.3: A commercial adenoviral vector plasmid map. The plasmid 
encodes for a viral genome defective of E1 and E3 regions, together with an 
ampicillin resistance gene for selection and a bacterial origin of replication for 
expansion. This vector is linearised with I-Ceu I and PI-Sce I enzymes and 
ligated with the shuttle plasmid bearing the gene of interest (Figure 3.2). After 
ligation the plasmid will encode for the E1-E3 defective adenoviral genome and 
the transgene under the transcriptional control of the CMV promoter. (BD 
biosciences product).	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3.1.1 Helper cell line preparation and seed stock expansion 
Hek293 cells, which are a human embryonic kidney cell line, were cultured in 
Dulbecco-modified Eagle medium (D-MEM, Gibco) supplemented with 10% 
foetal bovine serum (Life technology) and penicillin/streptomycin (Life 
technologies) at 37˚C in humidified incubator in 5% carbon dioxide pressure.  
The concentrated viral stocks, preserved in a -80˚C freezer, were thawed and 
used to infect one T175 (Corning) flask of 80% confluent Hek293 cells. When 
cytopathic effect was evident, i.e. when cells started to lose adherence and 
detach, cells were collected and snap-frozen in liquid nitrogen. Cells underwent 
three freeze/thaw cycles to allow cell lysis and virus release and then spun for 
15 minutes at 800xg. The supernatant was collected and used in the next step.  
3.1.2 Bulk virus expansion 
AdV seed stock was used to infect twenty 15 cm Petri dishes (Corning) of 80% 
confluent Hek293 cells. When the cytopathic effect was evident, cells were 
harvested and spun at 800xg for 15 minutes and supernatant discarded. The 
cells were resuspended in 26 ml of a buffered solution (100mM Tris pH 8) and 
underwent 3 cycles of freeze/thaw to allow cell lysis and virus release. The 
suspension was spun again (3500xg for 15 minutes) and the virus-containing 
supernatant collected. 
3.1.3 Caesium chloride gradient virus purification 
The obtained solution is a suspension of viral particles, cellular debris and is 
contaminated by cell growth medium and bovine serum. Properly packed 
virions are the more dense elements present in the solution. To obtain a pure 
suspension of concentrated virions, the solution undergoes ultracentrifugation 
on a caesium chloride (CsCl) step gradient (Figure 3.4). CsCl is highly soluble 
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in water and caesium has a very high atomic weight (good to obtain high-
density solutions) and low viscosity. CsCl is dissolved in a buffer (TD buffer 
137mM NaCl, 5.1mM KCl, 0.704mM Na2HPO4, 24.8mM Tris at pH 7.5) to the 
desired density. A high density CsCl solution (1.4 g/ml) was first layered in 
transparent ultracentrifuge tubes (Beckman) and a second layer of lower 
density CsCl solution (1.25 g/ml) was layered above the first. Finally the virus-
containing solution was split in half and deposed on top of the CsCl solutions 
(Figure 3.4A). The tubes were then ultracentrifuged for 2 hours at 15˚C at a 
speed of 25’000RPM (maximum RCF 113’960xg) in a Beckman preparative 
ultracentrifuge adapted with swinging buckets (L-80 ultracentrifuge, SW32 Ti 
buckets). The density of the virions lies between the densities of the two CsCl 
solutions, thus during the ultracentrifuge virions can pass through the top low-
density solution but cannot enter the high-density bottom phase. At the end of 
the centrifugation, virions appear at the interface between the CsCl phases as 
an opalescent band, while incomplete viral particles, cellular debris and other 
contaminating materials will remain above or inside the top phase (Figure 3.4B). 
The viral particles-rich phase was then collected from the interface by mean of 
puncturing the tube with a sterile needle (BD) adapted to a syringe. The 
collected solution was mixed with another CsCl solution (1.36 g/ml) in 
ultracentrifuge tubes and spun at 40’000 RPM (maximum RCF 194’432xg) at 
15˚C overnight in a Beckman preparative ultracentrifuge (Figure 3.4C) adapted 
with swinging buckets (L-80 ultracentrifuge, SW55 Ti buckets). The density of 
this CsCl solution is more similar to the density of the virions and during 
ultracentrifugation a density gradient is formed. Viral particles move through the 
solution to the isopycnic point, i.e. the point where the density of the virions is 
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equal to the density of the solution. This second ultracentrifuge cycle is used to 
further purify the viral particles from potential carryovers from the previous steps 
and to increase the concentration of the viral suspension. The viral particles-rich 
phase was collected again by mean of puncturing the tube with a needle and 
syringe (Figure 3.4D). The solution was moved in a 50 ml tube (Falcon) where 2 
ml of TSG buffer were added (150mM NaCl, 5mM KCl, 1mM Na2HPO4, 30mM 
Tris, 2mM MgCl2, 1.8mM CaCl2, 30% glycerol). This solution was then loaded in 
a dialysis cassette (Figure 3.4E) as explained in the next section.
 
Figure 3.4: Scheme of viral particles isolation and purification. (A) A 1.4 
g/ml CsCl solution is deposited on the bottom of the tube followed by a less 
dense solution (1.25 g/ml) to form the step gradient. Virus-containing 
supernatant obtained from the lysis of AdV-infected Hek293 cells is layered on 
top of the step gradient. (B) After ultracentrifugation for two hours two bands are 
observable, a top band containing empty and/or incorrectly packaged virions 
and a second one at the interface between the two gradients containing the 
concentrated correctly packaged full virions. (C) The tube is punctured and the 
virus-containing solution is mixed with a 1.36 g/ml CsCl gradient in an 
ultracentrifuge tube and spun overnight to obtain an isopycnic separation of the 
viral particles. (D) After the second ultracentrifuge a band is formed in the tube 
that contains concentrated viral particles. Again the tube is punctured to collect 
the band, which is then injected in a dialysis cassette (E) to remove the 
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impurities and the CsCl contamination. After overnight dialysis the virus-
containing solution is aliquoted and stored at -80˚C. 
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3.1.4 Dialysis  
At the end of the second ultracentrifugation the viral particles are evident in the 
tube as an opalescent band. This band contains now ultrapure suspension of 
viral particles, contaminated by caesium chloride buffer. To get rid of the 
contaminants, the solution needs a dialysis step. This was achieved via 
commercial dialysis cassette (Thermo Scientific): these cassettes have two 
semi-permeable membranes with specific diameters, which allow the passage 
of water and salts but not of larger molecules (such as proteins or, in this case, 
viral particles). The viral suspension obtained as explained above, was loaded 
inside the cassette with a syringe and needle. The loaded cassette was 
immerged in 2 litres of dialysis saline buffer (10mM Tris, 1mM MgCl2, 150mM 
NaCl, 10% glycerol). The cassette was left in the dialysis buffer overnight to 
allow chemical equilibrium. Since the semi-permeable membrane allows the 
free movement of salt ions, caesium can freely diffuse across it. The solution 
tends to reach osmotic equilibrium and since the solution inside the cassette is 
rich in caesium ions that are completely absent from the dialysis buffer outside, 
caesium will diffuse from the cassette to the dialysis buffer. Moreover, since the 
viral solution volume is relatively small (approximately 5-6 ml) and the dialysis 
buffer volume relatively large (2 litres) after dialysis the amount of caesium 
remaining in the viral solution is minimal. After the dialysis the virus was divided 
in 150 µl aliquots and stored at -80˚C. 
 
3.1.5 Titration of the viral plaque forming units  
There are several methods to quantify the amount of virus produced via the 
process reported above. The quicker and more straightforward consist in 
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measuring the absorbance of the virus suspension with the aid of a 
spectrophotometer: knowing the absorbance associated to the adenovirus is 
possible to calculate the number of viral particles per volume unit present in the 
solution. This method, although fast and reliable, does not take into account the 
viability of the viral particles: in fact the viral suspension also contains viral 
capsids devoid of viral genome, virus particles with a defective genome and 
misassembled virions that do not lead to an efficient target cell infection. 
Other titration methods allow the quantification of the plaque-forming units (pfu), 
which is the number of viral particles capable to induce a functional infection 
that, in the case of adenoviruses, culminates with the target cell lysis and the 
release of the viral progeny. On a monolayer of Hek293 cells, this corresponds 
to the formation of plaques: areas of the cellular monolayer where infected cells 
dye and leave an evident plaque in the cell culture vessel. Infection of confluent 
Hek293 cells with scalar dilutions of the viral suspension allows the calculation 
of the pfu per millilitre of solution.  
For this thesis, I decided to use a 96-wells plate-based end-point statistical 
method that reduces variability and handling errors that are typical of the more 
classic plaques formation assays methods. Briefly, Hek293 cells were plated in 
a tissue culture-treated 96-wells plate (Corning) at a density of 5x105 cells/ml of 
complete medium, 100 µl per well. Plates were returned to the incubator and 
left overnight. The next day serial dilutions of the viral stock were prepared in 
complete medium. The medium was removed and 100 µl of a specific dilution of 
infective medium (or normal medium) were added to the wells in a row-wise 
manner (e.g. wells A1 to A10 first dilution, B1 to B10 second dilution etc.). The 
last two columns were plated with uninfected medium and left as controls. The 
 105 
dilutions of the stock generally used were from 1:107 to 1:1014. For each virus to 
titrate, at least 4 replicate plates were prepared. Plates were then returned to 
the incubator and checked daily for cytopathic effect (CPE). At day 7 the plates 
were observed and scored under an inverted microscope: a well was 
considered infected when at least a plaque was observed. After the assay a 
statistical method (in this case Spearman and Karber method [221]) can be 
used to calculate the 50% Tissue Culture Infective Dose (TCID50) of the solution 
and from the TCID50/ml the pfu/ml can be deducted empirically multiplying the 
TCID value by 0.69.  𝑇𝑖𝑡𝑒𝑟  (𝑇𝐶𝐼𝐷!" 𝑚𝑙) = 10!!!(!!!.!) 
Where Z is the 𝐿𝑜𝑔!" of the dilution factor (in this case Z=1 for a 10-fold dilution 
factor) and X is the sum of the fractions of CPE-positive wells (this sum must 
take into account also the lower dilutions not plated, i.e. 10-1, 10-2 etc. as 
positive for CPE). For the assay to be considered reliable three conditions must 
be met: i) the control wells at the end of each row must be devoid of cytopathic 
effect; ii) the lowest dilution (e.g. 1:107 row) wells must all show plaque 
formation and iii) the highest dilution wells (e.g. 1:1014) must not show any 
cytopathic effect. After repeating the counting for all the replicate plates, the 
average was calculated and this value was considered the number of pfu per 
millilitre.  
3.2 Mouse handling and submandibular salivary gland retro-
cannulation 
For this thesis, I have used C57Bl/6 mice purchased from Charles River (UK) 
and housed in the biological services unit at the William Harvey Research 
Institute. Animals were maintained in standard conditions, with food and water 
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ad libitum. For all the experiments females aged between 11 and 13 weeks 
were used.  
The technique used to deliver AdV in the murine SG was first optimised for rats 
[20],[222],[223] and then re-adapted for mice. The basic apparatus consists of a 
100 µL Hamilton syringe (Sigma, UK) connected to a 301/2-gauge syringe 
needle (BD, UK) in turn connected via fine plastic tubing to the cannula (Figure 
3.5). The shaping of the cannula is explained in the next section.  
All the experiments were performed delivering either AdV or the viral vehicle 
alone as control. For some experiments, both glands of the same animal were 
cannulated with the AdV, for others only one gland was treated with the vector 
while the other was used as internal control and thus left either untouched or 
cannulated with the vehicle. Animals were culled at the relevant time-point 
under sodium pentobarbital terminal anaesthesia, delivered via an intra-
peritoneal (i.p.) injection. Blood and tissues were collected as stated in the next 
sections.  
 107 
 
Figure 3.5: Cannulation apparatus, scheme. The 100 µL Hamilton syringe is 
connected with the needle and AdV-containing solution is loaded in the syringe. 
The tubing is then connected and the glass cannula added last. After making 
sure that the cannula is open, liquid is pumped in the apparatus to remove dead 
volumes.  
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3.2.1 Glass cannulae shaping 
The small cannulae necessary to efficiently enter the SG excretory duct and 
deliver the AdV solution were obtained stretching sections of silica HPLC tubing 
(0.1 mm internal diameter, Sigma, UK) over a Bunsen burner flame. From each 
tubing section (approximately 5 cm long) two cannulae were obtained. This 
procedure reduces the diameter of the tubing to about 10/20 µm.   
 
3.2.2 Submandibular salivary gland cannulation 
For the procedure, mice were initially anaesthetised with a solution of ketamine 
(60 mg/kg) xylazine (12 mg/kg) in PBS, delivered with an i.p. injection. A 
homemade device was used to keep the mouth of the animal open and in the 
correct position (Figure 1.1A). All procedures were performed using an 
operating microscope. 
The Hamilton syringe was loaded with the viral solution or control vehicle, the 
syringe needle was also filled with the relevant solution to avoid dead-volumes. 
Once the Hamilton and needle were connected to the tubing and cannula, these 
were also filled with the solution to be transferred, thus applying a positive 
pressure to the Hamilton syringe plunge (Figure 3.5).  
The mouse tongue was lifted, exposing the orifices of the two submandibular 
excretory ducts (Figure 1.1B). The cannula was then carefully inserted in the 
chosen orifice. Upon successful insertion, a positive pressure was applied to the 
Hamilton syringe plunge and the solution slowly delivered in the gland. 
According to the viral titre, a volume between 10 and 50 µl was delivered, so to 
have the requested virus amount (108 pfu) injected in the gland. Any leakage 
was assessed and recorded.  
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After the procedure the animals were left to recover and upon successful 
recovery they were returned to the cages and left undisturbed until the next 
procedure or relevant culling day in time-course experiments.  
3.2.3 Salivary flow assessment  
Some of the animals were assessed for salivary flow impairment. This set of 
animals received AdV in one of the glands and vehicle in the contralateral, as 
internal control. Secretory function was assessed under terminal anaesthesia 
(sodium pentobarbital 75 mg/kg i.p.). The animals were anesthetised, placed on 
a warmed operating table so that the ventral side was exposed and rectal 
temperature was monitored. After removal of the ventral hair in the neck region, 
each submandibular duct was exposed by dissection from the ventral surface 
through the mylohyoid muscle. Individual submandibular ducts were localised, 
cut, cannulated with 0.1 mm HPLC tubing, and saliva secretion was induced via 
stimulation with pilocarpine (0.5 mg/kg i.p.), a non-selective muscarinic receptor 
agonist. Saliva was collected 5 minutes after pilocarpine administration and 
collected for 10 min. After collection into weighed tubes, the tubes were 
reweighed and the volume of saliva calculated (1 mg = 1 µl saliva).  
3.2.4 Systemic and local antibody-mediated NK cells depletion 
In order to deplete NK cells from the circulation, an anti-NK1.1 antibody has 
been used as previously reported [224]. Briefly, 200 µg of mouse anti-mouse 
NK1.1, clone PK136 (BioXcell), were administered i.p. on the day before 
cannulation. Animals were injected with the same dose every 48 hours until day 
8 after procedure (i.e. 1, 3, 5, 7 days post cannulation). Control group animals 
were dosed with control mouse immunoglobulins following the same schedule. 
To assess the effective depletion of NK cells, digested SG were stained for flow 
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cytometry using an anti-NK1.1 antibody in combination with an anti-CD49b 
antibody, another pan-NK cells marker (refer to Section 3.8 for details regarding 
tissue digestion and cells preparation for flow cytometry). As shown in Figure 
3.6, PK136 administration induced an almost tenfold depletion of the SG tissue-
resident NK cells in comparison to IgG-treated controls. NK cells depletion was 
observed both in SG and in spleen of PK136-treated animals.  
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Figure 3.6: Effects of anti-NK1.1 administration on the resident NK cells 
population. Anti-NK1.1 was injected i.p. from the day before the cannulation 
and every 48 hours until the culling date or up to day 8 post-cannulation. 
Depleting antibody injections induced effective NK cells depletion, as showed 
by the reduction of the NK1.1/CD49b double positive cells in comparison with to 
the Ig-treated controls (left and center, respectively). As reported in previous 
publications, the administration of the antibody induced a systemic depletion of 
NK cells, as shown by the absence of the NK cells pool in the spleen of PK136-
dosed animals (right). The plots in this figure show single viable cells gated as 
non-granulocytic CD45+/CD19-/CD3- cells.  
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3.3 Tissues and blood collection 
3.3.1 Blood collection and storage 
For terminal bleeding, after induction of terminal anaesthesia, unconscious 
animals were positioned on an operating table and blood was collected via 
intra-cardiac puncture using a fine needle 1 ml insulin syringe. After withdrawal, 
blood was collected in tubes containing a clotting agent (Startedt, Germany) 
and left for 2 hours at room temperature to allow clotting. Serum was then 
separated via centrifugation at 1000xg for 5 minutes, collected in fresh tubes 
and stored at -20˚C until use. 
3.3.2 Salivary glands, loco-regional lymph nodes and spleen dissection 
and storage 
Culled animals were dissected with dedicated tools. Sub-mandibular salivary 
glands, loco-regional lymph nodes and spleen were collected and stored 
according to the requested analysis.  
For histological studies spleens, lymph nodes and whole SG or part of them 
were embedded using plastic moulds filled with optimal cutting temperature 
(OCT) medium (Sakura fineteck, UK) and rapidly snap-frozen in isopentane pre-
cooled to optimal temperature in liquid nitrogen. Embedded specimens were 
stored at -80˚C until use. Tissue destined for RNA extraction and gene 
expression studies were stored in RNA-later stabilising solution (Life 
technologies), left overnight at 4˚C and then frozen and stored at -80˚C until 
use.  
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Small amounts of tissue from salivary glands treated with LucAdV were 
collected in test tubes and snap-frozen in liquid nitrogen and then stored at -
80˚C for luciferase activity assay. 
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Figure 3.7: Gross ventral anatomy of the mouse, the main lymph nodes 
are highlighted. From Texas Histopages. All rights reserved. 
http://ctrgenpath.net/static/atlas/mousehistology/Windows/lymphatic/lymphdiagr
am.html 
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3.4 Luciferase assay on LucAdv-treated salivary glands 
Bioluminescence, the emission of photons of visible light via a biochemical 
reaction, is present in several animal species. The enzymes responsible for the 
production of light go under the common name of “luciferases”, and the 
chemical-energy rich substrates that are catalysed by luciferases are called 
“luciferins”. Luciferases from different species of insects and jellyfishes have 
been cloned and used as reporter genes in numerous biological applications: in 
general cells are transfected, or infected with a viral vector coding for a selected 
luciferase. Once the substrate is provided to the cells, the enzyme starts to 
catalyse the reaction and produce light that can be measured and recorded. 
Interestingly, luciferase based technologies can be successfully applied both to 
in vivo and in vitro systems. In in vivo, luciferase-encoding cells can be injected 
into animals or the enzyme expression can be restricted to specific tissues in 
transgenic animals or viral vectors can be used and the enzymatic activity can 
be efficiently measured by high-sensitivity cameras once the substrate has 
been administered in live animals. The surrounding tissues will absorb most of 
the light emitted by the luciferase-positive cells and only few photons will hit the 
instrument’s sensor. Thus, in order to register these events and distinguish the 
light produced by the specimen form the noise the use of these cameras is 
necessary. With a different approach, to avoid the use of expensive sensors, in 
vitro cultured cells are first lysed to release the enzyme and the substrate is 
added directly to the lysate and light emission measured by instruments called 
luminometers. This latter approach can also be used to measure luciferase 
activity from tissues collected from luciferase-transfected animals, and this is 
the technique that I have used in this thesis. In details, tissues from LucAdV-
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treated and control animals, prepared and stored as reported above, were 
thawed on ice. Tissues were then transferred into homogenising micro-beads 
tubes (Precellys systems, Bertin Technologies, France) filled with 300 µL 
GloLysis lysis buffer buffer (Promega, USA) and lysed with a shaking micro-
beads homogeniser (Precellys systems, Bertin Technologies, France). Tubes 
were centrifuged to eliminate debris and 50 µL of the tissue lysate were 
transferred in black luminometer plates (Corning, UK) and 50µL of BrightGlo 
luciferase substrate (Promega, USA) were added. The mixture was left 5 
minutes at room temperature in the dark and then luminescence was quantified 
in a Microlumat Plus luminometer (EG&G Berthold, Germany) for 10 seconds. 
Luminescence was normalised for the protein concentration of the sample, 
calculated with a bicinchoninic acid (BCA) assay (Pierce, USA).  
3.4.1 Bicinchoninic acid (BCA) assay 
The BCA assay is widely used to calculate protein concentration as is largely 
unaffected by the presence of detergents, which are often used to lysate tissues 
and cells. In a BCA assay, a substrate containing cupric sulfate pentahydrate is 
added to the protein solution to measure. The peptide bonds of the protein 
reduce the copper and in this reduced form each copper ion chelate two 
molecules of bicinchoninic acid, also present in the substrate solution. In this 
form, bicinchoninic acid forms a purple-coloured product that strongly absorbs 
light at 562 nm. Temperatures above 37˚C facilitate the reduction of copper and 
make the reaction largely independent by the presence of cysteine bonds and 
tyrosine and tryptophan side chains that can influence the BCA-copper 
interaction. If this condition is met, the amount of coloured substrate produced 
by the reaction, dependent from the number of copper ions reduced, is directly 
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proportional to the amount of protein present in the sample. The colour value is 
measured in a spectrophotometer and it is compared to the colour value 
obtained from a standard curve of a known protein, usually bovine serum 
albumin (BSA).  
In this thesis a commercial kit for BCA assay (Pierce, USA) was used. Briefly, 
the BSA standard provided by the producer (2 mg/ml) was serially diluted with 
the lysis buffer used for the relevant application (e.g. RIPA buffer or glo-lysis 
buffer) to the following concentrations 1.5, 1, 0.75, 0.5, 0.25, 0.125, 0.025 
mg/ml. Twenty-five microliters of each standard or sample were plated in 
duplicates in a 96-wells ELISA plate (Corning). The substrate is obtained by 
mixing two solutions provided by the producer in a 50:1 ratio. Two hundred 
microliters of the substrate were added to each well and the plate was 
incubated at 37˚C for 30 minutes. Absorbance was read at 562nm and the 
average optical densities of standard duplicates were plotted against the 
concentration of the standards. The obtained curve was used to calculate the 
protein concentration of the samples.  
3.5 Immunohistochemistry and immunofluorescence 
3.5.1 OCT samples handling and cutting 
OCT-embedded tissues were removed from the mould and attached to a small 
cork. Five microns sequential sections were obtained by cutting the cork-
attached specimens in a cryostat (Leica, Germany) and mounted on polarised 
glass slides (SuperFrost Plus, VWR, USA). Slides were dried overnight at room 
temperature and the next day slides were stored in plastic boxes at -80˚C until 
use. Prior to use, slides were allowed to adjust to room temperature.  
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3.5.2 Haematoxylin and eosin staining 
All the histological specimens underwent haematoxylin and eosin (H&E) 
staining in order to assess the microscopic structure of the tissue. H&E staining 
is based on two different dyes that allow differentiation of cellular nuclei and 
cytoplasm. In particular, haematoxylin stains nucleic acids with a deep 
blue/purple colour, while eosin stains the cytoplasm with a red/pink colour that 
varies intensity according to the pH. Tissue slides prepared as reported above, 
were fixed in a 4% paraformaldehyde buffered solution for 10 minutes and then 
washed in distilled water for 5 minutes. Slides were then transferred in a jar 
containing haematoxylin for 1 minute and then rinsed in tap water to remove the 
dye excess. Slides were transferred in a jar containing eosin for 2 minutes and 
then washed in distilled water for 5 minutes. Slides then were dehydrated with 
two changes two minutes long of absolute ethanol, followed by two changes 2 
minutes long of xylene. Slides were blotted on absorbent paper to remove the 
excess of solvent and immediately fixed using DPX mounting medium (Sigma, 
UK). Haematoxylin and eosin stained slides were acquired with a bright field 
motorised microscope (BX61) from Olympus equipped with an Olympus digital 
camera (DP26) and were analysed with the CellSense software from Olympus.  
3.5.3 XGal staining to detect beta-galactosidase activity 
For the SG treated with LacZAdV a staining developed to reveal the β-
galactosidase activity in transfected cells was used. Infected cells express the 
bacterial enzyme, which is capable to specific cleave the β-glycosidic bonds. 
When adding a specific substrate containing a β-glycosidic that changes colour 
when the bond is hydrolysed, it is possible to identify the infected cells that 
express the enzyme. Typically, an intense blue nuclear staining identifies the 
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cells transfected by bacterial β-galactosidase, allowing an easy distinction from 
rare senescent cells that can give a non-specific pale blue cytoplasmic staining. 
Tissue slides prepared as reported above were adjusted to room temperature 
and then fixed in a 4% paraformaldehyde buffered solution for 10 minutes. 
Slides were then washed with two changes 5 minutes long in PBS. Slides were 
then moved in a jar containing a X-gal solution (1mg/ml 5-bromo-4-chloro-3-
indolyl-β-D-pyranoside, 5mM K4[Fe(CN)6]·3H2O, 5mM K3[Fe(CN)6], 5mM 
EGTA, 2mM MgCl2, 0.02% NP-40 in PBS) at 37˚C in an incubator without 
addiction of CO2, overnight or until colour development. Slides were then 
washed with two changes 5 minutes long in PBS and counter-stained for 30 
second in haematoxylin. Slides were washed in tap water and mounted in DPX 
medium. Images were acquired with a bright field motorised microscope (BX61) 
from Olympus equipped with an Olympus digital camera (DP26) and were 
analysed with the CellSense software from Olympus.  
3.5.4 Immunofluorescence 
Immunofluorescence microscopy allows the usage of one or multiple antibodies 
to stain the same slide. Where classic bright-field immunohistochemistry 
permits generally the use of no more than two different antibodies, 
immunofluorescence staining easily allows detection of three/four epitopes 
thanks to the different chemistries commercially available.  
All the staining protocols used are based on several essential steps: i) slides 
were thawed and allowed to reach room temperature; ii) slides were fixed either 
in acetone at -20˚C or in a solution of 4% paraformaldehyde in PBS at room 
temperature for ten minutes; iii) to block the non-specific binding of the 
antibodies to the sample, slides were incubated with a blocking solution (1% 
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bovine serum albumin, 10% horse serum in TBS) for 15 minutes at room 
temperature; iv) the slides were then incubated with the various antibodies 
according to the detection technique required (explained in the next sections). 
All the different washes were performed for 5 minutes at room temperature in 
TBS buffer. At the end of the detection protocol, if required, slides were 
incubated with 4',6-diamidino-2-phenylindole (DAPI) solution (5 µg/ml in TBS 
from Life Technologies) for 5 minutes at room temperature to counterstain the 
nuclei. After the last wash, slides were mounted with a glass coverslip sealed 
with a solution of poly-vinyl alcohol (Mowiol 4-88, Calbiochem) and left to set in 
the dark for two hours at room temperature or overnight at 4˚C.  
All the antibodies used in this thesis were titrated prior to use. The various 
antibodies and dyes used for this work, their producing company, catalogue 
number and dilution are reporter in Table 3.1. 
Table 3.1: Primary antibodies used for IF staining. 
Two different instruments were used to acquire the fluorescence from the 
slides, a classic motorised epifluorescence microscope (Olympus BX61) 
equipped with a high-definition digital camera (Hamamatsu, Orca-R2) and a 
confocal microscope from Leica (DM5500 Q, TCS SPE). Epifluorescence 
images were analysed with the CellSense software from Olympus, while images 
Antigen Raised in Conjugation Clone Producer 
Cat. 
number Dilution 
CD3e Hamster Biotin 500A2 BD 553239 1:200 
B220 Rat PE RA3-6B2 Biolegend 103208 1:200 
B220 Rat Alexa647 RA3-6B2 Biolegend 103229 1:200 
FDC Rat N/A FDC-M1 BD 551320 1:100 
PNAd Rat Biotin MECA-79 Biolegend 120804 1:100 
GL7 Rat Biotin GL7 Ebioscience 13-5902 1:50 
CD11c Hamster Alexa488 N418 Biolegend 117311 1:200 
F4/80 Rat N/A CI:A3-1 Sertotec MCA497G 1:100 
Lyve-1 Goat N/A Poly R&D AF2125 1:100 
AdV5 Rabbit N/A Poly ABCAM ab6982 1:100 
Pan 
Cytokeratin Mouse N/A C-11 Biolegend 628601 1:100 
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acquired with the confocal microscope were analysed with the LeicaAF software 
suite from Leica.  
 
Table 3.2: Secondary/tertiary antibodies used for IF staining. 
3.5.4.1 Staining procedures: two steps detection 
For this detection method I first used an un-conjugated purified primary 
antibody raised against the epitope of interest. After the blocking step described 
above, the slide was incubated with the primary antibody diluted in blocking 
solution. The incubation time was either one-hour at room temperature or 
overnight at 4˚C in a humidified chamber. The slide was then washed in buffer 
and the specimen was incubated with a fluorophore-conjugated secondary 
antibody raised against the Fc portion of the primary antibody, diluted in 
blocking solution. Incubation time for the secondary antibodies was one hour at 
room temperature in the dark. For example, if the primary antibody was raised 
in rat, the secondary antibody used was a fluorophore-conjugated anti-rat 
antibody. The list of the secondary anctibodies used in this thesis is reported in 
Table 3.2. 
Reactivity Raised in Conjugation Producer Cat. number Dilution 
Rat Goat Alexa555 Invitrogen A21434 1:200 
Rat Chicken Alexa488 Invitrogen A21470 1:200 
Goat Rabbit Alexa488 Invitrogen A11078 1:200 
Rabbit Goat Alexa488 Invitrogen A11034 1:200 
Biotin N/A Alexa488 Invitrogen S32354 1:300 
Biotin N/A Alexa555 Invitrogen S21381 1:300 
Mouse IgG1 Goat Alexa555 Invitrogen A21127 1:200 
Rat Goat Biotin Serotec 301008 1:200 
Rabbit Goat Biotin Dako E0432 1:200 
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3.5.4.2 Staining procedures: directly conjugated antibodies 
In some cases, directly fluorophore-conjugated primary antibodies were 
available and have been used for the direct detection of the target. In this case, 
after the blocking step, the sample was simply incubated with the antibody 
diluted in blocking solution for one hour at room temperature in the dark, the 
slide was washed in buffer and the sample prepared for imaging.  
3.5.4.3 Staining procedures: biotinylated antibodies 
This method requires primary antibodies conjugated with biotin. After the 
incubation with the primary antibody, the specimen is incubated with 
fluorophore-conjugated biotin binding proteins, such as avidin or streptavidin. 
This method allows several molecules of fluorophore-conjugated protein to bind 
the same biotin-conjugated antibody, and thus provides strong signal 
amplification. When this methodology was used, an additional step of blocking 
was necessary prior to the protein block step, to neutralise the endogenous 
biotin that might provide a non-specific signal. Therefore, after sample fixing, 
slides were washed in buffer and incubated with an avidin solution (Dako) for 5 
minutes, washed in buffer and incubated with a biotin solution (Dako) for 5 
minutes. After this step, slides were blocked in blocking solution and then 
incubated with the biotin-conjugated primary antibody diluted in blocking 
solution. Slides were then washed in buffer and incubated with fluorophore-
conjugated streptavidin diluted in blocking solution.  
3.5.4.4 Staining procedures: three steps detection 
In some cases, to achieve signal amplification when a biotinylated primary 
antibody was not available, a three steps protocol was used. Briefly, after 
avidin/biotin block (described above) and incubation in blocking solution, slides 
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were incubated with a purified primary antibody (as described in the two-steps 
method) diluted in blocking solution for one hour at room temperature. The 
slides were then washed in buffer and incubated with a biotin-conjugated 
secondary antibody diluted in blocking solution for one hour at room 
temperature. After washing in buffer, slides were then incubated with 
fluorophore-conjugated streptavidin diluted in blocking solution for one hour in 
the dark.  
3.5.4.5 TUNEL assay for the detection of apoptotic cells 
Cells undergoing apoptosis go through a series of consecutive and well-
regulated processes that characterise the programmed cell-death mechanism. 
Among these apoptosis hallmarks, there is the digestion of the nuclear genetic 
material by endonuclease enzymes. This process produces a vast amount of 
nicks in the DNA. The terminal deoxynucleotidyl transferase dUTP nick end 
labelling assay, or TUNEL assay, relies on the capacity of the enzyme terminal 
deoxynucleotidyl transferase (TdT) to catalyse the addiction of deoxyuridine 
triphosphate (dUTP) to the DNA nicks. dUPT monomers used in the assay are 
marked (e.g. they can be radio-labelled or conjugated with a specific chemical 
moiety) and thus can be detected and measured. In my experiments, the 
TUNEL assay I used (Trevigen TACS2 TdT Fluo kit) for the detection of 
apoptotic nuclei is optimised for immunofluorescence detection and relied on 
biotin-cojugated dUTP monomers. Briefly, slides were fixed in PFA 4% and 
permeabilised with cytonin solution, a bland permeabilising agent provided by 
the manufacturer, for 30 minutes at room temperature. The TdT enzyme might 
require specific ions according to the tissue analysed and the embedding 
technique used: the best working conditions for the enzyme need to be 
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determined empirically. For OCT-embedded frozen SG tissue, the labelling 
mixture was prepared using cobalt cation stock. After incubation with the 
enzyme, the slides were washed in the suggested buffer and incubated with the 
provided streptavidin-conjugated fluorophore, counterstained with DAPI and 
mounted for fluorescence microscopy observation. 
3.5.5 Evaluation of the leukocyte infiltration in the salivary glands 
From a clinical point of view the lymphocytic infiltrate in the SG of SS patients is 
graded according to the Chisholm and Mason system [124],[146],[225],[226] 
that is based on the detection of inflammatory foci (a focus being defined as 
more of 50 periductal lymphocytes in 4 mm2 of tissue area). For this thesis and 
the grading of infiltrates forming in murine SG we used a different method 
proposed from my laboratory in 2005 [31]. According to this system, cellular 
aggregates with 10–50 periductal lymphocytes are defined as grade 1 
aggregates (G1). Grade 2 aggregates display >50 periductal lymphocytes and 
are divided in non-segregated (NS-G2) and segregated (S-G2) on the basis of 
the presence of B/T cell compartmentalisation. Grade 3 aggregates (G3) are 
characterized by >50 periductal lymphocytes and the presence of a GC-like 
structure, based on the detection of a network of FDCs. The size of the 
aggregates is easily assessable with a haematoxylin and eosin staining, while 
to determine the segregation status and the presence of FDC networks I used 
immunofluorence staining. In particular, for the B/T cell segregation antibodies 
against CD3ε (T cells) and B220 (B cells) were used on the same slide. To 
determine the presence of FDC networks an antibody against FDC-M1 (FDC 
networks) was used either alone or in tandem with B220.  
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Figure 3.8: Immunostaining of sequential sections of SS salivary glands. 
For this thesis the grading system proposed by Barone et al., Arthritis. Rheum. 
2005 was used and it is reported in figure. Left, from top to bottom: increasing 
grades of aggregation and organization in different patients with SS. (A) 
Cellular aggregates with 10–50 periductal lymphocytes are defined as grade 1 
aggregates (G1). (B) Grade 2 aggregates display >50 periductal lymphocytes 
and are divided in non-segregated (NS-G2, D) and segregated (S-G2, E) on the 
basis of the presence of B/T cell compartmentalisation (in this picture visualised 
via CD3/CD20 staining). (C) Grade 3 aggregates are characterized by >50 
periductal lymphocytes and the presence of a GC-like structure, based on 
histologic features of a GC-like structure and the detection of a network of FDCs 
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(here visualized via CD21 staining) on sections sequential to those stained for 
CD3 and CD20. In panel (F) a SG from a patient with non-specific chronic 
sialoadenitis is reported. From [31], copyright 2005.  
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3.6 PCR and quantitative real-time Taqman PCR 
3.6.1 Tissue total RNA extraction 
RNA was extracted from tissue using the Qiagen RNeasy mini kit according to 
manufacturer instructions. Tissues stored in RNA later at -80˚C were thawed on 
ice, weighted and an amount equivalent to approximately 20 mg was put in a 
sterile RNAse-free test tube with 600 µl of RLT buffer containing with 10 µl/ml of 
β-mercaptoethanol. Tissues were either homogenised with the aid of a rotor-
stator (one cycle of approximately 20 seconds) or with a beads homogeniser. In 
this last case homogenising micro-beads tubes (Precellys systems, Bertin 
Technologies, France) were filled with 600 µL of RLT buffer and lysed with a 
shaking micro-beads homogeniser (Precellys systems, Bertin Technologies, 
France). After homogenisation, either with rotor-stator or micro-beads, tubes 
were centrifuged at maximum speed (approximately 10’000xg) for 3 minutes 
with a bench-top microcentrifuge to eliminate debris and the homogenate 
transferred in fresh RNAse-free tubes. A volume of 70% ethanol was added to 
the lysate and the obtained solution readily mixed by pipetting. In the next step 
the solution was transferred in special silica membrane mini-columns fitted with 
2 ml collection tubes and centrifuged for 15 seconds at a speed >8000xg. The 
ethanol added in the previous step precipitates the nucleic acids that then bind 
the silica membrane during the centrifugation, while the aqueous solution is 
eluted in the collection tubes and discarded. After a wash step achieved adding 
350 µl of buffer RW1 to the column and centrifuging as above, a solution 
containing DNAse-I enzyme was added on the silica membrane according to 
manufacturer’s instruction to get rid of the DNA (lyophilised DNAse-I was 
reconstituted in 550 µl of distilled RNAse-free water and 10 µl of the solution 
 128 
containing the enzyme were added to 70 µl of buffer RDD and finally the 
obtained 80 µl were added to the silica membrane and left at room temperature 
for 15 minutes). To stop the enzymatic cleavage of DNA, 350 µl of buffer RW1 
were added to the column and the column centrifuged as described. The flow-
through was discarded and 500 µl of buffer RPE were added and the column 
centrifuged as described previously to wash away remaining contaminants. This 
step was repeated again this time with a centrifugation time of 2 minutes and 
the flow-through was discarded. The column was then transferred in a 1.5 ml 
RNAse-free collection tube and RNA bound to the silica membrane and devoid 
of protein and DNA contaminants was eluted by the addition of 30 µl of RNAse-
free distilled water and centrifugation at a speed >800xg for 1 minute. Elution 
was immediately transferred on ice, quantified and then stored at -80˚C until 
use.  
For FACS sorted cells (see section 3.8.2) RNeasy Micro kit (Qiagen) was used 
according to the manufacturer instruction. The procedure is essentially identical 
to that described above, with minor modification to reduce loss of nucleic acids. 
RNA was eluted in 12 µl of RNAse-free water and elution was immediately 
transferred on ice, quantified and then stored at -80˚C until use. 
3.6.2 Total RNA quantification 
Total RNA was quantified using a ThermoScientific Nanodrop 2000 device. The 
Nanodrop is substantially a spectrophotometer adapted to work with small 
volumes (1-2 µl). The device was first blanked using RNAse-free distilled water 
and then one microliter of the RNA solution obtained as described above was 
deposed on the Nanodrop pedestal and the arm closed. Absorbance was then 
read at 260 nm (nucleic acids absorbance) and 280 nm (protein absorbance) 
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and the quantity of RNA calculated according to the molar-extinction coefficient 
for single-stranded RNA. The amount of protein contamination was evaluated 
via the 260nm/280nm absorbance ratio: for pure RNA this ratio is approximately 
2.0 and for my purposes any value ≥1.7 was considered acceptable.  
3.6.3 Reverse transcription 
The enzyme reverse transcriptase (RT) is capable to convert RNAs into 
complementary DNA (cDNA). RTs are typical of retroviruses that need the 
enzyme to propagate into the host. Several commercial RTs are available and 
are used to convert messenger RNAs into cDNA for downstream applications. 
To convert mRNA obtained from cells and tissues into cDNA for my thesis I 
have used the Thermoscript RT-PCR system from Life Technologies. 
Thermoscript is the name of the RT enzyme is used in this kit and it is obtained 
via engineering of the enzyme cloned from avian myeloblastosis virus. The 
mutations introduced into the enzyme sequence make the enzyme less prone 
to degrade RNA and resistant to temperature up to 70˚C. Following the 
manufactures instructions, 1 µg of RNA obtained and quantified as described 
above was mixed with 1 µl of a 50 µM solution of Oligo(dT). These are 
deoxythymidine oligonucleotides that bind to the poly-adenosine 
monophosphate tail of mRNAs and provide a double-strand necessary for the 
Thermoscript enzyme to start the reaction. To the same solution 2 µl of a 10 nM 
solution of deoxyribonucleotides triphosphate (dNTP) were added: dNTPs 
provide the bases that the enzyme uses to synthesise the cDNA. The solution 
was then brought to a final volume of 12 µl with nuclease-free distilled water. 
Samples were then incubated for 5 minutes at 65˚C to induce denaturation of 
the RNA tertiary structures and then quickly placed in ice to induce Oligo(dT) 
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annealing to the mRNA poly(A) tails. At this point, 8 µl of a master mix 
containing 15 units of Thermoscript enzyme, 1 µl of 0.1 M dithiothreitol (DTT), 
40 units of RNAseOUT, 4 µl of 5x cDNA synthesis buffer and 1 µl of nuclease-
free water were added to the previous solution. RNAseOUT is a commercial 
RNAse inhibitor and DTT serves as its stabiliser in the reaction. The solution 
was then placed in a thermalcycler (Applied Biosystems 9700) for 1 hour at 
50˚C to allow the Thermoscript to synthesise cDNA followed by a step at 85˚C 
for 5 minutes to inactivate the enzyme. As a final step, elimination of the mRNA 
or other contaminating RNAs from the solution was achieved by adding 2 units 
of RNAse H to the solution that was left for 30 minutes at 37˚C. The synthesised 
cDNA was brought to a final concentration of 10 ng/µl with nuclease-free water 
and stored at -20˚C until use. 
RNA extracted from FACS-sorted cells was significantly less abundant than that 
extracted from tissues. For this reason the maximum volume of RNA allowed by 
the RT kit was used to produce cDNA from these samples, independently from 
the starting RNA concentration. Obtained cDNA was not further eluted and was 
stored to be used directly in the Fluidigm  
3.6.4 Quantitative real-time Taqman PCR and Fluidigm Dynamic Array 
Polymerase chain-reaction (PCR) is a process that amplifies a specific DNA 
sequence during sequential amplification cycles. In real-time PCR reactions, the 
buffer in which the reaction takes place is added with a fluorescent dye that 
changes its fluorescence emission in function of the level of the amplification 
achieved for each single cycle, that is in real-time as opposite to the classic 
end-point PCR where the amplification level is assessed only at the end of the 
reaction. Several different real-time PCR techniques exist, whit specific up and 
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down sides. In this thesis, I have used the TaqMan real-time PCR system. In 
this method in the master mix are present not only two sets of primers that 
define the sequence of cDNA that will be amplified, but also a probe 
complementary to a cDNA sequence located in the region defined by the primer 
pair. The probe is conjugated with a fluorescent dye and a fluorescence 
quencher. Moreover, the enzyme used in this reaction is a modified version of 
the Taq polymerase used in classic PCR: the TaqMan enzyme not only 
polymerases oligonucleotide sequences complementary to the template cDNA, 
but also has an exonuclease activity that allows the hydrolysis of the probe 
bound to the cDNA. For each cycle of amplification then, the TaqMan enzyme 
starts the amplification at the primer-annealing site and during the synthesis of 
the complementary strand it encounters and digests the probe. The quencher is 
thus released from the fluorescent dye and fluorescence can be measured.  
The real-time PCR was run in duplicates in 384-well plates (Applied 
Biosystems) with 10 ng/well initial amount of cDNA. The probes used were 
bought conjugated with the FAM dye from a commercial producer 
(LifeTechnologies) and used with a commercial master mix (Applied 
Biosystems). The reaction took place in an ABI Prism 7900HT machine and 
data were collected and analysed with the SDS software suite (Applied 
Biosystems). The thermal cycling conditions were as follows: 2 minutes at 50˚C, 
10 minutes at 95˚C, 45 cycles of a denaturation step at 95˚C for 15 seconds 
and an annealing/extension step at 60˚C for one minute. A calibrator sample 
was used for every plate and consisted of either spleen, Peyer’s patches or SG 
from a control animal.  
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To relative quantification was obtained using the comparative threshold cycle 
(Ct) method. The Ct cycle of the endogenous control (normally mammalian 18S 
rRNA) was used to normalise for the initial cDNA amount of each sample by 
subtracting from the average between Ct duplicates of the gene of interest the 
average of the endogenous control, obtaining in this way the ΔCt value. To 
calculate the ΔΔCt value, the ΔCt of each sample was subtracted to the chosen 
reference sample (usually PP or SG from a control animal). The ΔΔCt value for 
each sample was then use to calculate the relative quantification (RQ value) 
using the equation RQ=2-ΔΔCt. The number two in the equation represents the 
doubling of the amplification product for every cycle of PCR, considering an 
optimal efficiency of the PCR. For TaqMan PCR, this approximation refers to a 
high efficiency reaction where the fluorescence doubles for each cycle of 
amplification. In order to confirm the PCR efficiency, in initial set-up experiments 
serial 25 dilutions (i.e. 1:1, 1:32; 1:1,032) of a control cDNA tissue positive for 
the gene of interest (i.e. spleen cDNA) were used and the observed CT values 
reflected the expected difference of 5 cycles of amplification for each sample 
dilution. 
For the real-time PCR analysis of FACS-sorted cells a different technique was 
used that allowed the relative quantitation of gene expression starting from 
small amounts of initial mRNA. The sorted cDNA samples, extracted with the 
RNeasy micro kit and retrotranscribed with the Thermoscript kit as described in 
the above sections, were loaded on a 48x48 Fluidigm Dynamic Array integrated 
fluidic circuits (IFCs) chip together with the real-time master-mix (Applied 
Biosystems) and TaqMan probes (Lifetechnologies) described above. 
Microfluidic chips allow the use of nano-volumes of cDNA, master mix and 
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probes in comparison with the micro-volumes necessary for the 384-wells plate 
method described above. The system can load up to 48 different samples 
requiring as little as 5 µl of each sample at 5 ng/µl concentration to run as many 
as 48 different assays (45 genes of interest and 3 housekeeping genes). Any 
chip can thus run 2’304 single real-time reactions at a time. The Fluidigm chip, 
loaded with samples and reagents, was then run on a Fluidigm Biomark HD 
system. As calibrating sample, I used the same Peyer’s patches sample used 
for the 384-wells plate system and the three housekeeping genes used were 
eukaryotic 18s, β-actin and hypoxanthine-guanine phosphoribosyltransferase 
(HPRT). The PCR reaction started with a cycle of 10 minutes at 95˚C, followed 
by 40 cycles formed by a 95˚C for 15 seconds denaturation step followed by a 
60˚C for one-minute annealing/elongation step. Relative quantitation was 
calculated using the 2-ΔΔCt method described above.  
A table with the list of all the primers and probes used for this thesis is reported 
in Table 3.3. 
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Gene Product mRNA Accession Number Assay ID Source 
Mouse AID NM_009645 Mm00507774_m1 Applied Biosystems 
Mouse 
CXCL13 NM_018866 Mm00444533_m1 Applied Biosystems 
Mouse CXCR5 NM_007551 Mm00432086_m1 Applied Biosystems 
Mouse CCL19 NM_011888 Mm00839967_g1 Applied Biosystems 
Mouse CCR7 NM_007719 Mm00432608_m1 Applied Biosystems 
Mouse BAFF NM_033622 Mm00446347_m1 Applied Biosystems 
Mouse IL-4 NM_021283 Mm00445259_m1 Applied Biosystems 
Mouse IL-21 NM_021782 Mm00517640_m1 Applied Biosystems 
Mouse Ltβ NM_008518 Mm00434774_g1 Applied Biosystems 
Mouse LtβR NM_010736 Mm00440235_m1 Applied Biosystems 
Mouse CCL5 NM_013653 Mm01302427_m1 Applied Biosystems 
Mouse CCL7 NM_013654 Mm00443113_m1 Applied Biosystems 
Mouse CCR1 NM_009912 Mm00438260_s1 Applied Biosystems 
Mouse HPRT NM_013556 Mm00446968_m1 Applied Biosystems 
Mouse β-actin NM_007393 4352341E Applied Biosystems 
Eukaryotic 18S X03205.1 4319413E Applied Biosystems 
 
Table 3.3: TaqMan probes used for gene expression analysis. 
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3.7 Serum antibodies characterization 
3.7.1 Western blot analysis using serum antibodies for detection 
A Western blot method is commonly used to detect the presence of a 
determined protein in cell culture or tissues. The technique consists in two main 
steps: the first is the polyacrylamide gel electrophoresis (PAGE) where the 
proteins present in a solution are separated on the basis of their molecular 
weight; the second process, the immunoblot, is the transfer of the separated 
proteins from the polyacrylamide gel to a membrane that is then incubated with 
an antibody against the protein of interest and then detected with an enzyme-
labelled antibody directed against the primary antibody.  
In my thesis I have used the Western blot technique not to detect the presence 
of a certain protein in a solution, but to assay sera from treated and untreated 
animals for the presence of antibodies against adenoviral proteins. For this 
reason, cell lines were infected with luciferase or LacZ-encoding adenoviruses 
or left uninfected and the cell lysates obtained underwent electrophoresis and 
immunoblot. At this stage, blotted membranes were incubated with sera from 
AdV- or control-treated animals culled at different time-points that were used as 
primary antibodies. As a principle, instead of using a primary antibody with 
known specificity to detect the presence of the specific target protein on the 
blotted membrane, membranes containing adenoviral proteins were used to 
detect the presence of specific antibodies in the sera.  Enzyme-conjugated anti-
mouse antibodies were used in the last step to detect anti-viral antibodies 
bound to the viral proteins.  
To achieve this, confluent Hek293 cells were infected with LacZAdV, LucAdV or 
left uninfected. Cells were returned in the incubator at 37˚C for 48 hours. At the 
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end of the incubation period, the medium was discarded and the cells washed 
in PBS. A lysis buffer (RIPA buffer, 50mM Tris, 150mM NaCl, 0.5% sodium 
deoxycholate, 1% NP-40, 0.1% sodium dodecyl sulphate, pH=8) containing 
protease inhibitors (Complete mini EDTA-free, Roche) was then added to the 
wells to disrupt plasma membranes and free and stabilise the host and viral 
proteins.  
The protein content of the lysates was quantified with a bicinchoninic acid 
(BCA) assay (Pierce, USA). Cell lysates were diluted in a 5x Laemli solution 
(10% sodium dodecyl sulphate, 50% glycerol, 25% β-mercaptoethanol, 0.01% 
bromphenol blue and 0.312 M Tris HCl, pH=6.8) and left on a hotplate at 100˚C 
to denaturise for 5 minutes. β-mercaptoethanol is a reducing agent, which helps 
breaking the sulphide bonds among peptides. The sodium dodecyl sulphate 
(SDS) molecules present in the solution and in the lysis buffer help to 
denaturise the proteins as the non-polar moiety binds to the hydrophobic amino 
acids of the proteins exposing the negative portion of SDS to the buffer and 
giving thus a negative charge to the hydrophobic residues of the protein. 
Moreover, the negatively charged moiety of SDS also binds to the positive 
residues, neutralising them. Eventually, during the treatment at 100ºC, 
disulphide bonds are reduced by β-mercaptoethanol and the high temperature 
allows denaturation of the proteins into their primary structure that is maintained 
by SDS molecules by neutralising the positive charges and giving to the 
polypeptide a strongly negative charge. Bromophenol blue is a blue dye that 
helps monitoring the migration of the proteins in the next steps.  
The cells lysates were loaded on a commercial polyacrylamide gel (Nu-PAGE, 
4-12% bis-tris, Invitrogen) in an electrophoresis tank (Invitrogen) filled with 
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running buffer (5mM MOPS, 5mM Tris, 0.1% SDS, 0.1mM EDTA) and a 
constant electric tension of 100V was applied to the tank for approximately 1.5 
hours. The proteins suspended and denatured in the loading buffer have a 
strong negative charge and when the electric field is applied, they migrate into 
the polyacrylamide towards the anode. During the migration the proteins 
separate in bands according to their size and the composition of the gel matrix: 
smaller peptides migrate faster, while bigger proteins migrate slower. Per every 
gel lane I loaded the equivalent of 25 µg of protein. At the end of the 
electrophoresis, the separated bands were transferred to a nitrocellulose 
membrane with the aid of a commercial semi-dry system (iBlot, Invitrogen) 
according to manufacturer’s instructions. The efficiency of the transfer was 
assessed incubating for few minutes the membrane with a 0.1% Ponceau red 
solution in acetic acid: Ponceau red binds proteins in a non-specific manner and 
thus allows a rapid visual check of a successful and equal transfer. The 
membrane was then washed from the red dye for 10 minutes in TBST (TBS 
0.1% Tween-20) on a rocking shaker. The membrane was then incubated in a 
solution containing 5% powder milk in TBST for 3 hours at room temperature. 
Incubation with the milk solution blocks protein non-specific binding.  
At this point, membranes were incubated either with a commercial anti-
adenovirus antibody (goat anti-adenovirus 5 whole antiserum, AB6982, Abcam, 
dilution 1:4’000) as a positive control or with sera from the treated mice at a 
dilution of 1:100 in a 5% milk TBST solution, overnight at 4˚C. The membrane 
was then washed 3 times for 5 minutes in TBST and incubated with a 
horseradish peroxidase-conjugated detection antibody against the primary (in 
this case goat anti-mouse IgG from Sigma for the membranes incubated with 
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mice sera or rabbit anti-goat IgG from Dako for the membranes incubated with 
the commercial anti-adenovirus antiserum). Secondary antibodies were diluted 
in blocking solution and the membranes incubated for 1 hour at room 
temperature.  
To detect the binding of the detection antibody to the protein of interest, an 
enhanced chemiluminescence (ECL) substrate is used. The ECL substrate 
contains luminol that is oxidised by the peroxidase-linked antibodies present on 
the membrane. Luminol in its excited state decays to the ground state emitting 
light at 428 nm. The light emitted from the membrane is used to expose an X-
ray film that is then developed. After 3 washes in TBST the membrane was 
incubate with ECL (Amersham Life Science), wrapped in transparent film and 
left at room temperature for one minute. The membrane was then used to 
expose an autoradiography film for various times in a dark room equipped with 
red-light illumination. After exposure the films were developed in an automated 
developing machine and studied.  
3.7.2 Anti-nuclear antibodies (ANA) detection in serum 
Levels of anti-nuclear IgG antibodies (ANA) were assessed using an indirect 
immunofluorescence method. The human epithelial cell line 2, or HEp-2, is 
classically used for this assay as HEp-2 cells have a large nucleus and a high 
rate of mitosis thus being rich of mitosis-associated antigens. The rationale 
behind this test is that anti-nuclear antibodies present in serum react with the 
nuclei of the cell line and can thus be detected using an appropriate 
fluorophore-conjugated secondary antibody (in the case of murine serum, anti-
mouse immunogluobulins FITC-conjugated) on a fluorescence microscope. For 
this thesis twelve-spot slides coated with Hep2 cells were bought from 
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BioSystems (Spain) and each spot was incubated with 20 µl of diluted serum for 
1 hour at room temperature or overnight at 4˚C. The dilutions used were 1:80, 
1:160 or 1:320 and sera were diluted in a solution of 2% BSA, 0.05% Tween-20 
in PBS. These dilutions were used to parallel the dilutions used in clinic to 
diagnose the presence of ANA in human serum. As a positive control I used 
pooled sera from autoimmune MRLlpr/lpr animals (a murine strain that develops a 
lupus-like syndrome with a plethora of different anti-nuclear antibodies, a kind 
gift of Dr. Francesco Carlucci, Imperial College, London) serially diluted to end-
point. As negative control, pooled sera from 12 weeks old untreated C57Bl/6 
wild-type female mice were used. To detect binding of serum antibodies to the 
HEp-2 cells, slides were washed twice in PBS for 5 minutes and incubated for 
30 minutes at room temperature with a fluorophore-conjugated antibody against 
the Fc portion of mouse IgGs (Sigma) diluted 1:200 in the dilution buffer used 
previously. After washing in PBS, coverslips were mounted and images were 
acquired either with a motorised epifluorescence microscope (Olympus BX61) 
equipped with a high-definition digital camera (Hamamatsu, Orca-R2) or with a 
confocal microscope (Leica DM5500 Q, TCS SPE).  
3.7.3 Anti-adenovirus antibodies detection in serum  
Detection and relative quantitation of the different classes of anti-adenovirus 
immunoglobulins present in the sera of AdV-treated mice were assessed using 
indirect enzyme-linked immunosorbent assay (ELISA) methods.  
In indirect ELISA an antigen (in this case viral particles) is added to the wells of 
an ELISA-treated 96-wells plate. The antigen is suspended in a buffer solution 
that facilitates the binding to the plate wells. After an appropriate incubation, the 
antigen is removed and the binding sites not coated with the antigen and the 
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non-specific binding sites are neutralised by adding a blocking solution 
containing irrelevant proteins. Once the incubation with the blocking solution is 
finished, the blocking solution is removed and a primary antibody against the 
antigen of interest is added to the wells. After the incubation with the primary 
antibody, wells are washed and a solution containing an enzyme-conjugated 
secondary antibody against the primary antibody is added to the wells. After this 
incubation, wells are again washed and a substrate for the enzyme conjugated 
the secondary is added and colour development is observed and measured. 
Generally, samples are loaded in duplicates and two dilutions for every sample 
are loaded on the plates. Usually, a standard curve of known concentrations of 
an antibody against the antigen of interest is added to the plate to allow 
absolute or relative quantitation. Moreover, one of the wells is normally 
incubated without the primary antibody to assess the blank, or baseline 
absorbance, for the assay. For the purpose of this thesis, as sera from 
cannulated animals and controls were to be tested for the presence of anti-viral 
antibodies, the ELISA plates were coated with the same amount of AdV 
particles and the sera were used as primary antibodies (see  
 
 
Table 3.4 for details of the dilution used). A standard curve was obtained using 
serial dilutions from a pool of different sera obtained from animals cannulated 
and culled at different time points. Data were expressed as arbitrary units (AU) 
with the highest value assigned to the higher concentration.  
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Figure 3.9: General scheme of indirect ELISA. The antigen is used to coat 
the plate and an enzyme-conjugated primary antibody is used to detect the 
antigen. In my experiments, sera from treated and control animals were used as 
primary antibodies and a secondary anti-mouse conjugated-antibody was used 
to detect the presence of specific anti-virus antibodies in sera. Figure from 
Wikipedia.  
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In details, ELISA Maxisorp 96-well plates (Nunc) were coated with 100 µl/well of 
a 5 µg/ml solution of adenovirus diluted in carbonate/bicarbonate buffer 
(Sigma). AdV concentration was determined reading the absorbance of the 
AdV-containing solution at 280 nm with a Nanodrop device, after blanking the 
instrument with TSG buffer. Plates were incubated overnight at 4°C in a moist 
chamber (or 2 hours at 37°C). Plates were then washed 3 times with PBS. Non-
specific binding was blocked incubating plates for 1 hour at 37°C with 100 
µl/well of a solution 1% bovine serum albumin (BSA) in PBS. Plates were 
washed 3 times in PBS. Plates were incubated with standards, positive and 
negative controls and samples diluted in PBS containing 1% BSA and 0.05% 
Tween. Standards were obtained pooling the sera from treated animals at 
various time-points. The negative control consisted of pooled sera of female 12 
weeks old untreated animals. The optimal dilution for standards and samples 
was determined during preliminary experiments. The dilutions used are 
reported in Table 3.4. Plates were incubated for 1 hour at 37°C and then 
washed in PBS 3 times. 100 µl of a HRP-linked or biotinylated anti-mouse 
immunoglobulin antibodies diluted in PBS containing 1% BSA and 0.05% 
Tween 20 (Sigma A2554: anti-mouse IgG(H+L)-HRP 1:10’000) 
Plates were incubated for 1 hour at 37° and then washed 3 times in PBS. In the 
case of biotinylated antibodies, a further incubation step with HRP-conjugated 
streptavidin was necessary (dilution 1:5’000, Biolgend). Binding was detected 
using 75 µl/well of BD OptEIA TMB substrate reagent set (GE healthcare). 
Reaction was stopped upon colour development with 30 µl/well of 2M H2SO4. 
Absorbance was read at 450 nm with an ELISA plate reader. Relative 
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concentrations were calculated from the standard curve and expressed as 
arbitrary units (AU)/ml.  
 
 
 
 
Table 3.4: Standard and sera dilutions used for immunoglobulin ELISA. 
3.8 Flow cytometric analysis and cell sorting 
In a flow cytometer, a fluidic stream is created where cells drawn from a solution 
can pass only one at a time in front of a laser beam. When the laser light hits 
the cell, photons are scattered in every direction according to the physical 
parameters of the cell they hit, in particular to its size and complexity (i.e. 
granularity). Inside the cytometer, photomultipliers measure the photons 
scattered forward to the laser (forward scatter, FSC) and at an angle of 45° to 
the light-path (side scatter, SSC): the FSC is in relation to the size of the cell, 
while the SSC to the complexity and granularity of the cell. Together with these 
basic physical parameters, flow cytometers can also measure the fluorescence 
emitted by the cells hit by the laser light. In flow cytometry, before being 
analysed by the cytometer, cells are incubated with fluorophore-conjugated 
antibodies directed against specific antigens. When exposed to laser-light of 
specific wavelength, the fluorophores emit fluorescence that can be recorded by 
the photomultipliers and analysed. With this technology, size and complexity of 
a cell can be associated with information about the presence and abundance of 
specific cellular markers. The data collected are showed in a single dimension 
(histogram) or plotting two or more parameters against each other (dot plot).  
 Total IgGs 
Standard Highest 1:100 Then 1:2 
Samples 1:100/1:200 
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Florescence-activated cell sorting (FACS) systems are based upon the very 
same principle of flow cytometry and are also able to select and separate a 
determined population from the analysed cell suspension for downstream 
applications. Generally, in these flow cytometers the fluidic stream containing 
the cells is arranged to have a large separation between a cell and the following 
one. Moreover, the stream is set to break in individual droplets containing only 
one cell just after the interrogation point. After the interrogation point, a metal 
ring can give a positive or negative charge to each single droplet passing by, 
according to the physical parameters and fluorescence readings associated to 
the cell just analysed. The charged droplets then pass through two charged 
metal plates that can deflect them towards containers on the basis of the 
charge of the droplets.  
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Figure 3.10: basic schematic of a flow cytometer. Laser light is directed 
against the fluidic stream containing cells passing one at a time in the 
interrogation point. A forward light scatter detector is placed directly in front of 
the laser emitter, while an array of detectors is placed at a 45˚ angle to detect 
side scattered light and fluorescence. A bandpass filter is associated to each 
detector to separate and discriminate the various wavelengths produced at the 
interrogation point. 
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3.8.1 Tissue preparation for flow cytometric analysis/sorting and cell 
culture 
To obtain a homogenous suspension of cells to be analysed via flow cytometry, 
salivary glands, spleens and lymph nodes were enzymatically digested to 
dissolve the extracellular matrix and release cells. When needed (e.g. spleen), 
red blood cells where eliminated from the cell suspension using a lysis buffer. 
Before surface staining with antibodies, non-specific binding to Ig receptors was 
blocked with a solution containing anti-Fc receptor specific antibodies and dead 
cells were marked using either nuclear dyes or new generation viability dyes.  
3.8.1.1 Enzymatic tissue digestion 
Harvested tissues were rapidly stored in 1.5 ml tubes in 500 µl of RPMI medium 
(Gibco) supplemented with 2% foetal bovine serum (Life technology). Tissue 
were then minced in medium using dissecting scissors and transferred in 5 ml 
FACS tubes (BD) and 1 ml of digestion medium was added. Digestion medium 
consisted of RPMI 2% FBS, 3.7 mg/ml collagenase-D (Roche), 30 µg/ml 
DNAse-I (Sigma). Tubes containing minced tissue in digestion medium were 
then incubated for 30 minutes at 37°C under continuous stirring (2 mm 
magnetic stirring bars, VWR) at 500 rpm. After this first incubation tissue was 
vigorously pipetted to favour mechanical dissociation and 15 µl of 0.5 M EDTA 
(Gibco) were added to stop the enzymatic reaction. The solution was incubated 
for additional 5 minutes at 37°C under continuous stirring.  
The cellular suspension obtained was passed through a 40 µm nylon cell 
strainer (BD) and the filter was washed with 10 ml RPMI 2% FBS and the flow-
through was collected in 50 ml test tubes (BD) and centrifuged for 5 minutes at 
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400xg. The supernatant was discarded and the cell pellet suspended in the 
appropriate buffer for downstream applications.   
3.8.1.2 Red blood cells lysis 
For flow cytometric analysis of spleens, red blood cells (RBC) need to be 
removed from the solution as they might interfere with staining, data acquisition 
and analysis. To do so, the suggested volume of a commercial ammonium 
chloride solution (Biolegend) was added to spleen cell pellets for 5 to 10 
minutes to favour RBC lysis. The solution obtained was spun down for 5 
minutes at 400xg and suspended in the appropriate buffer for downstream 
applications.  
3.8.1.3 Fc-receptor block and live/dead cells discrimination 
Prior to the staining with specific antibodies, the suspension containing the 
appropriate number of cells was incubated with anti-CD16/32 antibodies 
cocktail to block the non-specific binding of the staining antibodies to the Fc-
receptors present on several hematopoietic cell types. In particular, 1 µl of a 
commercial Fc-blocking cocktail (TrueStain, Biolegend) was added the cells 
suspended in 50 µl of 1x PBS. The solution was incubated for 15 minutes at 
room temperature prior to the next step. 
To exclude dead cells from the analysis two strategies are available: the use of 
a nuclear dye non-permeable to cell membrane or the use of new generation 
viability dies resistant to fixation and permeabilisation. In the first case, a 
nuclear dye such as propidium iodide or DAPI is added to the staining cocktail: 
dead cells lose membrane integrity and are permeable to the dye that 
irreversibly stains the nuclei. Dead cells will be positive for the dye and will be 
excluded from the analysis. In the second case, live and dead cells are stained 
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with new generation dyes that bind amine groups on proteins: live cells with 
uncompromised plasma membrane will bind the dyes only on their surface, 
while dead cells will incorporate and bind the dyes also in the intracellular 
compartment. Eventually, dead cells will incorporate significantly more dye than 
live cells and will be easily distinguishable. These dyes resist fixation and are 
suitable for permeabilisation protocols as they are applied to the cells before 
any kind of staining. In this thesis I have used both methods: in the case of 
DAPI, a 1:10’000 dilution of the 5 mg/ml stock solution (LifeTechnologies) was 
used after the surface staining described in the next section; in the case of 
fixable dyes, a commercial kit from Biolegend was used (Zombie Aqua or 
Zombie NIR) prior to surface staining according to the manufacturer 
instructions.  
3.8.2 Surface antibody staining, acquisition and sorting 
After Fc-receptors block and fixable dye for live/dead discrimination were 
applied to the cell suspension, cells were spun at 400xg for 5 minutes and 
suspended in 50 µl of the staining solution containing the relevant conjugated-
antibodies in PBS 2% FBS. To determine the antibody concentration to use, 
titration of each antibody was performed in advance. Cells were incubated in 
staining cocktail for 30 minutes in the dark. After this step 500 µl of PBS 2% 
FBS were added to the tubes and cells were spun again at 400xg for 5 minutes. 
The supernatant was decanted and cells were resuspended in the appropriate 
volume (300-500 µl) of PBS 2% FBS for flow cytometric analysis.   
Samples were acquired on LSR Fortessa flow cytometer or on FACS Aria II 
(BD) cell sorter with FACSDiva software (BD). Data were analysed using 
FlowJo 8.7 or FlowJo X (Tree star) for MacOs X systems.  
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Sorted cells for mRNA extraction and expression analysis were collected in 15 
ml Falcon tubes containing PBS, centrifuged for 20’ at 400xg. The supernatant 
was then discarded and the cell pellet dissolved in 350 µl of Qiagen RLT buffer. 
Lysates were either readily processed for RNA extraction or stored at -80˚C.  
3.8.3 Antibodies, antibodies panels and gating strategies 
A list of antibodies used in this thesis is reported in Table 3.5. Flow cytometry 
was used on spleen and SG samples. Although different panels have been 
used to discriminate different populations of cells, a general gating strategy was 
adopted. A gate based on leukocytes physical parameters was first drawn on a 
FSC versus SSC dot plot. To exclude doublets and clumps of cells, events 
gated in the leukocytes gate were then visualised as SSC height versus SSC 
width and FSC height versus FSC width: the height of the peak generated by an 
event recorded at the interrogation point of a flow cytometer (i.e. where the cell 
is hit by the laser light) reflects the intensity of the light that hits the 
photomultipliers, and this parameter depends on the voltage applied to the 
photomultiplier; the width reflects the time that the cell takes to pass in front of 
the interrogation point, thus is directly proportional to the size of the cell and 
independent from the voltages applied to the photomultipliers. Gating events 
using the height of the peak versus the width of it excluding those events with a 
high width allows an efficient exclusion of cellular doublets and clumps.  
Dead cells were then excluded gating out events positive for DAPI or live/dead 
fixable dyes. Live, single cells with the characteristic of leukocytes were then 
selected for their positivity for the pan-haematopoietic marker CD45. From this 
general population, the cells unnecessary for the analysis were excluded by 
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marking them with antibodies carrying the same fluorophore, thus collecting 
them in the same “dump” channel.  
To determine the right position of the various gates, “fluorescence minus one” 
(FMO) controls were performed for every antibody in order to thoroughly define 
the negative and positive populations.  
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Figure 3.11: General gating strategy for flow cytometry experiments. 
Stained single cell sample suspensions in the appropriate buffer were acquired 
by flow cytometer. A) The first gate was drawn considering the physical 
characteristic of size (FSC) and complexity (SSC) of mononuclear cell 
suspensions. These first gated cells were then selected comparing the height 
and the width of their FSC and SSC signal, so to exclude cell 
doublets/agglomerates with a high peak-width (B and C). Single cells were then 
selected for the presence of the common hematopoietic marker CD45 (D) and 
from these, those positive for viability dyes were excluded (E, here using 
Zombie Aqua/NIR dye, but with similar results using DAPI). F) B and T 
lymphocytes were removed from the analysis gating out those cells positive for 
CD3 and CD19 and NK cells were enumerated via their expression of NK1.1 
marker (G, NKT cells would not be present at this stage because they express 
CD3 and would be excluded with B and T cells in F). Myeloid cells were 
selected thanks to the expression of CD11b on their surface (H) and the SSC-
high CD11c-negative granulocytes were gated out at this stage (I, this 
population is also positive for the eosinophil granulocytes Siglec-F as shown in 
section 5.1.3). Neutrophil granulocytes were gated as Ly6C+Ly6G+ cells (J), 
while the Ly6G- population was gated either according to the expression of 
F4/80 and Ly6C (K) or F4/80 and CD11c (L). In K monocytes were gated as 
F4/80-positive and Ly6C-positive to Ly6C-high, while F4/80+/Ly6C- were 
considered macrophages; in L, bona fide DCs were gated as F4/80-/CD11c++.   
  
 153 
Antigen Fluorophore Producer  Catalogue number  Clone Dilution 
CD11b BV605 BIOLEGEND 101237 M1/70 1:200 
CD11c ALX488 BIOLEGEND 117311 N418 1:200 
CD19 APC/H7 BD 560143 1D3 1:200 
CD19 PB BIOLEGEND 115523 6D5 1:200 
CD3e PB BIOLEGEND 100334 145-2C11 1:50 
CD3e APC/H7 BIOLEGEND 100330 145-2C11 1:100 
CD45 PerCP/Cy55 BIOLEGEND 103132 30-F11 1:800 
F4/80 PC7 BIOLEGEND 123114 BM8 1:200 
Ly6C PE BIOLEGEND 128007 HK1.4 1:400 
Ly6C ALX647 BIOLEGEND 128010 HK1.4 1:400 
Ly6G APC/H7 BIOLEGEND 127623 1A8 1:400 
NK1.1 BV421 BIOLEGEND 108732 PK136 1:200 
NK1.1 PE BIOLEGEND 108708 PK136 1:400 
Siglec-F BV421 BD 562681 E50-2440 1:200 
Siglec-H APC BIOLEGEND 129611 551 1:400 
Table 3.5: List of the antibodies used for flow cytometry experiments. 
3.9 Statistical analysis 
Differences in quantitative variables were analysed by the Mann–Whitney U test 
when comparing two groups and by the non-parametric Kruskal-Wallis test 
followed by Dunn’s post-hoc test to compare the differences between each 
variable among multiple groups. Spearman’s rank test was used to assess the 
presence of correlation between quantitative variables. χ2 with Yates’ correction 
when required or Fisher’s exact test when appropriate was used to evaluate 
associations of qualitative variables in the different groups. All the statistical 
analyses were performed using GraphPad Prism version 5.01 for MacOS X 
(GraphPad, San Diego, CA). A p value <0.05 was considered statistically 
significant. 
  
 154 
Chapter 4 | Results 
 
 155 
4 Development and validation of an inducible model of 
sialoadenitis and breach of self tolerance 
4.1 Optimisation of the intra-gland delivery method and replication 
of preliminary observations  
Preliminary observations from our laboratory showed that the administration of 
high doses of reporter gene-encoding AdV in the SG of wild-type C57Bl/6 
animals induced a strong inflammatory response that, over a time of three 
weeks, lead to periductal infiltrates. These preliminary findings allowed us to 
speculate that a strong antigenic challenge provided by AdV administration 
could induce ELN in the SG of the animals.  
Thus, during my PhD work I first aimed to replicate these results. In this section 
I will report the dose-response dynamic of the AdV-mediated genetic transfer 
and the time-course of expression of the transgene encoded by the AdV.  
4.1.1 Optimisation of the intra-gland delivery method and analysis of the 
dynamic of AdV gene-transfer 
Delivery of replication-deficient AdV in murine submandibular SG via 
retrocannulation of the excretory duct has previously been described as a 
suitable and efficient tool for transient local gene transfer [227]. With the help of 
Professor Gordon Proctor (King’s College, London, UK) I adapted a retrograde 
cannulation technique that was previously developed in rats [222] using 
customized glass cannulae that proved to be a reliable method for specific 
delivery of small volumes (up to 50 µl) in the sub- mandibular glands. The 
apparatus used to keep the animals in the correct position, the insertion of the 
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cannula in the gland orifice and the effect of cannulation of a blue dye in only 
one of the two submandibular SG are depicted in Figure 4.1 A-C. This 
preliminary set of experiment proved that the delivery in the SG was restricted 
to the submandibular SG, leaving the sublingual gland and the contralateral SG 
unaffected by the procedure. To study the dose-response relationship between 
the amounts of the viral infective particles delivered and the activity of the 
reporter gene, I used an E1-E3-deleted replication-defective human adenovirus 
5 encoding for firefly luciferase under the control of a CMV promoter (LucAdV).  
As reported in Figure 4.1 D, increasing luciferase activity was observed using 
increasing doses of LucAdV within the first week post-cannulation, which then 
decreased over the next 2 weeks.  
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Figure 4.1: Retrocannulation of the submandibulary salivary gland. A) A 
metal paperclip is shaped to accommodate the animal’s upper incisors, while a 
suture thread passed around the lower incisors is connected to a weight to keep 
the mouth open. In (B) the glass cannula (highlighted in red) is inserted directly 
in the salivary gland orifice beneath the papilla, highlighted here with a pale 
blue dye and circled in yellow. (C) Delivery of 50 µl of a dye through the left 
excretory orifice only stains the left submandibular gland (SM) but not the 
sublingual gland (SL) nor the contralateral gland (C SG). Luciferase activity in 
the salivary glands of infected animals during the first week post-procedure is 
dependent on the dose of LucAdV delivered (D), but by week two this dose-
dependency is lost. Every symbol represents the mean of the luciferase activity 
of 3 salivary glands.  
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4.1.2 AdV delivery to the SG progressively induce SS-like periductal 
inflammatory foci in wild-type C57BL/6 mice 
Histological analysis of the cannulated glands demonstrated that AdV doses of 
108 PFU/gland, but not vehicle control (or doses <107 PFU), induced from week 
2 post-cannulation the formation of lymphomonocytic infiltrates organized as 
periductal aggregates, which by week 3 post-cannulation strongly resembled 
lymphocytic foci found in SS patients (Figure 4.2 D–F and Figure 4.10 B-D). 
The formation of lymphoid aggregates was invariably preceded by a rapidly 
induced diffuse inflammatory infiltrate, which resolved within the first week post-
cannulation to be replaced by typical periductal focal infiltration by week 2 post-
cannulation (Figure 4.2 D–F). Importantly, this phenomenon was independent 
from the reporter gene used, because it was also triggered by same amounts of 
LacZAdV (Figure 4.10 B–D) with no significant difference in terms of prevalence 
and size of the periductal foci comparing the two viruses. Delivery of virus-
vehicle alone did not induce any significant inflammation and/or 
lymphomonocytic infiltration (Figure 4.2 A-C). The mean and standard error of 
the mean (SEM) of the number of periductal foci developing in the salivary 
glands after delivery of either LucAdV or LacZAdV at the different time points is 
reported in Figure 4.2 G. 
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Figure 4.2: AdV delivery to the SG progressively induce SS-like periductal 
inflammatory foci in wild-type C57BL/6 mice. (A-F) Representative 
haematoxylin and eosin microphotographs showing inflammatory responses 
induced by local administration of either vehicle (A-C) or LucAdV (D-F). After 
AdV delivery, diffuse lymphomonocytic infiltration in the first week (D) is 
followed by progressive organization of periductal inflammatory aggregates 
during week 2 (E) and week 3 pc (F), periductal foci circled in black. Vehicle 
delivery induces negligible inflammation (A-C). The mean ± SEM of the number 
of periductal foci/gland following either LucAdV or LacZAdV delivery at different 
time points is reported in (G). (**p<0.01 between AdV and vehicle-treated mice 
at each time point, minimum of 10 mice per time point). 
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4.2 A novel inducible model of ectopic lymphoid neogenesis  
Next, I aimed to investigate whether the periductal inflammatory foci triggered 
by the adenoviral infection displayed features of TLS. To be defined as a model 
of ELN, several key characteristics need to be present; i) organisation of B and 
T cell in segregated areas, ii) presence of specialised vasculature such as HEV, 
iii) expression of lymphoid chemokines, iv) development of FDC networks and 
v) markers of functional germinal centres.  
In this section, I will discuss my findings regarding the above-mentioned criteria. 
4.2.1 Progressive development of T/B cell segregation and FDC networks 
following AdV infection in the submandibular glands 
I started evaluating the progressive acquisition of SLO features by the 
inflammatory foci, i.e. T/B cell segregation, presence of specialised HEV and 
differentiation of FDC networks. Double immunofluorescence sequential section 
analysis of submandibular gland infiltrates was performed using CD3/B220 and 
B220/FDC-M1 in order to assess the presence of T/B cell compartmentalization 
and FDC network formation. Initial infiltrates (within week 1) were mostly diffuse 
and characterized by a predominance of T cell followed by a progressive influx 
of B cells and the development of highly organized lymphoid structures with T 
and B lymphocytes localising in discrete areas (week 2-3) (Figure 4.3 A-C). 
Thus, upon AdV delivery T and B cells serially enter the glands first with a non-
segregated pattern and then gradually develop an organized segregated 
disposition in up to 70% of the aggregates (Figure 4.3 G). Furthermore, I 
observed differentiation of FDC networks within the B cell rich areas in the 
context of segregated infiltrates in over 60% of the mice at week 3 post-
cannulation (Figure 4.3 D-F and H). Finally, as shown in Figure 4.3 E-F and I-J, 
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sequential section analysis demonstrated that T/B-segregated aggregates are 
characterised by the differentiation of HEV in the T cell-rich area (Figure 4.3 I-J) 
and FDCs within the B cell follicle (Figure 4.3 E-F).
 
Figure 4.3: Progressive development of T/B cell segregation and FDC 
networks following AdV infection in the submandibular glands of C57BL/6 
mice. A-C) Microphotographs showing double immunofluorescent staining for 
CD3 (T cells, in green) and B220 (B cells, in red) of frozen sections from AdV-
treated C57BL/6 SG. Nuclei are counterstained with DAPI (blue). Early diffuse 
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infiltration is dominated by T cells (A) with subsequent recruitment of B cells 
showing initial T/B cell compartmentalization within the first 2 weeks post-
cannulation (B). By week 3 post-cannulation over 60% of periductal foci display 
full segregation of T and B cells in separate areas (C, G). (D-F) 
Microphotographs of AdV-treated C57BL/6 submandibular glands at week 3 pc 
showing differentiation of FDC networks as demonstrated by staining for FDC-
M1 (D, in brown and E in red). FDC networks invariably develop in the context 
of the B cell rich area of the aggregates (F) in over 60% of AdV-treated 
C57BL/6 mice shown in (H), where the bars represent the percentage of the 
glands that have at least one FDC structure against the total number of 
infiltrated glands). (I) Quadruple immunofluorescence staining for T cells (CD3, 
in green) and HEV (PNAd, in red), B cells (B220, in white) with nuclei 
counterstained in DAPI (in blue) and (J) enlargement from image I showing 
triple staining for T cells (CD3, in green), HEV (PNAd, in red) with blue nuclear 
counterstain (DAPI) showing that PNAd+ HEV selectively localise in the T cell 
rich area of segregated aggregates. Bars in pictures represent 100 microns 
except for (J) where the bar is 50 microns long.	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4.2.2 ELN in submandibular glands is preceded by ectopic expression of 
the lymphoid chemokines/Ltβ pathway 
Production of lymphoid chemokines CXCL13, CCL21, and CCL19 is of pivotal 
importance in the development of TLS in chronic autoimmune diseases, 
including SS [3],[228]. Induction and secretion of lymphoid chemokines has 
been shown to rely on the expression of the heterotrimeric Ltβ [20],[223],[229]. 
To verify the involvement of these regulators of TLS in the model, I assessed 
the ectopic mRNA expression of CXCL13 and CCL19 and their cognate 
receptors CXCR5 and CCR7, as well as the Ltβ/LtβR axis in the cannulated 
SG. A list of the TaqMan probes used for expression analysis is presented in 
Table 3.3. As shown in Figure 4.4 A–F, CXCL13/CXCR5 and CCL19/CCR7 
mRNA transcripts were abundantly upregulated in AdV-treated mice, as 
compared with vehicle-treated mice, and their ectopic expression was 
consistent with the progressive detection of TLS in the SG, reaching their peak 
of expression between week 2 and 3 post-cannulation. Of relevance, Ltβ, 
CXCL13/CXCR5, and CCL19/CCR7 mRNA displayed significant upregulation 
within the first week post-cannulation, suggesting very early involvement of 
these factors in the formation of TLS in this inducible model of lymphoid 
neogenesis. To confirm the presence and expression pattern of lymphoid 
chemokines at a protein level, multicolour confocal microscopy was used to 
detect CXCL13 or CCL21 together with B220/CD3. As shown in Figure 4.4 G-
N, in the context of segregated aggregates, CXCL13 and CCL21 retained their 
expression pattern within the B and T cell-rich areas, respectively, suggesting a 
prominent role in directing T/B cell segregation. 
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Figure 4.4: Development of TLS in C57BL/6 submandibular glands is 
preceded by ectopic expression of the lymphoid chemokines/Ltβ pathway. 
(A–F) Quantitative TaqMan real-time PCR time-course analysis of CCL19 (and 
its receptor CCR7) (A, D), CXCL13 (and its receptor CXCR5) (B, E), and Ltβ 
(and its receptor) (C, F) mRNA transcripts showing abundant upregulation after 
AdV delivery in the submandibular glands. Earliest upregulation was observed 
for CXCL13 and Ltβ mRNA, whereas peak of expression of these factors was 
detectable in parallel with full histological development of TLS (A–E). 
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Conversely, LtβR expression appears unaffected by AdV treatment (F). Data 
are expressed as mean ± SEM of the fold increase compared with an internal 
calibrator. *p < 0.05, **p < 0.01, ***p < 0.001 between AdV- and vehicle-treated 
mice at each time point, minimum of 10 mice/time point. (G–N) 
Microphotographs of multicolour confocal microscopy analysis confirming 
protein expression of lymphoid chemokines CXCL13 (I, in blue) and CCL21 (M), 
and showing colocalisation of CXCL13 within the B cell-rich area (G–J) and of 
CCL21 within the T cell-rich area of the aggregate. (K–N). B cells are shown in 
red (B220) and T cells in green (CD3). Original magnification x200 (G–N). 
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4.2.3 AdV-induced TLS in submandibular glands acquire characteristics 
of functional ectopic germinal centers 
I next assessed the presence of features typically associated with germinal 
centre function such as differentiation of germinal centre B cells and expression 
of AID. As shown in Figure 4.5, sequential section analysis (Figure 4.5 A–D) 
demonstrated that T/B-segregated aggregates characterized by the 
differentiation of HEV in the T cell-rich area and FDCs within the B cell follicle 
support the activation of numerous GL7+ germinal centre B cells. The 
appearance of GL7+ germinal centres was strongly associated with functional B 
cell activation as demonstrated by the detection of high levels of mRNA 
transcripts for AID (Figure 4.5 E), the enzyme required for Ig somatic 
hypermutation (SHM) and class-switch recombination (CSR). Of relevance, 
ectopic induction of AID was also associated with the expression of several 
cytokines that are known to cooperate in directly promoting AID expression in B 
cells, such as IL-4, BAFF, and IL-21 (Figure 4.5 F–H). Overall, these data 
demonstrate that post-AdV infection TLS support the development of functional 
niches of B cells that acquire the machinery necessary to undergo SHM and 
CSR at these ectopic sites. 
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Figure 4.5: AdV-induced TLS in C57BL/6 submandibular glands acquire 
characteristics of functional ectopic germinal centers. (A–D) Sequential 
immunofluorescence staining of AdV-treated submandibular gland sections of 
C57BL/6 mice at 3 wk pc showing that highly organized TLS characterized by 
HEV (A, red), T/B cell segregation (B, B220 in red and CD3 in green), and FDC 
networks (C) support the differentiation of GL7+ germinal center B cells (D, 
B220 in red and GL7 in green). (E–H) Quantitative TaqMan real-time PCR time-
course analysis of salivary gland expression of AID mRNA (E) and transcripts 
for cytokine downstream AID activation, such as IL-4, BAFF, and IL-21 (F–H). 
AID expression peaks in parallel with the development of fully formed TLS and 
is associated with significant upregulation of IL-4, BAFF, and IL-21. Bars in 
pictures (A–D) are 50 μm long. Data are expressed as mean ± SEM of the fold 
increase compared with an internal calibrator. *p < 0.05, **p < 0.01 between 
AdV- and vehicle-treated mice at each time point, minimum of 10 mice/time 
point.  
 
  
 170 
4.3 Development of exocrine dysfunction and autoimmunity: a 
model of SS-like disease  
The results reported in the previous sections confirmed that upon AdV delivery 
in the SG of wild-type C57Bl/6 animals, ELN takes place in the mucosa. By 
three weeks post-treatment, the lymphoid infiltrates formed in the SG fulfilled 
the main characteristic of SLO: B/T cell infiltration and segregation, expression 
of lymphoid chemokines, presence of germinal centre markers. These 
structures are also highly reminiscent of the inflammatory foci found in SS SG. 
The set of experiments reported in the following section aimed to confirm 
whether the model in our hands was also a model of SS. To confirm this, I 
searched for two hallmarks of human SS: loss or reduction of salivary flow and 
presence of humoral self-reactivity.  
4.3.1 Sustained reduction in salivary flow post-AdV infection 
SS patients are characterized by an excretory dysfunction of the salivary (and 
lacrimal) glands that leads to mouth (and eye) dryness, also denoted as sicca 
syndrome. To assess whether AdV delivery induced exocrine dysfunction in the 
affected gland, I cannulated each mouse with 108 PFU AdV in one the 
submandibular glands and with vehicle control in the contralateral gland. At 
appropriate time points after cannulation, pilocarpine-stimulated salivary flow 
was measured from each individual gland separately. A significant and acute 
reduction in salivary flow (Figure 4.6) was observed within week 1 post-
cannulation. Surprisingly, albeit less drastic, at weeks 2 and 3 post-cannulation, 
a significant reduction in saliva production was still evident in AdV-treated mice 
characterized by the presence of lymphocytic aggregates in SG with an 
otherwise reconstituted acinar and ductal architecture. This suggests that within 
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the observed period, immune cell infiltration induces a functional impairment 
that does not allow the full recovery of the excretory function of the glands. 
  
 172 
 
Figure 4.6: Sustained reduction in salivary flow post-AdV infection of 
C57BL/6 mice submandibular glands. Column graphs comparing salivary 
flow in the AdV-treated submandibular and the contralateral gland at weeks 1, 
2, and 3 pc. Salivary flow is measured as milligram of saliva produced in 10 
min/body weight after pilocarpine stimulation. Exocrine dysfunction in the AdV-
cannulated glands can be observed up to 3 weeks post-cannulation. Data are 
expressed as mean ± SEM. *p < 0.05 between AdV- and vehicle-treated mice 
at each time point, minimum of five mice/time point. 
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4.3.2 Development of ANA after AdV delivery in the submandibular 
glands 
In patients with SS, the formation of immune cells infiltrates in the SG is 
associated with the presence of circulating autoantibodies against nuclear 
antigens and ribonucleoproteins [146],[225],[226]. Thus, I next investigated 
whether this model of AdV- induced sialoadenitis was associated with breach of 
self-immunological tolerance and development of anti-nuclear antibodies. The 
presence and titre of ANAs was determined using Hep2 cells as substrate. An 
initial serum dilution of 1:80 was chosen because this is considered significant 
in clinical tests for autoimmunity in patients. As shown in Figure 4.7 B–E, no 
sera from AdV-cannulated mice within week 1 post-cannulation displayed ANA 
positivity. Conversely, ANA reactivity was detected in 30.7% of mice by week 2 
post-cannulation, and this percentage increased to 75% in animals culled at 
week 3 post-cannulation. Finally, age/sex-matched vehicle control C57BL/6 
mice did not show any reactivity. Taken together, these observations 
demonstrate that AdV-induced sialoadenitis in non-autoimmune prone mice is 
associated with the induction of humoral autoimmunity toward nuclear antigens. 
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Figure 4.7: Development of ANA after AdV delivery in the submandibular 
glands of C57BL/6 mice. Representative microphotographs of 
immunofluorescent detection of ANA using Hep2 cells as substrate (A, B) 
demonstrating strong nuclear reactivity in sera of AdV-treated (B), but not in 
vehicle-cannulated (A), C57BL/6 mice 3 weeks post-cannulation (dilution 1:80). 
ANA reactivity was progressively evident over time in AdV-cannulated C57BL/6 
mice (C), with 75% of mice displaying ANA positivity by week 3 pc (D). In C 
each triangle represents a single animal. Original magnification  x400 (A–B). 
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4.3.3 Different patterns of apoptosis can be observed at various time 
points in AdV-treated submandibular glands 
As reported in sections 1.2.2 and 1.2.4, amplified presence of apoptotic bodies 
and self-antigens in an environment prone to favour an adaptive immune 
response might be partially responsible for breach of self-tolerance leading to 
the initiation and perpetuation of the autoimmune process. Moreover, I reported 
in section 4.1.2 that in AdV-treated SG the acinar structures are almost 
completely lost in the early phases after virus delivery, but recovery of the 
parenchyma is observable at week 2 and it appears complete by week 3 post-
cannulation. Thus, I assayed the level and extent of apoptosis in cannulated SG 
at different time points to verify whether programmed cell death was taking 
place in my model and could be responsible for the loss of acinar structures and 
the development of self-reactivity against intracellular antigens.  To do so, 
slides from AdV-treated animals at 1, 2 and 3 weeks post-cannulation were 
thawed at room temperature and stained with a TUNEL assay kit to mark 
apoptotic cells. During the early phases of inflammation apoptosis was readily 
detectable and abundant in the treated glands and apoptotic cells could be 
detected in all the compartments of the SG, including ductal structures and 
glandular parenchyma (Figure 4.8 A and B). Interestingly, as soon as week 2 
post treatment and during week 3, the amount of apoptotic cells declined and 
they preferentially localised into the periductal aggregates (Figure 4.8 C-F).   
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Figure 4.8: Early and late apoptosis following AdV-delivery in the 
submandibular glands of C57BL/6. TUNEL assay identifying apoptotic cells 
(in green with DAPI nuclear counterstaining in blue) in the salivary glands of 
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AdV-treated mice at 1 (A, B), 2 (C, D) and 3 (E, F) weeks post-cannulation. 
Within the first week apoptotic cells are abundant and diffuse within the 
parenchyma of the AdV-treated glands (A), often within the ductal epithelium, 
highlighted in white (B). By week 2 and 3 post-cannulation the degree of 
apoptosis is reduced with TUNEL-positive cells almost exclusively localized 
within periductal foci (C-F). White bars in pictures are 100 μm in length.  
  
 178 
4.4 Viral persistence and immune system evasion 
ELN takes place in response to a chronic antigenic stimulation, whether 
endogenous or endogenous [3]. As I reported in the introduction of this thesis, 
there are examples of viral infections where the infection itself is the first driver 
of TLS formation (i.e. influenza virus). I also reported data in support of the 
hypothesis that a chronic infection, such as HCV, can drive first ELN and then 
breach of tolerance towards self-antigens thanks to the capacity of the virus to 
evade the immune system and establish a chronic infection. In this section, I 
report the results of my investigation regarding the persistence of the 
adenovirus in the SG of treated animals. I will first describe the anti-viral 
systemic humoral response and then I will report observations regarding the 
survival of infected cells as a result of an inefficient immune clearance.  
4.4.1 AdV delivery induces the development of IgG humoral response 
I first started to assay the presence of anti-virus antibodies in the sera of AdV-
treated animals in a qualitative manner using a western blot approach. Probing 
the sera of treated and control animals against a western blot membrane 
blotted with AdV-infected cells lysates, I observed that sera from AdV-
cannulated mice, but not control C57BL/6, progressively displayed a strongly 
antiviral activity from day 5 post-cannulation onward (Figure 4.9 A). To have a 
relative quantitation of this antiviral response, I characterised via ELISA assay 
the specific IgG response to the virus in sera of treated and control animals. As 
expected, sera from control animals and collected from AdV-treated mice during 
the first week after cannulation did not show any specific anti-AdV activity 
(Figure 4.9 B). By week two, an IgG response against AdV components is 
observable and the concentration of the immunoglobulins continues to increase 
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in time.  These data show how the cannulation procedure induces a strong 
humoral activation that leads to the development of a specific antiviral IgG 
response by week two after treatment. This response increases in time and 
highlights an adaptive immune activation against the virus.  
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Figure 4.9: AdV delivery induces the development of IgG humoral 
response. A) Western blot showing progressive development of anti-AdV IgG 
in the serum of AdV-treated, but not vehicle-cannulated mice. Protein extracts 
from AdV-infected (+) and uninfected (−) Hek293 cells were run in parallel. (Left 
to right) Vehicle-treated C57BL/6 mouse serum at 20 days post-cannulation, 
commercial anti-AdV antiserum, sera from AdV-cannulated mice at different 
time points (5, 9, 12, 15, 20, 23 days post-cannulation). Anti-AdV responses are 
observed as early as day 5 post-treatment and are mainly directed against 
proteins of the viral core and capside. B) Anti-AdV class G immunoglobulins 
ELISA assay performed on sera from cannulated animals at 1, 2, 3 and 4 
weeks after procedure and controls show an increasing titre of anti-AdV IgG 
starting from week 2 pc. Data are expressed as mean ± SEM. *p < 0.05, 
**p<0.01, ***p<0.001 between AdV- and vehicle-treated mice at each time 
point, minimum of five mice/time point. 
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4.4.2 Infected ductal epithelial cells are not efficiently cleared by the 
immune system 
Given the observation reported above about the development of a strong IgG 
response against the AdV in treated animals, an efficient clearance of the virus-
infected cells by the time the humoral response is developed and anti-AdV IgGs 
are detectable in blood was expected. To confirm this, I followed the fate on 
AdV-infected cells using luciferase-encoding AdV for cannulation and 
monitoring the persistence of luciferase activity in the glands as a read-out of 
viral persistence. As expected, I detected a significant drop of luciferase activity 
after the first week post-cannulation (Figure 4.10 A), however luciferase activity 
was detectable in the glands at all the time-points analysed (i.e. week 4 post-
cannulation). This finding suggested that despite a strong and specific humoral 
response directed against the viral components, AdV-infected cells are not 
efficiently cleared from the glands.  
This observation is extremely important in the context of ELN in general and SS 
in particular. In fact, as I reported in the introduction, several viruses have a 
tropism for the SG mucosa and some of them are known to establish a life-long 
chronic infection. Moreover, some of these sialotropic viruses tend to infect and 
replicate in the ductal cells of the gland, leaving the acinar cells uninfected 
[204]. With this in mind, I performed a staining on SG sections to identify the 
virus-infected cells. To do so, I adopted two different strategies: I either used a 
β-galactosidase-encoding AdV (LacAdV) to detect the enzymatic activity in the 
gland, or performed an immunofluorescent staining to detect AdV components 
in the tissue. As shown in Figure 4.10 B–D, staining for β-galactosidase 
demonstrated early widespread distribution of the virus within the gland (Figure 
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4.10 B). By week 2 post-cannulation, the LacZAdV was almost exclusively 
localised within ductal epithelial cells surrounded by initial inflammatory 
aggregates (Figure 4.10 C). Confirmation of this came by double 
immunostaining with an anti-AdV and an anti-cytokeratin antibody (Figure 4.10 
E-J) that showed how, at 3 days post-cannulation, AdV particles selectively co-
localise within ductal epithelial cells. 
These data demonstrate that ductal epithelial cells, particularly in intercalated 
ducts, are a preferential site for viral persistence, an observation which is highly 
relevant as intercalated ducts are typically surrounded by periductal 
lymphomonocytic aggregates not only in this novel model of SS-like 
sialoadenitis, but also in other spontaneous animal models of SS as well as in 
patients with SS.   
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Figure 4.10: Infected cells persist in the gland and are mainly ductal 
epithelial cells. (A) Luciferase activity assay in LucAdV-infected glands shows 
persistent signal well above background levels up to 4 weeks pc (mean ± SEM 
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of luciferase activity, **p < 0.01, ***p < 0.001 between AdV- and vehicle-treated 
mice at each time point, minimum of 10 mice/time point.). (B–D) Representative 
microphotographs of submandibular glands infected with LacZAdV and stained 
for β-galactosidase (X-Gal, with nuclear counterstaining with haematoxylin, 
some ductal structures highlighted in black). Numerous X-Gal+ cells are present 
in the gland within the first week pc (B, arrowheads). By week 2 pc, only ductal 
epithelial cells, often surrounded by periductal inflammatory infiltrates, show 
enzymatic activity (C). By week 3 pc, no residual X-Gal+ cells are detectable 
(D). The scale bars represent a length of 100 μm (B–D). (E-M) Double 
immunofluorescence staining for AdV (green) and a pan-cytokeratin marker 
(red) in AdV-treated (E-J) and vehicle-treated salivary glands (K-M). Expression 
of AdV5 proteins from day 3 post-cannulation is exclusively detectable within 
ductal but not acinar epithelial cells. The scale bars represent a length of 50 
µm. 
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5 A tightly organised recruitment and activation of 
innate immune cells precedes the formation of ELS 
in response to AdV infection 
5.1 Recruitment rate and tissue positioning of different innate 
immune cells subsets following AdV delivery 
As reported in the introduction, several studies previously focused on the 
cellular events that trigger lymphoid organogenesis, while the mechanisms 
preceding ELN formation in non-lymphoid tissues are less known (section 
1.1.3). Whilst previous investigations primarily employed genetically modified 
animals to induce TLS via the ectopic expression of lymphoid chemokines/Ltβ, 
the AdV-induced model of TLS that I described in the previous chapter offers 
the unique opportunity to tightly dissect the early phases of TLS formation 
following a more physiological stimulus such as pathogen infection. In this 
chapter, I will describe the results of experiments aimed at clarifying the 
dynamics of the immune infiltration developing within the first week post-viral 
cannulation in order to pinpoint the cell types involved in initiation and 
maintenance of the salivary immune response preceding TLS formation. 
This part of my PhD project relied mostly on the study of single cell suspension 
obtained at different time points from murine submandibular glands from both 
AdV-cannulated animals and control mice. In all cases, careful experimental 
controls were implemented, including the use of FMO analysis for the 
assessment of flow-cytometric staining specificity as well standard control 
procedures such as the incubation with Fc-block cocktail and live/dead 
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discrimination dyes as described in the Methods Chapter (Section 3.8). 
Additionally, to account for any potential effect of the enzymatic digestion on the 
expression different immune cells markers, in each flow cytometry experiment 
at least one spleen from C57Bl/6 mice was digested and stained as a positive 
control. Importantly, in the flow cytometric data reported in the next sections the 
abundance of any cell population is always expressed as a percentage of a 
parent population (e.g. percentage of the total cells, percentage of CD45+ cells, 
etc), and an absolute quantification of the number of the cells is missing. This 
depends from the fact that those reported below are still preliminary data. This 
is clearly an issue that needs to be addressed, in particular considering some of 
the events that take place in the gland upon AdV infection, such as extensive 
apoptosis and strong cell infiltration, that might substantially affect the total 
number of cells present in the gland. Thus further experiments, comprehensive 
of an absolute quantitation of the cell numbers, will be necessary to support the 
findings presented here. Despite this caveat, the flow cytometry data presented 
in this section, together with immunofluorescence images and gene expression 
data, clearly illustrate the events sequence and the cell dynamic that take place 
in the SG upon AdV infection.  
5.1.1 The early SG immune cell infiltration in response to AdV infection is 
dominated by both Ly6CHi inflammatory monocytes and neutrophil 
granulocytes and is followed by NK cells infiltration and activation.  
From the initial haematoxylin and eosin staining performed as described in the 
previous Chapter (Section 4.1.2), it was immediately evident that the first 
immune response following viral infection of the salivary gland was 
characterised by a polymorphic and extensive  immune cell infiltration with a 
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peri-acinar diffuse inflammation, associated with tissue oedema and disruption 
of the parenchymal structure (Figure 4.2 D and Figure 4.3 A). To better evaluate 
the extent of this initial inflammation and characterise the nature of the 
haematopoietic cells present in the gland in the first 5 days after infection 
compared to the steady state, isolated mononuclear cells were stained for 
CD45, and the percentage of CD45+ in the whole gland lysate was calculated 
(Figure 5.1, top). The resident hematopoietic population in the murine 
submandibular glands accounts, at steady state, for approximately the 5% of 
the whole gland cellularity. Conversely, as early as 1 day post-cannulation, the 
percentage of CD45+ cells dramatically increased to reach almost 30% of the 
cells present in the gland at the peak of acute inflammation. From day 3 post-
AdV delivery onward, a constant decrease in the general percentage of CD45+ 
cells was observed, although the difference in infiltrating leukocytes between 
control and treated glands was still highly significant at 5 days post-cannulation 
and onwards.  
From the immunofluorescence staining for TLS performed in the previous 
Chapter of this thesis (Figure 4.3 A) I excluded that the massive infiltration 
observed during the first days post-infection could be due to B and T 
lymphocytes recruited from the periphery as in the SG tissue of animals culled 
within one week post-cannulation B220+ B cells were almost undetectable and 
the CD3+ T cell could only account for a small minority of the total number of 
CD45+ leukocytes observed in flow cytometry.  
Because NK cells represent one of the major components of the resident 
leukocyte populations in the salivary glands in homeostatic conditions and they 
have a well-known role in pathogen clearance upon viral infection [230],[231], I 
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first sought to investigate whether the increase in CD45+ cells was due to an 
enlarged presence of these cells. To identify NK cells, in the flow cytometry 
panel CD3ε+ and CD19+ cells were excluded and NK cells were identified as 
CD3ε-/NK1.1+. This strategy allowed the identification of bona fide NK cells as 
in C57Bl/6 mice NK1.1 is a pan-NK marker and the exclusion of CD3ε+ cells 
avoided the contamination of CD3ε+/NK1.1+ NKT cells. At steady state, the 
percentage of salivary gland CD3ε-/NK1.1+ NK cells among CD45+ leukocytes 
is almost 20%, but, unexpectedly, relative percentage of NK cells radically 
dropped to 5% at 1 day post-procedure (Figure 5.1, bottom). From these data, I 
speculated that the percentage of NK cells decreased due to other cell types 
responsible for the early growth of the leukocyte population in the salivary 
glands within the first 24-48h post-cannulation. Conversely, from day 3 to day 5 
post-cannulation, NK cells accounted for almost 40% of the total CD45+ cells, 
suggesting a selective expansion of NK cells in the salivary glands following the 
early acute immune response. The increase in NK cells was both relative to the 
CD45+ population and absolute compared to the salivary glands steady state 
NK.1.1 subsets as the prevalence CD45+ cells was still significantly higher in 
AdV cannulated mice compared to vehicle control and non-cannulated animals.  
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Figure 5.1: AdV treatment triggers a strong increase in leukocyte 
percentage that is only partially due to NK cells. Top) Leukocytes were 
gated as viable single cells and their percentage calculated against the total 
amount of cells obtained from enzymatic digestion of the gland. NK cells 
(bottom), defined as single viable CD45+/CD3- cells, appear to diminish during 
the first day post-infection, probably due to a strong increase in other CD45+ 
cells populations observed in the top panel. By day 2 post-cannulation, the 
percentage of NK cells among leukocytes is comparable to control glands and 
by day 4 it is significantly higher, suggesting either an influx of NK cells from 
periphery or an in situ proliferation. Data expressed as mean ± SEM, at least 4 
glands per time point, *p < 0.05, **p<0.01 between AdV-treated and control 
animals. 
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Since during infection the first cells recruited are generally polymorphonucleate 
cells and inflammatory monocytes, which extravasate from the circulation and 
localise to the affected tissue, I next investigated whether infiltrating myeloid 
cells were responsible for the observed increased in the number of CD45+ cells 
following AdV infection. 
Using the same basic strategy described above, myeloid cells were first 
identified using an anti-integrin αM (CD11b) antibody that is strongly expressed 
on cells from the innate immune system. CD11b+ cells were further subdivided 
based on the presence and expression levels of Ly6G+ and Ly6C as follows: i) 
Ly6G+/Ly6CInt neutrophils and ii) Ly6G-/Ly6CHi monocytes. Ly6G is a neutrophil 
granulocytes specific marker, while Ly6C is widely expressed on the cell 
membrane of different leukocytes, among which, plasmacytoid DCs [232], T 
cells [233],[234], neutrophil granulocytes, monocytes and macrophages 
[235],[236]. Nevertheless, Ly6C can be readily used as a monocyte marker in 
combination with other antigens. In particular, CD45+/CD3-/CD19-/NK1.1-
/CD11b+/Ly6G- cells with a high expression of Ly6C were considered of 
monocyte origin and are commonly described as inflammatory monocytes.   
As shown in Figure 5.2, Ly6C bright monocytes and Ly6G+ polymorphonucleate 
cells represented over 40% of the leukocytes present in the gland 1 day after 
infection. Interestingly, while neutrophils were retained in the infected glands for 
less than 48 hours (Figure 5.2 B), Ly6CHi monocytes persisted for a longer time 
(Figure 5.2 A), before differentiating in resident macrophages (as discussed in 
Section 5.2.1).  
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Figure 5.2: Inflammatory monocytes and neutrophil granulocytes 
represent more than half of the inflammatory infiltrate populating the 
glands 1 day post-cannulation. Single viable CD45+/CD3-/CD19-/NK1.1-
/CD11b+/Ly6G- cells with high expression of Ly6C marker were considered 
inflammatory monocytes (A) while CD45+/CD3-/CD19-/NK1.1-
/CD11b+/Ly6CInt/Ly6G+ were classified as neutrophil granulocytes (B). Together 
at 1 day post-cannulation these two populations represented more than half of 
the initial infiltrate, but as monocytes number remained elevated during the 
course of 5 days after cannulation, neutrophils rapidly decreased and were 
almost undetectable by 4 days post-AdV delivery. Data expressed as mean ± 
SEM, at least 4 glands per time-point. 
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5.1.2 Plasmacytoid dendritic cells are present in the untreated salivary 
gland and their number increases upon infection 
Plasmacytoid dendritic cells (pDC) are professional type-I interferon producers 
both in human and mouse [237]. Belonging to the innate immune system, this 
cell subset is specially equipped to respond to viral infections as they 
constitutively express TLR7 and TLR9. In response to viral ligand pDC produce 
large amounts of IFN-α and IFN-β [238]. Plasmacytoid DCs can also respond to 
bacterial stimuli and can produce other inflammatory cytokines such as TNF-α 
and IL-12 [238]. Moreover, pDC express both inflammatory and homeostatic 
chemokines receptor and thus can migrate both to inflamed tissues and to SLO 
[232],[237]. As I reported in Section 1.2.5.1, plasmacytoid DC and type-I 
interferons are also associated with several autoimmune diseases. For these 
reasons, I investigated whether also pDC were infiltrating the salivary glands 
upon viral challenge compared to steady state. To characterise pDCs, single 
cells with the physical characteristic of leukocytes were selected for their 
expression of CD45 and from these cells, CD11c+ cells were gated and from 
this subset B220+/Siglec-H+ cells were considered pDCs (Figure 5.3 A) [239].  
As it appears from the preliminary experiments reported in Figure 5.3 B, pDCs 
were barely detectable in the resting salivary glands, representing a very small 
percentage of resident leukocytes. Upon infection, the number of Siglec-H+ 
pDCs increased in parallel with the inflation of CD45+ cells, particularly from day 
3 post-cannulation onward.  
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Figure 5.3: B220+/CD11c+/Siglec-H+ pDC percentage increases during the 
early phases of infection. A) Representative plot from a 4 days post-
cannulation AdV-treated gland. CD11c+ cells were plotted for their expression of 
B220 and Siglec-H, pDCs are gated as double-positive cells. B) Histogram 
representing the Siglec-H+ pDCs percentage of the total CD45+ hematopoietic 
cells infiltrating the SG upon AdV-challenge. Data represent mean ± SEM, at 
least 3 glands per time-point.   
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5.1.3 The CD11b+/SSCHi cells present in the SG and increasing upon 
infection resemble eosinophil granulocytes 
While analysing the plots for cannulated animals between 1 and 5 days post-
procedure, an unexpected population showing high SSC was detected. As this 
population showed physical characteristics (i.e. high SSC) and expression 
markers (in particular CD11c) different from the other CD11b+ cells, it was 
excluded from the monocyte-macrophage analysis presented in the next 
sections. My first idea was that these cells might have been neutrophil 
granulocytes, but they were not positive for the neutrophil marker Ly6G. A more 
detailed analysis of these cells revealed that they were also F4/80+ and had a 
variable expression of Ly6C (from high to negative) while they were consistently 
CD11c negative. When I gated this population as CD11b+/CD11c-/SSCHi I 
observed a constant increase in their percentage among the leukocytes during 
the course of infection (Figure 5.4 A). Given the complexity of this subset 
indicating probably a high presence of granules in the cytoplasm, I sought to 
investigate whether these cells were eosinophil or basophil granulocytes or 
mast cells. Basophils and mast cells constitutively express the high affinity 
receptor for IgE immunoglobulins FcεRI, while eosinophil granulocytes can be 
identified using the sialic acid-binding immunoglobulin-type lectins F (Siglec-F) 
[240]. Indeed, CD11c+/SSCHi cells were strongly positive for Siglec-F but only a 
small percentage was FcεRI positive (Figure 5.4 B).  
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Figure 5.4: A high-complexity population with phenotype corresponding 
to eosinophil granulocytes is present in the gland in the early phases of 
inflammation. A) Histogram representing CD11b+/CD11c-/F480+/Siglec-F+ 
granulocytes characterised by high side-scatter. This population shows a trend 
to increase as soon as day 1 post-cannulation and its percentage against 
CD11b+ myeloid cells infiltrating the gland results significantly higher than 
controls for most of the observed time-points. The representative plot in B 
shows that when staining the CD11c-/SSCHi population for Siglec-F and FcεRI, 
the cells resulted positive for the eosinophil marker (Siglec-F) but only a small 
percentage stained for FcεRI, excluding the possibility that the cells were mast 
cells or basophil granulocytes. Data in A represent mean ± SEM, at least 4 
glands per time point, *p < 0.05, **p<0.01 between AdV-treated and control 
animals.  
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5.2 The role of NK cells and myeloid cells in the formation of SS-
like lesions and the development of TLS 
5.2.1 Recently extravasated monocytes progressively acquire the 
macrophage marker F4/80 and concomitantly downregulate Ly6C 
On a careful analysis of the data reported above, I noticed that Ly6C bright cells 
did not seem to disappear from the infected salivary gland over time, but rather 
appeared to downregulate the expression of Ly6 (Figure 5.5 A). Previous 
studies reported that recently extravasated monocytes can lose expression of 
Ly6C and acquire the F4/80 macrophage marker [236] during their 
differentiation into monocyte-derived macrophages. Thus, I investigated 
whether this phenomenon was also taking place in the virus-infected salivary 
glands. The differentiation of monocytes into macrophages was followed 
studying CD11b+ cells according to their expression of Ly6C versus F4/80. 
The analysis was conducted on viable CD19-/CD3-/NK1.1-/Ly6G-/ CD11b+ 
deprived of the CD11c-/SSCHi population and the results reported in Figure 5.5 
B are expressed as percentages of this population. F480+/Ly6C+ cells were 
considered blood-recruited monocytes and F480+/Ly6C- cells were considered 
macrophages. Monocytes, that represent approximately 5% of the myeloid cells 
in the resting salivary gland, increased to over 80% as soon as day 1 post-
cannulation and this percentage remained stable for the first 3 days after 
procedure (in Figure 5.5 B). This strong increase in monocytes compressed the 
relative amount of macrophages that represent more than 80% of the resident 
CD11b+ cells in the non-stimulated gland. However, by day 4 post-cannulation, 
the percentage of Ly6C+ cells significantly decreased in parallel with the 
increased relative amount of F4/80+ macrophages in keeping with the 
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progressive entering of inflammatory macrophages within the pool of salivary 
gland macrophages.  
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Figure 5.5: Infiltrating monocytes lose expression of Ly6C as they 
differentiate into macrophages. CD11b+/Ly6G-/F4/80+/Ly6CHi monocytes 
downregulate Ly6C expression as soon as day 2 post-cannulation (A) while 
they retain the expression of F4/80. Upon the strong inflammation that develops 
after infection the percentage of Ly6G-/Ly6C-/F480+ macrophages among the 
CD11b+ myeloid cells suddenly decreases in favour of a strong increase of the 
inflammatory monocytes (B). Both the flow cytometry plots and the statistic view 
of this shift suggest that infiltrating monocytes differentiates into macrophages 
soon after their access to the gland. Data represent means ± SEM, Untreated = 
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4 glands; 1 dpc = 7 glands, 2 dpc = 6 glands, 3 dpc = 6 glands, 4 dpc = 6 
glands, 5 dpc 8 glands, **p<0.01 between AdV-treated and control animals.   
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5.2.2 A distinct subset of non-resident CD11c+ dendritic cells infiltrates 
the salivary gland upon viral infection and precedes TLS 
development. 
Dendritic cells, as professional antigen presenting cells, continuously probe 
tissues for antigen and once activated at site if inflammation upregulate CCR7 
expression and migrate to secondary lymphoid organs where they present the 
antigen to T cells. DCs are also important for TLS maintenance in mice, as 
selective ablation of CD11c+ DCs resulted in disruption of iBALT forming in 
murine lungs after influenza virus infection, probably due to their capacity to 
activate the Ltβ pathway [58]. To test the role of DCs in my model, myeloid cells 
were analysed in function of their expression of CD11c (integrin αX). This 
integrin can be also expressed on monocytes and macrophages at lower levels, 
thus only F4/80-/CD11cHi cells were considered true myeloid DCs. At steady 
state, Ly6C-/F4/80+ resident macrophages are positive for CD11c and F480-
/CD11cHi DCs represent only 5% of CD11b+ cells (Error! Reference source 
not found. A and B) 
When inflammation begins at days 1 and 2 post-procedure, the relative 
percentage of DCs decreased only slightly despite the strong influx of 
Ly6C+/F480+ monocytes, suggesting that a parallel increase in the number of 
DCs was taking place (Error! Reference source not found. B). In support to 
this hypothesis, at day 4 post-cannulation, when the number of CD45+ cells had 
more than halved compared to day 1 post-cannulation but was still significantly 
higher than in control glands (Figure 5.1, top), the relative percentage of 
CD11cHi/F480- DCs was still significantly higher than in control glands (Error! 
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Reference source not found. B), indicating an inflammation-induced increase 
of this population.  
 
Figure 5.6: The percentage of CD11cHi/F480- DCs present in the gland 
increases with the progression of the infection. A-B) CD11b+/F480-/CD11cHi 
DCs percentage increases during the first 5 days after viral infection and is 
significantly higher than controls by 4 days post-cannulation. Data represent 
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means ± SEM, at least 4 glands per time-point, **p<0.01 between AdV-treated 
and control animals. 
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5.2.3 NK depletion does not affect inflammatory monocytes infiltration, 
macrophages differentiation and DCs accumulation in the 
cannulated SG 
The anti-tumour and anti-viral function of NK cells has been known since the 
first description of this cell type [241]. Surprisingly, despite the wide interest 
regarding AdV-mediated gene therapy, few studies focused on the effect of the 
adenoviral vectors themselves on the immune system in general and on NK 
cells in particular. Ruzek et al. studied specifically the NK cells reaction to 
adenoviral vectors in mice and concluded that NK cells are activated by 
replication-defective AdV even if the vector does not encode for any transgene. 
Moreover, they also proved that UV-treated but not heat-denatured AdV vectors 
can induce a NK response, suggesting that the structural integrity of virions is 
more important than the viral genome in the stimulation of anti-viral activity 
[242]. In another scenario involving a non-viral pathogen, i.e. a murine model of 
intestinal inflammation triggered by T. gondii, a NK cells subset resident in the 
gut was shown to be responsible for the recruitment of inflammatory monocytes 
that eventually contributed to the tissue damage [243]. Furthermore, the cross-
talk between NK cells and monocytes, macrophages and DCs has been 
recently reported both in human and mouse disease models [244],[245]. For 
these reasons, I hypothesised that the intra-gland AdV delivery triggered a NK 
cells response that in turn lead to the considerable monocyte infiltration 
described in the previous sections.  
To test this hypothesis, I performed a selective depletion of NK cells using a 
mouse anti-mouse NK1.1 antibody that proved to be a quick and highly efficient 
system for NK ablation from the circulation and within the SG, as reported in 
 206 
Section 3.2.4). Mice treated with the NK-depleting antibody and Ig control were 
cannulated and culled at 1, 3, 5 and 7 days post-AdV delivery. SGs were 
digested and analysed by flow cytometry using the same gating strategy 
described above for the monocyte/macrophage populations.  
Contrarily to what expected, the absence of NK cells modified the relative 
percentages of DCs and monocytes only at 1 and 3 days post-cannulation, 
respectively (Figure 5.7). By day 5 after AdV delivery, and at all the observed 
time-points for the F480+/Ly6C- macrophages, no statistical difference was 
observed between anti-NK1.1-treated and control mice, suggesting that 
resident NK cells were not responsible for the chemotactic signals driving 
myeloid cells accumulation in the SG upon AdV delivery.  
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Figure 5.7: NK depletion only temporarily affects relative abundance of 
myeloid populations. Flow cytometry analysis of SG myeloid populations in 
presence or absence of NK cells. The ablation form the SG of the NK cells 
population only affected the relative amount of F480-/Ly6C-/CD11cHi DCs and 
Ly6C+/F480+ infiltrating monocytes at 1 and 3 days post-cannulation. Data 
represent means ± SEM. For the Ig control group observations number is 1 dpc 
= 4, 3 dpc = 4, 5 dpc = 8, 7 dpc = 4; for anti-NK1.1 group observations number 
is 1 dpc = 5, 3 dpc = 5, 5 dpc = 9, 7 dpc = 4; *p<0.05 between NK-depleted and 
Ig control-treated animals. 
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5.2.4 NK cells selective depletion does not affect SG TLS formation, 
number and organisation upon AdV infection 
After the analysis of the flow cytometric data reported above and the 
unexpected results, I decided to use the same depletion scheme inside the 
AdV-triggered ELN model to test whether the absence of NK cells would affect 
the development of TLS in the cannulated glands.  
Animals were treated with the depletion antibody and Ig control and AdV-
cannulated as described in Section 3.2.4 and animals were culled at 3, 7 and 
17 days post-cannulation. SG were used for mRNA expression analysis (3, 7 
and 17 days post-cannulation time-points) and histological analysis (17 days 
post-cannulation). 
Surprisingly, when analysing histological specimens collected during the third 
week post-AdV delivery (17 days after procedure) from NK-depleted and control 
animals, I observed no difference in TLS formation and organisation between 
the two groups. In particular, as shown in Figure 5.8 A, peri-ductal lymphocytic 
aggregates formed and appeared similar in size and segregation between 
control and NK-depleted mice. The histological evaluation of the number of G2 
aggregates and the level of segregation also confirmed that NK cells were 
dispensable for the ELN process (Figure 5.8 B). To confirm these observations, 
I assessed the expression of the genes involved in the ELN process on AdV-
cannulated NK-depleted and control-treated animals. In accordance with the 
histological evidence, at 2 and 3 weeks post-treatment there was no significant 
difference in the expression of lymphoid chemokines and their receptors 
between depleted animals and controls (Figure 5.8 C). Also, the absence of NK 
cells did not affect the functionality of TLS forming in the SG upon AdV delivery, 
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as the expression of AID did not change between the two groups.  Although the 
final formation and functionality of TLS were unaltered by the lack of NK cells, 
at 3 days post cannulation I observed a significant increase in the expression of 
CCL19, CXCR5 and Ltβ in treated animals in comparison to controls. Albeit 
preliminary, this observation suggests that the ablation of NK cells might 
influence the Ltβ/lymphoid chemokines in the very early inflammatory response, 
but this effect is rapidly compensated as soon as day 7 after treatment and 
does not affect the final TLS formation and organisation in the SG.  
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Figure 5.8: NK depletion does not affect TLS formation, organisation and 
functionality. (A) Microphotograph showing no difference in infiltration and 
segregation of B (B220, red) and T (CD3, green) lymphocytes in AdV-treated 
SG in NK-depleted mice (right) and controls (left). Scale bar represent 50 μm. 
(B) Comparison of the number of G2 aggregates (left) and ratio between 
segregated and non-segregated G2 aggregates (right) in AdV-treated SG from 
anti-NK1.1-treated and control mice. (C) Real-time analysis of the expression of 
lymphoid chemokines and receptors, Ltβ/LtβR and AID in SG at 3, 7 and 17 
days post-cannulation. Data represent means ± SEM, at least 4 glands per 
time-point, *p<0.05, **p<0.01 between NK-depleted and control animals.  
 
  
An
ti N
K1
.1
Co
ntr
ol 
IgG
0
5
10
15
20
18 dpc
N
um
be
r o
f G
2 
ag
gr
eg
at
es
 p
er
 g
la
nd
ns
An
ti-N
K1
.1
Co
ntr
ol 
IgG
0
20
40
60
80
100
18 dpc
Se
gr
eg
at
ed
 G
2/
to
ta
l G
2 
(%
)
ns
CD3/B220
Control IgG Anti-NK1.1
A B
C
3 d
pc
7 d
pc
17
 dp
c
0.0
0.5
1.0
1.5
CCL19
m
R
N
A
 e
xp
re
ss
io
n
fo
ld
 in
cr
ea
se
**
3 d
pc
7 d
pc
17
 dp
c
0.0
0.2
0.4
0.6
0.8
LTb
m
R
N
A
 e
xp
re
ss
io
n
fo
ld
 in
cr
ea
se
*
3 d
pc
7 d
pc
17
 dp
c
0.0
0.2
0.4
0.6
0.8
CCR7
3 d
pc
7 d
pc
17
 dp
c
0.0
0.5
1.0
1.5
2.0
LTbR
*
3 d
pc
7 d
pc
17
 dp
c
0.0
0.1
0.2
0.3
0.4
CXCL13
3 d
pc
7 d
pc
17
 dp
c
0.00
0.01
0.02
0.03
0.04
0.05
AID
Control IgG
Anti-NK1.1
3 d
pc
7 d
pc
17
 dp
c
0.00
0.01
0.02
0.03
0.04
0.2
0.4
0.6
CXCR5
*
7 7
 211 
5.2.5 Developing TLS display structural segregation of different myeloid 
cells: DCs infiltrate newly formed B/T cell aggregates while 
macrophages are excluded from ectopic follicles 
To further characterise the dynamic positioning of macrophages and myeloid 
DCs in the virus-infected SG during the course of TLS development, I 
performed immunofluorescence staining for F4/80 and CD11c in tissue sections 
from animals infected with AdV and culled at 3, 10 and 18 days post-
cannulation.  
To test whether resident macrophages, that co-express F4/80 and CD11c in 
flow cytometry, were also double positive in immunofluorescence, I first 
performed a double staining for the two antigens on tissue sections. As shown 
in Figure 5.9, in resting conditions F4/80+ macrophages were interspersed in 
the gland and localised preferentially around the acinar and ductal structures of 
the gland. CD11c+ DCs also localised proximal to ductal structures. The staining 
for F4/80 and CD11c did not show any overlap. 
Three days post-cannulation numerous CD11c+ DCs were interspersed in the 
gland parenchyma, more often associated with ductal structures (Figure 5.10 
B). In comparison with the control gland, their number appeared increased in 
accordance with the flow cytometry data (Figure 5.10 A and Figure 5.6 B). At 
later time-points the close association with salivary ducts was even more 
evident (Figure 5.10 C) and at 10 days post-cannulation most CD11c+ DCs 
were intimately associated with inflammatory foci forming in the proximity of 
ductal structures. Interestingly, during the third week after infection, when TLS 
assumed their more complex and segregated form (Figure 4.3 C), DCs were 
strongly associated with the ectopic follicles (Figure 5.10 D).  
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Although, as expected by the flow cytometry data, the presence of F4/80+ 
macrophages strongly increased in the inflamed gland at 3 days post-
cannulation in comparison to controls (Figure 5.10 E and F), these cells were 
surprisingly excluded from TLS and typically organised as cuffs of highly dense 
F4/80+ cells surrounding T/B cell follicles. This phenomenon was already 
present at week 2 post-cannulation but became immediately evident 3 weeks 
after AdV delivery when TLS were fully formed and sustained a GC response 
(Figure 4.5). To my knowledge, this is the first demonstration that different 
myeloid subsets segregate in discrete areas during TLS development, 
suggesting that different chemotactic gradients drive on one side the positioning 
of DCs within TLS and on the other a follicular exclusion of F4/80 macrophages. 
(Figure 5.10 G and H).  
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Figure 5.9: F4/80 macrophage marker and CD11c DC marker expression 
do not overlap in double IF-stained SG tissue. This control salivary gland 
section has been stained for F4/80 (red) and CD11c (green, arrowheads) and 
nuclei were counterstained with DAPI (blue). Macrophages are present around 
the ductal structures and interspersed in the gland parenchyma. DCs also share 
a diverse distribution in the gland and often associate with ductal epithelium but 
their number at steady state is lower than macrophages. Scale bar is 50 μm 
long.  
  
DAPI/CD11c/F480
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Figure 5.10: CD11c+ DCs increase in number after infection and co-
localise in the inflammatory foci while F4/80+ macrophages are excluded 
from the infiltrates. Top row microphotographs showing CD11c+ DCs (in 
green, nuclei counterstained in blue) at steady state associate preferentially 
with ductal structures (control) but upon infection their number increases and 
they present a sparse distribution (3 dpc). As the ELN process progresses, DCs 
associate with the nascent inflammatory foci (10 dpc) and by three weeks post-
cannulation they localise preferentially within the infiltrates (18 dpc). Bottom row 
F4/80+ macrophages (in red, nuclei counterstained in blue) are more abundant 
than DCs at steady state. Upon infection (control) macrophage distribution is 
diffuse, but during the organisation of the TLS there is an evident association of 
these cells with the forming infiltrates (3 dpc) but opposite to DCs, 
macrophages are systematically excluded from the foci (10 and 18 dpc) and 
tend to form a cap along the edge of the infiltrates.. 
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5.2.6 CD11c+ dendritic cells associate with B220+ B and CD3+ T cells in 
the early phases of ELN and preferentially with CD3+ T cells in the 
late stages. 
Given the presence of CD11c+ DCs inside the inflammatory foci during the 
development of TLS, I sought to identify whether DCs associated preferentially 
with the B cell rich or T cell rich areas. To do so, I performed a triple IF confocal 
staining for CD11c+ DCs, CD3+ T cells and B220+ B cells in SG of animals 
culled at 1, 2 and 3 weeks after cannulation. As shown in Figure 5.11 (top 
panels), in the early phases of the AdV-induced inflammation prior to the 
migration of B and T cells, DCs were abundantly present in close association 
with ductal structures. Conversely, by week 2 post-cannulation, when significant 
numbers of B and T were present in the infected gland, DCs strongly migrated 
towards the forming ectopic follicle with CD11c+ cells closely intertwined with 
both B and T cells (Figure 5.11, middle panels). Finally, at the peak of TLS 
formation at week 3 post-cannulation, DCs were strongly associated with ductal 
structures but also in intimate contact with CD3+ cells, but not B220 B cells, in 
the T cell-rich areas of the periductal infiltrates, suggesting active antigen 
presentation to T cells and a possible direct role in TLS formation (Figure 5.11, 
bottom panels).  
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Figure 5.11: CD11c+ DCs are present during all stages of ELN in the SG 
and when TLS are fully formed their presence is enriched inside the T cell 
areas. Microphotographs showing CD11c+ DCs in green, CD3+ T cells in red 
 218 
and B220+ B cells in blue. Upon infection DCs number increase and they exhibit 
a sparse distribution with some cells showing an uncharacteristic round shape 
(top). During the second week after infection as the ELN process advances, 
DCs associate with the forming inflammatory infiltrates in contact with both B 
and T cells (middle). By 3 weeks post-cannulation DCs are present within the 
infiltrates only in correspondence of the T cell area while they surround, but are 
excluded from, the B cell areas (bottom). 
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5.2.7 During the first week after AdV infection myeloid cells express 
inflammatory and lymphoid chemokines in a bimodal fashion  
Given the novel observations that I reported in the above sections, I decided to 
perform a preliminary set of experiments to investigate whether the number 
increase and the specific positioning of F4/80+ and CD11c+ myeloid cells was 
associated with a ELN-related expression profile. Essentially I hypothesised 
that the myeloid cells observed in the gland upon AdV-infection actively 
contributed to the formation of TLS thank to the production of lymphoid 
chemokines and activation of the LTβ pathway. 
In order to test this hypothesis, I cannulated wild-type mice and collected the 
SG between 2 and 7 days after the procedure. The glands were digested and 
the cell suspension was stained with fluorescent antibodies for FACS. In this 
first set of experiments I only sorted viable non-eosinophil-like CD45+/CD3-
/CD19-/NK1.1-/CD11b+/F480+/CD11c+ cells, corresponding to a mixed 
population of monocytes/macrophages and DCs. The same population sorted 
from untreated animals was used as control. As the number of sorted cells from 
each gland was very small, SG from different mice that underwent the same 
treatment were pooled and the extracted and retrotranscribed RNA was 
analysed with the Fluidigm technology, a new TaqMan real-time PCR 
techniques that allows efficient gene expression analysis using small amounts 
of starting RNA material (see 3.6.4 for details). The results of the expression 
analysis are reported in Figure 5.12. Albeit not significant as only preliminary 
data were collected, interestingly the expression analysis showed that myeloid 
cells infiltrating in the gland upon AdV-infection indeed upregulate CCL19, 
CXCL13 and LTβ mRNA expression, in particular towards the end of the first 
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week after cannulation. On the contrary, the expression levels of the 
inflammatory chemokines CCL5, CCL7 and the CC-chemokines receptor CCR1 
were strongly increased between day 2-4 after cannulation but progressively 
decreased in from day 5-7. CCL5 is an inflammatory chemoattractant for 
eosinophils and basophils but also T cells; CCL7 is a monocyte specific 
inflammatory chemokine while CCR1 is the receptor for a plethora of 
inflammatory chemokines, among which CCL2, CCL7 but also CCL5 and is 
expressed mainly in monocyte/macrophages and NK cells [246]. If confirmed in 
larger experiments (currently on-going), these data would support the idea of a 
bimodal chemokine production by the myeloid cells present in the gland: an 
initial production of inflammatory chemokines that induces the infiltration of the 
gland by inflammatory cells from the periphery is followed by a second phase of 
lymphoid chemokines synthesis able to attract B and T cells and modulate TLS 
formation. 
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Figure 5.12: Inflammatory and lymphoid chemokines expression by 
myeloid cells in the first week after AdV-delivery follows opposite trends. 
Sorted non-esonophil-like CD45+/CD3-/CD19-/NK1.1-/CD11b+/F480+/CD11c+ 
cells were analysed for the expression of inflammatory chemokines CCL5 and 
CCL7 and receptor CCR1 and lymphoid chemokines CCL19, CXCL13 and LTβ. 
The preliminary data for the first 6 days after treatment show a time-dependent 
increment of expression for lymphoid chemokines that is paralleled by an 
opposite trend for inflammatory chemokines that are higher in expression soon 
after infection than toward the end of the first week post-cannulation. Data 
represent mean ± SEM from at least 3 experiments on cells pooled from at least 
4 SG. The statistical test failed to reach a p value ≤ 0.05 between control and 
treated groups for every gene tested, probably due to the small number of 
observations, in particular for the control group where n=3 (2-4 dpc group and 
5-7 dpc group have both n=9). 
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Chapter 6 | Discussion 
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6 Discussion 
The formation of TLS in the target organ of several chronic inflammatory 
conditions, including SS, has long been recognized [2],[3],[14],[47],[138],[247]. 
TLS formation is highly relevant to SS as germinal centre-like structures in the 
labial salivary glands are independent predictors of increased disease severity 
and evolution towards B cell lymphomas [141],[143].  
The lack of reliable inducible animal models of ectopic lymphoid neogenesis 
has limited our understanding of the mechanisms leading to the formation of 
TLS in the salivary glands. Murine models of inducible sialoadenitis with some 
features of SS in response to systemic or local viral infection have been 
reported. However, in order to induce sialoadenitis previous work relied either 
on the use of fully infectious and replicating sialotropic viruses in autoimmune 
prone mice such as lpr/lpr mice [202],[248], or replication-deficient AdV vectors 
harbouring genes encoding for pro-inflammatory mediators such as IL-17 [249]. 
In addition, no comprehensive demonstration that viral-induced sialoadenitis 
can progress towards the formation of functional TLS and resembles the main 
physiopathological characteristics of SS (i.e. the formation of autoantibodies 
and the development of exocrine dysfunction) has been provided as yet.  
As reported in this thesis, during my PhD I developed and validated a novel 
model of inducible lymphoid neogenesis that rapidly develops in the 
submandibular glands of wild-type C57Bl/6 mice in response to local delivery of 
replication-deficient adenoviral vectors. In this model of sialoadenitis, immune 
cell infiltration rapidly progresses from a diffuse inflammatory process towards 
the formation of periductal lymphocytic aggregates that further evolve into 
highly organised TLS within 3 weeks from viral infection. This process is 
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reproducible and synchronous with lymphocytic foci developing in 100% of the 
mice by week 2 post-cannulation and evolving by week 3 post-cannulation into 
fully formed TLS characterised in approximately 70% of the mice by T/B cell 
segregation and formation of FDC networks with germinal centre-like structures 
sharing high similarity to the human counterpart [31].  
The formation of TLS has been suggested to be the result of a tightly regulated 
series of immunological and molecular processes with recapitulation of the main 
pathways involved in lymphoid organogenesis in prenatal life [250]. Embryonic 
lymphoid organ development is critically dependent on lymphoid chemokines 
CXCL13, CCL19 and CCL21 which are produced by VCAM-1+ICAM-1+LTβR+ 
mesenchymal “organizer” cells in response to close interaction with CD3-
CD4+CD45+IL-7Rα+RANK+ lymphoid “inducer” cells (Lti) expressing the 
membrane-bound heterotrimeric (α1β2) member of TNF family LTβ 
[2],[44],[250]. The establishment of a positive feedback loop between lymphoid 
chemokines and LTβ is critical in promoting the development of the stromal and 
vascular architecture of SLO, including the differentiation of HEVs [229]. 
Although a role for adult LTi cells in ELN has been often speculated, to date we 
have only proof that these cells can take the place of neonatal LTi in transgenic 
mice that lack them [48],[49]. Conversely, evidence from transgenic models of 
TLS has questioned the relevance of Lti in ectopic lymphoid neogenesis in adult 
life [251]. Similarly, lymphoid chemokine expression in patients with TLS 
developing during chronic inflammatory diseases, including SS [30]-
[32],[126],[136], suggests that the lymphoid chemokines/LTβ pathway in 
inducible TLS formation is regulated by cellular and molecular mechanisms 
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which are different from the conventional interactions observed during 
embryonic development. 
In this thesis I showed that, following AdV delivery, early up-regulation of 
lymphoid chemokines CXCL13, CCL19 and CCL21 mRNA preceded the 
development of TLS and peaked in concomitance with fully functional TLS. Of 
interests, lymphoid chemokines retained their discrete expression pattern 
observed in SLOs, with CXCL13 confined to the B cell-rich areas of the 
periductal aggregates and CCL21 in the surrounding T cell area. This suggests 
that the progressive recruitment and positioning of T and B cells subsets 
following AdV infection in the salivary glands are not random events but follow 
tightly regulated chemoattractive gradients. Additionally, this evidence 
establishes this inducible model of TLS as a suitable platform to dissect the 
dynamic expression, source of production and hierarchical importance of the 
critical factors regulating ectopic lymphoid neogenesis. 
Importantly, in my PhD work I have also demonstrated that AdV-induced TLS 
not only recapitulate the cellular and molecular organization of SLO but also 
support functional B cell activation with expression of AID, the enzyme which 
initiates somatic hypermutation (SHM) and class switch recombination (CSR) of 
the Ig genes [252], leading to affinity maturation and differentiation of memory B 
and plasma cells [253],[254]. Expression of AID in the salivary glands required 
the formation of TLS acquiring markers of germinal centres such as FDC 
networks and GL7, similarly to SS patients [38]. AID expression and 
subsequent CSR in naïve B cells can be directly induced by a combination of 
cytokines among which BAFF, IL-4, IL-10 and IL-21, even in the absence of B-
cell receptor cross-linking [255]-[259]. Accordingly, in this model AID transcript 
 227 
levels were strictly associated with the expression of BAFF, IL-4 and IL-21 
mRNA suggesting a functional role for these factors in downstream B cell 
activation.  
Because the architectural, cellular and molecular features of TLS in this model 
were highly reminiscent of those observed in SS, I also investigated whether 
typical features of the human disease were also present in this model. The two 
hallmarks of SS are i) the breach of self-immunological tolerance towards 
nuclear antigens resulting in the detection of circulating autoantibodies and ii) a 
progressive exocrine dysfunction, which results in the classical signs and 
symptoms of mouth/eye dryness (sicca syndrome). Interestingly, at week 3 
post-cannulation 75% of the AdV-cannulated mice developed positivity for IgG 
ANA, in comparison none of the vehicle controls displayed evidence of 
autoimmunity. Interestingly, onset of ANA was preceded by the rapid and 
abundant induction of epithelial cells apoptosis following AdV infection, as 
demonstrated by the presence of pyknotic nuclei and positive TUNEL staining. 
In SS autoimmunity, the involvement of the TLR on epithelial cells and B cells is 
likely to play a major role. In particular, it has been shown that ductal epithelial 
cells release a high level of the B cell survival/BAFF upon sensing viral dsDNA 
via the TLR3 and the type I IFN pathways [160]. Similarly, B cells express 
TLR7, which recognizes ssRNA (including viral RNAs, usually released within 
phagosomes), and TLR9, which recognizes unmethylated CpG DNA motifs 
(including dsDNA viruses, such as herpes viruses) [260]. In keeping with an 
important role of TLRs in direct viral recognition by B cells, TLR9 ligation on B 
cells has strongly been implicated in the enhancement of antiviral immune 
responses within GC [261]. In the context of viral-induced autoimmunity, the 
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release of nuclear material from apoptotic/necrotic cells as a direct result of viral 
replication or the resulting cytotoxic immune response likely represents a 
continuous source of potential autoantigens, and the rapid release of apoptotic 
material might be the leading cause of ANA generation in my model. In this 
regard, it will be interesting to dissect whether TLS forming in the SG are 
directly involved in the generation of autoantibodies over and above draining 
lymph nodes, as previously demonstrated for TLS in patients with SS [32],[140] 
and proposed in a mouse model of the disease [42].  
In addition to the breach of self-tolerance, I also showed that the development 
of sialoadenitis and TLS following AdV infection was also accompanied by 
prolonged exocrine dysfunction. This is extremely interesting because while 
hyposalivation would be expected in the early stage post-viral infection given 
the high degree of diffuse inflammation and acinar loss, it was surprising to 
observe a lack of secretory recover up to 3 weeks post-cannulation when the 
glandular parenchyma returned to a normal appearance, with the exception of 
the formation of focalised periductal lymphoid aggregates. Although I did not 
elucidate the pathophysiologic mechanisms responsible for such hyposecretion 
in this model, which might be due to viral and/or immune mediated 
mechanisms, these observations would be in keeping with indications in 
patients with SS that exocrinopathy in the context of focal sialoadenitis is 
primarily due to a functional rather than anatomical impairment [262] as also in 
patients with SS, particularly at early stages of disease, the loss of salivary flow 
is not paralleled by a synchronized loss of secretory units in the diseased 
tissue. These observations have also been confirmed in another mouse model 
of virus-triggered sialoadenitis, where murine cytomegalovirus administered i.p. 
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induces salivary impairment well before the appearance of immune infiltration 
and viral colonisation of the SG [263].  
 
Interestingly, I also found that in this model formation of TLS was invariably 
associated with the persistence of the transgene product within the salivary 
glands at least up to 4 weeks after AdV delivery, despite the viral inability to 
replicate, the presence of cytotoxic cells (e.g. NK cells) and production of AdV-
specific IgG response as soon as the second week after infection. Strikingly, I 
observed prolonged viral and transgene protein expression only within ductal 
epithelial cells, an observation in keeping with the well-known tropism for the 
ductal cells in the SG shown by several viruses (such as CMV in rodents and 
humans and EBV and HCV in humans, that can establish a lifelong infection 
[168],[264]) and the  inability of ductal cells to clear viral pathogens described 
both in rodent and human salivary glands [197],[204]. The reason why SG 
represent such a permissive site for persistent viral infection is only partially 
understood, but it is possible to speculate that viral persistence might depend 
on the ability of viruses to adapt to and evade immune recognition, but also on 
the fact that mucosal sites are naturally skewed toward a Th2 humoral immunity 
and recent reports regarding the specific environment-driven SG NK cells 
functional phenotype seem to confirm this hypothesis [265].  
 
In the second part of my thesis, which was focused on the dissection of the 
series of very early events happening in response to viral infection in the 
submandibular glands prior to TLS formation, I clarified the dynamic rate and 
degree of immune cell infiltrations from the peripheral compartment. Of 
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relevance, I discovered that, similar to the formation of TLS, also the 
recruitment and positioning of innate immune cells within the virus-infected 
salivary glands seems to follow tightly regulated mechanisms.   
First, I showed that neutrophil granulocytes are abundantly recruited to the 
salivary gland within the first 24-48 hours after infection. The presence of 
neutrophils in response to a viral infection is somewhat surprising but potentially 
not irrelevant in the context of the development of an adaptive immune 
response and autoimmunity. In fact, several unexpected functions have been 
recently associated to this subset of polymorphonuclear leukocytes and among 
those the capacity to promote B cell immunoglobulin production in the spleen 
marginal zone via the secretion of B cell survival factors such as BAFF, APRIL 
and IL-21 [266],[267]. Interestingly, the formation of neutrophil extracellular 
traps (NET), which is another important and unique feature of these 
granulocytes, has been recently recognized as a potential mechanism for the 
development of autoantibodies to citrullinated proteins, one of the key 
mechanism in the development of RA [268].   
Plasmacytoid DCs, natural type-I interferon producing cells [237] involved in 
viral control, were present within the SG during the first 5 days post AdV 
infection and showed a trend towards increment in their number. This evidence 
is also relevant for the human disease as SS salivary glands are characterized 
by a strong type-I interferon signature [269],[270] which is associated with the 
presence of activated pDC in the SG infiltrate. pDCs have been shown not only 
to respond to classic viral stimuli but also by autoantibodies and antimicrobial 
peptides secreted by activated neutrophils [153]. In turn, activated pDCs 
promotes an increased inflammatory activity in several target immune cells and 
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also B cell survival and antibody production. [271]. Thus, the recruitment of 
pDCs in the gland upon AdV delivery observed in my model might boost 
immune activation in the early phases of infection but it could also promote B 
cell in situ activation, potentially rescuing autoreactive clones and supporting 
breach of self-tolerance. This series of events has been proposed to take place 
in the SG of virus-infected SS patients during the development of the disease 
[272] and my model could be the perfect tool to test the relevance  of this 
hypothesis.  
Eosinophil granulocytes-resembling cells were also observed to gradually 
appear in the gland after infection. The presence of eosinophils in a mucosal 
tissue is not surprising, but whether or not these cells have a role either in viral 
control, TLS formation and/or induction of adaptive immunity and breach of 
tolerance is difficult to ascertain at this stage. Recently eosinophils have been 
found important not only in defence against parasitic infection and in allergic 
reactions but also in anti-viral protection [273], thus the only speculation 
regarding the presence of these cells in my model that is probably safe to make 
with the little evidence in my hands, is that the Th2-skewed mucosal milieu 
might be encouraging the recruitment of a type-2 associated cell type, i.e. 
eosinophil granulocytes, together with classic type-1 immune cells such as NK 
cells and inflammatory monocytes.  
 
Together with neutrophils, inflammatory monocytes are the most abundant 
infiltrating cell type in the first 72 hours post-infection of the SG. From previous 
data and the preliminary flow cytometry data that I presented in this thesis, it is 
very likely that most of the infiltrating monocytes differentiate into macrophages 
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and monocyte-derived DCs [236],[274]. Monocytes and monocyte-derived 
macrophages and DCs can execute a plethora of different functions from 
pathogen control to tissue remodelling and re-establishment of homeostatic 
conditions going through modulation of the innate and adaptive immune 
system. Moreover, resident macrophages are essential for the steady state 
condition of the tissue and patrolling DCs continuously enter and leave the 
peripheral tissues probing for pathogens and alarm signals. For this reasons it 
is very difficult to speculate regarding a specific role of these cells in my model, 
as I expect them to be involved at different levels in the host-pathogen 
interaction, TLS formation and tissue repair. Nevertheless, previous data 
supports several interesting observations that I made during my thesis which 
are worth discussing. In terms of TLS development in the context of 
autoimmunity, it has been shown that cells from the monocyte-macrophage 
lineage can produce the B cell-attracting chemokine CXCL13 in RA patients’ 
synovium [59]. Resident and/or monocyte-derived macrophages could 
contribute to ELN also via the induction of lymphoid chemokines production by 
stromal cells. In fact, TNF overexpression by F4/80+ macrophages in the 
intestine of LTi-deficient mice was sufficient to induce the acquisition by stromal 
cells of an “organiser” phenotype that eventually led to the formation of 
mesenteric lymph nodes in animals normally devoid of these structures [56].  
In my model I also observed an increase of the DC population in the SG after 
AdV-delivery. The increase in CD11c+ DCs might be important both in 
organisation and maintenance of TLS in the infected SGs. In fact, in a 
transgenic mouse model of ELN in the thyroid, interaction between CD3+CD4+ 
T cells and CD11c+ DCs is essential for TLS formation [251], while in an 
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influenza virus-induced TLS formation murine model, CD11c+ DCs were 
necessary for TLS maintenance in the lungs but not for the initiation of ELN 
[58].  
In support for a role of the above-mentioned cellular subsets in the formation of 
TLS, in a set of preliminary experiments I showed that inflammatory 
chemokines are more strongly expressed by F4/80+/CD11c+ cells present in the 
gland between days 2 and 4 after AdV delivery than between days 5 and 7. 
Conversely, in the same time frame, lymphoid chemokines expression, initially 
low or absent, increases. With these data in hand, it is tempting to speculate 
that resident macrophages and myeloid cells that infiltrate the gland rapidly 
after infection produce an initial set of chemotactic signals that promote further 
accumulation of inflammatory cells in the gland. The observed differentiation of 
inflammatory myeloid cells into macrophages and DCs that follows this initial 
phase, characterised by the downregulation of Ly6C expression and 
upregulation of F4/80 and CD11c markers, corresponds to a dampening of the 
inflammatory chemokines genes expression and an increase of the 
lymphocytes attracting signals, namely Ltβ, CCL19 and CXCL13. The 
positioning of CD11c+ DCs relative to the lymphoid aggregates forming in the 
infected glands observed in IF also supports the idea that this subset in 
particular might actively participate to the secretion of chemotactic signals that 
first attract and then organise and maintain B and T cells infiltrates during the 
ELN process. This last point certainly deserves more studies (more detailed 
future plans are reported in Chapter 7), as the specific pattern of localisation for 
DCs and macrophages in relation to B and T cells that I described here for the 
first time might be extremely important for the formation and maintenance of 
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TLS structures in the SG mucosa and consequently for the development and 
progression of SS.  
The possible high relevance of the myeloid compartment for the development of 
TLS in the SG is also indirectly supported by another set of experiment where I 
dissected the role of NK cells, a cellular type strongly involved in viral control 
and clearance, in the formation of these structures. When systemically and 
locally deprived of NK cells, wild-type mice still developed TLS with the same 
dynamic and magnitude of the control-treated animals. Interestingly, in contrast 
with other model of mucosal infection and inflammation [243], NK depletion also 
did not affect the number of infiltrating monocytes and the development of the 
macrophage and DC subsets in the AdV-treated SG compared to controls. 
Thus, not only the augmented presence of NK cells in the gland observed in the 
first week after infection is not paralleled by an efficient viral clearance as 
shown by the persistence of infected cells up to 4 weeks after cannulation, but 
NK cells are also dispensable for the monocytes infiltration and differentiation 
and TLS formation in this model. This, again, supports the idea that the SG 
mucosa differs from other tissues and other types of mucosa in terms of anti-
viral defence and cross-talk with the peripheral and local myeloid compartment. 
Whether NK depletion affects viral persistence, salivary flow reduction and 
production of ANA upon SG infection is still to be tested, but given the 
observations reported above I expect that lack of NK cells might not influence 
viral clearance and thus the general progression of ELN in my model as it has 
been described in this thesis.  
Thus, in this model induction of TLS likely derives from lack of viral clearance 
resulting in prolonged antigenic exposure which is a potent trigger for TLS 
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formation, as previously suggested in other models of ectopic lymphoid 
neogenesis such as chronic graft rejection {Thaunat:2010ec} and autoimmune 
insulitis in NOD mice [71]. Therefore, this model has the potential to unravel the 
intimate physiopathological viral-host interactions leading to the formation of 
TLS in SS. 
In conclusion, I developed a novel model of AdV-induced lymphoid neogenesis 
which has the potential to shed light on the critical interactions between viral 
infection, formation of TLS, breach of immunological tolerance and exocrine 
dysfunction in the salivary glands, providing a suitable platform to investigate 
the mechanisms regulating TLS formation in response to viral infection and their 
role in the development of features typical of SS. 
 
As a final remark, I would like to collate the observations that this model has 
already provided, and I have presented in this thesis, with previous literature to 
provide a hypothesis that links persistent viral infections, ELN in the salivary 
glands and development of breach of tolerance and autoimmunity.  
From my preliminary data it is possible to speculate that resident and infiltrating 
myeloid cells, probably with the help of stromal cells, can activate the lymphoid 
chemokines pathway and trigger the initiation of the ELN program in response 
to pathogen infection of the salivary gland mucosa. In predisposed individuals, 
for example those with an aberrant activation of the type-I interferon pathway, 
viral infection might furthermore lead to an abnormal activation of NK and CD8+ 
T cells but also promote B cells survival and antibody production [153]. Ectopic 
lymphoid follicles forming in the SG, not only are favourable niches for 
lymphocytic activation and proliferation, but in response to infection they are 
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rich in autoantigens released by apoptotic and necrotic cells. Moreover, TLS 
could attract from the periphery autoreactive lymphocytes rescued from 
apoptosis by a persistent latent viral infection (e.g. EBV in B cells and HTLV-1 
in T cells) [275] and promote their survival and differentiation toward disease-
specific autoreactive cells [276],[277] eventually leading to the symptoms and 
manifestations of SS. This hypothesis is summarised in Figure 6.1. 
 237 
 
 
Figure 6.1: Evolution of TLS in response to viral infection in the SGs and 
development of autoimmunity. (A) Viral infection of the SG mucosa induces 
activation of epithelial and stromal cells and resident macrophages, triggering 
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the production of inflammatory chemokines and the expression of adhesion 
molecules on blood vessels, leading to the recruitment of innate immune cells 
from the peripheral compartment to the SG. Inflammatory chemokines attract 
inflammatory monocytes and within the first week from infection, T cells leading 
to the secretion of inflammatory cytokines (e.g., IFN-γ, TNF-α, IL-1β) that in 
turn, activate resident NK cells and drive macrophage polarization and a Th1-
mediated antiviral response. (B) Despite potent antiviral immune responses, 
several viruses (e.g., CMV, EBV, and Coxsackie) can escape immune 
surveillance, leading to lack of viral clearance and persistent infection, 
preferentially within ductal epithelial cells. Chronic antigen stimulation promotes 
the ELN program. This triggers the activation of the LTβ pathway and the 
production of lymphoid chemokines CXCL13, CCL19, and CCL21 by stromal 
cells and monocyte-derived cells with the accumulation of B and T cells in the 
gland. (C) In the context of persistent chronic stimulation, the LTβ condition 
vessels to acquire a HEV phenotype with expression of PNAd, whereas CCL19 
and CCL21 facilitate T lymphocyte influx and organize the T cell area of the 
ectopic follicle. Similarly, stromal cells via CXCL13 production promote the 
organization of the ectopic B cell follicle. Further differentiation of FDCs leads to 
the GC response, which is sustained by the production of B cell-activating 
cytokines, such as BAFF and IL-21, leading to in situ activation and proliferation 
of B cells. TLS fail to exclude autoreactive B cells from entering the ectopic GC, 
leading to breach of self-tolerance and development of autoimmunity. In this 
context, immune-modulating viruses, such as HTLV-1 in T cells and EBV in B 
cells, further promote autoreactive T and B cell survival in the periphery and 
their preferential recruitment in the ectopic B cell follicles, whereby autoreactive 
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EBV-infected B cells undergo plasma cell differentiation and autoantibody 
production. Republished with permission of Society of leukocytes biology, from 
[277], 2013; permission conveyed through Copyright Clearance Center, Inc. 
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7 Future plans 
The model that I have developed during my PhD and presented in this thesis 
has the main characteristic of being extremely flexible and apt to the study of 
several immunological pathways, spanning from host-pathogen interaction to 
the role of TLS formation in physiological conditions but also involving breach of 
self-tolerance and the onset of autoimmunity.  
Despite the wide spectrum of extremely interesting questions that my model 
could potentially answer, there are several topics that I would like to tackle in 
the short and middle term. Specifically, in the short term I plan to i) complete the 
studies on the NK compartment and ii) strengthen the initial observations on the 
lymphoid chemokines expression by DCs and macrophages. In the medium 
term and according to the results produced by the short term experiments I plan 
to: iii) block the infiltration of and/or deplete the inflammatory monocytes to 
functionally prove the relevance of these cells in ELN formation; iv) track the 
inflammatory monocytes infiltration in the SG upon AdV delivery and prove their 
differentiation into resident macrophages and/or DCs.  
I will now describe in some more details these goals. 
i) Completion of the analysis of the NK cells role in the AdV-infected SG. 
Reports on the role of NK cells in the murine CMV-driven model of salivary 
gland infiltration are controversial [263],[265],[278]. I already showed in this 
thesis that NK cells depletion does not affect TLS formation and myeloid cells 
infiltration. In the discussion, I hypothesised that NK depletion would not affect 
the breach of tolerance observed in this model nor the viral clearance. If 
development of ANA is dependent on the formation of functional GC in the 
infected salivary glands and since NK depletion in my hands does not affect 
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ELN formation and functionality, I expect that NK cells absence will not modify 
the observed prevalence of anti-nuclear antibody generation. For the same 
reason, as viral presence and persistence seems to be essential for the 
formation and maintenance of TLS in the gland and absence of NK cells did not 
modify these processes, I expect that NK depleted mice will not have significant 
differences in the level of viral control.  
To prove these hypotheses I plan to use the same experimental approach 
described above, i.e. cannulation of the salivary glands of depleted and control-
treated mice, culling of the mice the third week post-procedure and collect 
serum for ANA test. Salivary gland collected at this time-point will be digested 
and prepared for luciferase assay. As a parallel approach to measure viral 
persistence, part of the gland tissue could be prepared for expression analysis 
using the reporter gene transcript as a target to prove whether NK cells 
absence changes the amount of virus-infected cells in the gland. Contextually, I 
plan to take advantage of an in vivo imaging system to monitor the luciferase 
activity in the gland of NK-depleted animals and control. The system has the 
advantage to allow continuous monitoring of the transgene activity and for this 
reason I plan to acquire reporter activity measures at several time points after 
cannulation, to test if there is a difference in the early versus late response to 
viral infection in NK-depleted mice in comparison to controls.  
 
ii) Test the hypothesis that macrophages and DCs in the gland are 
producer of lymphoid chemokines and thus contribute to ELN formation 
and maintenance. In this thesis I showed that infiltrating monocytes potentially 
differentiate into macrophages and dendritic cells. I also presented preliminary 
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observations suggesting that these infiltrating myeloid cells, in line with previous 
literature in mouse lung infection [58],[279] and human SS SG [59], might 
contribute to the ELN program by expressing lymphoid chemokines toward the 
end of the first week after infection, thus favouring the influx of lymphocytes. 
Hence, as a further short-term goal, I plan to reinforce these observation with 
more targeted experiments. Namely a) FACS sorting of CD11cHi DCs and 
F4/80+ macrophages from AdV-treated mice glands collected at various time-
points in the first three weeks after procedure and real time expression analysis 
on this population for the chemokines genes; b) double IF staining for lymphoid 
chemokines and CD11c or F4/80 on samples collected at various time-points. 
These two relatively simple experiments, if confirming the preliminary 
observations, would rapidly provide support to the hypothesised role of DCs 
and macrophages in TLS formation and maintenance. Moreover, this approach 
would also allow for discriminating the role of each specific population.  
 
iii) Blockade/depletion of the SG infiltrating monocytes. According to the 
results of the plans reported in i) and ii), I envisage a more functional approach 
to assay the role of monocyte/macrophages/DC populations in ELN formation. 
Similarly to what I have done for NK cells, I plan to deplete circulating 
monocytes or to block their access to the AdV-treated gland. To do so, several 
strategies are available and I am already conducing preliminary experiments to 
identify the more suitable to my purposes. Clodronate-containing liposomes 
delivered intra-venously have proved to provide an efficient depletion of the 
circulating monocytes in several models [280]-[282]. The depletion is reported 
to be only temporary, as monocytes start to repopulate the blood as soon as 24 
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hours after depletion [280] and this could represent an issue for my model, as 
new a wave of recently bone-marrow emerged monocytes could infiltrate the 
gland even if the circulating counterpart has been efficiently depleted. 
Nevertheless, this seems a sound approach and a widely validated one, which 
deserves further investigation.  
A different approach to the complete ablation of the monocyte population from 
blood would be to block the access of these cells to the infected salivary gland. 
To do so, I will need to understand the exact nature of the chemotactic gradient 
that drives the inflammatory influx. If I manage to achieve this, I can then try to 
block the inflammatory infiltration using chemokine-binding drugs or chemokine-
receptors antagonists. The cells isolated from the gland via FACS sorting as 
described above would be my starting point in this project, as I plan to assay 
the expression levels of inflammatory chemokines and receptors in these 
populations at very early time-points after AdV-delivery (e.g. 1, 2, 4, 8, 12 hours 
post-cannulation). In parallel, I plan to collect SG from untreated wild-type mice 
and either digest the tissue and plate the cells and/or directly plate pieces of 
undigested tissue. I will then infect the wells with doses of AdV comparable to 
those used in the cannulation. Tissue and cells will be collected and analysed 
for inflammatory chemokines gene expression and supernatants will be 
assayed for chemokines presence. There are many monocyte-attracting 
chemokines and monocytes express several different chemokine receptors in 
an often redundant and overlapping fashion [246], thus isolating a sole 
chemokine responsible for inflammatory cells infiltration might prove difficult, but 
I am confident that I will be able to isolate at least some of the inflammatory 
chemokines pathways activated by AdV infection. As an alternative to this ex 
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vivo approach or in parallel to it, I could use an in vitro system: a murine salivary 
gland epithelial cell line is already present in this laboratory that I could culture 
and infect with the virus and analyse at various time-points to study the 
epithelial contribution to the chemotactic gradient.  
 
iv) Monocyte infiltration and differentiation tracking in vivo. Another 
medium-term goal in the study of the relevance of the monocyte/macrophage 
family in the formation of TLS would be the tracking of the monocytes from the 
blood to the SG and the analysis of their final fate to demonstrate whether these 
cells can effectively differentiate in tissue macrophages and/or DC in the SG. To 
do so, in the context of my model I plan the passive transfer of blood or bone 
marrow monocytes from a wild-type untouched donor to a recipient animal, in 
the presence or absence of AdV-cannulation. Several approaches exist to track 
transferred cells: the labelling of monocytes from donor animals (e.g. CFSE 
labelling); the use of congenic strain to differentiate donor and recipient cells 
(e.g. CD45.1 versus CD45.2 animals); the use of the widely validated 
CX3CR1gfp/gfp transgenic mouse that also allows the identification of the 
different blood monocyte populations [283],[284] or a combination of these 
approaches. I have already started experiment with CFSE labelling and 
collected preliminary experiments in CX3CR1gfp/gfp transgenic mice, which 
support the hypothesis that inflammatory monocytes recruited following AdV 
infection enter the local myeloid pool.  
All these experiments could hopefully provide some novel cellular target and 
molecular pathways in the context of ELN formation and breach of self-
tolerance in response to viral infection that not only might shed new light on 
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these processes but could also be of relevance for the human counterpart. 
Specifically this model and the data that it could provide might help in dissecting 
the host-pathogen interactions in the SG mucosa and the role of TLS in the 
generation of protective immunity, but the findings could also pinpoint new 
targets useful to better understand the pathogenesis and evolution of SS 
disease.   
 247 
List of publications related to this work  
The work presented in this thesis lead to several publications. 
Published papers in peer-reviewed international journals: 
• Bombardieri M., F. Barone, D. Lucchesi, S. Nayar, W. B. van den Berg, 
G. Proctor, C. D. Buckley, C. Pitzalis “Inducible tertiary lymphoid 
structures, autoimmunity, and exocrine dysfunction in a novel model of 
salivary gland inflammation in C57BL/6 mice.” Journal of Immunology, 
Volume 189, Issue 7, pp. 3767-3776, 2012.  
• Lucchesi D., M. Bombardieri. “The role of viruses in autoreactive B cell 
activation within tertiary lymphoid structures in autoimmune diseases.” 
Journal of leukocyte biology, Volume 94, Issue 6, pp. 1191-1199, 2013. 
• Lucchesi D., C. Pitzalis, M. Bombardieri. “EBV and other viruses as 
triggers of tertiary lymphoid structures in primary Sjögren's syndrome.” 
Expert review of clinical immunology, Volume 10, Issue 4, pp. 445-455, 
2014. 
Papers in preparation: 
• Pontarini E. and Lucchesi D., Bombardieri M., D. Mavilio. “Recruitment 
and activation of NK cells in murine salivary glands regulate early 
immune response to viral infection but are dispensable for inducible 
lymphoneogenesis and autoimmunity” 
• Murray-Brown W., Lucchesi D., Pontarini E., De Courcey J., Pitzalis C., 
M. Bombardieri. “Lesional expression of IL-21 correlates with ELS 
formation in Sjögren’s syndrome patients salivary glands ” 
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Appendix 
Solution and buffers used for this work: 
- Complete culture medium for Hek293 cells: Dulbecco-modified 
Eagle’s medium (D-MEM) supplemented with 10% heat-inactivated FBS 
(Gibco), 100 µg/ml streptomycin and 100 U/ml penicillin G (Life 
technologies). 
- Infected cells collection buffer (100mM Tris pH 8): 12.141 gr Trizma 
(Sigma) dissolved in 1 litre of distilled water, brought to pH with HCl 
- TD buffer: NaCl 137 mM, KCl 5.1 mM, Na2HPO4 0.704 mM, Tris 24.8 
mM brought to pH 7.5 with HCl  
o CsCl gradient ρ=1.25: 36.16 gr CsCl (Sigma) in 100 ml TD buffer  
o CsCl gradient ρ=1.4: 62 gr CsCl (Sigma) in 100 ml TD buffer  
o CsCl gradient ρ=1.35: 51.2 gr CsCl (Sigma) in 100 ml TD buffer  
- TSG buffer: 90 ml solution A + 450 µl solution B + 38.4 ml glycerol 
o Solution A: NaCl 150 mM, KCl 5 mM, Na2HPO4 1 mM, Tris 30 
mM (all from Sigma) brought to a final pH of 7.4 
o Solution B: MgCl2 200 mM, CaCl2180 mM  
- Dialysis buffer: Tris 10 mM, MgCl21 mM, NaCl 150 mM,10% glycerol. 
Final pH 7.4.  
- 1x PBS: 144 mg/L KH2PO4, 9 gr/L NaCl, 796 mg/L Na2HPO4 without 
calcium and magnesium, pH 7.3-7.5 (Lonza) 
- XGal (β-galactosidase detection solution): 1 mg/ml 5-bromo-4-chloro-
3-indolyl-β-D-pyranoside, 5 mM K4[Fe(CN)6]·3 H2O, 5 mM K3[Fe(CN)6], 5 
mM EGTA, 2 mM MgCl2, 0.02% NP-40 (all from Sigma) in PBS 
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- TBS: Tris 50 mM, NaCl 150 mM, pH 7.6  
- IF blocking/dilution buffer: 1% bovine serum albumin (Sigma), 10% 
horse serum (Gibco) in TBS 
- RIPA biffer: Tris 50 mM, NaCl 150 mM, sodium deoxycholate 0.5%, NP-
40 1%, sodium dodecyl sulphate 0.1%, pH 8 
- 5x Laemli solution: sodium dodecyl sulphate 10%, glycerol 50%, β-
mercaptoethanol 25%, bromphenol blue 0.01% and Tris 0.312 M, pH 6.8 
- PAGE running buffer: MOPS 5 mM, Tris 5 mM, sodium dodecyl 
sulphate 0.1%, EDTA 0.1 mM  
- ANA dilution/blocking buffer: BSA 2%, Tween-20 0.05% in PBS 
- Carbonate/bicarbonate buffer: carbonate/bicarbonate 0.5 M, pH 9.6 at 
25˚C (capsules from Sigma reconstituted in distilled water) 
- Tissue digestion buffer: 2% foetal bovine serum (Life Technologies), 
3.7 mg/ml collagenase-D (Roche), 30 µg/ml DNAse-I (Sigma) in RPMI-
1640 (Gibco) 
- FACS buffer: 2% foetal bovine serum (Life Technologies) in PBS 
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